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1 Introduction 
1.1 The clinical picture and diagnosis of proximal spinal muscular atrophy 
Spinal muscular atrophies (SMA) present as a broad spectrum of diverse clinical 
pictures. All spinal muscular atrophies are caused by the loss of lower motor neurons in 
the spinal cord, resulting in denervation of especially voluntary muscles leading to 
muscle weakness and atrophy as main symptoms of the disease. The occurrence of the 
atrophy may differ between proximal or distal, symmetrical or asymmetrical muscle 
atrophy. Also a wide mode of inheritance is found, ranging from sporadic occurrence 
over X-chromosome linked to recessive or dominant heredity. Possible forms of spinal 
muscular atrophies include X-linked disease (XL-SMA), spinal muscular atrophy with 
respiratory distress (SMARD), spinal and bulbar muscular atrophy (Kennedy’s disease), 
and distal spinal muscular atrophy. 
 Autosomal recessive proximal spinal muscular atrophy is the most common form of 
spinal muscular atrophies and, therefore, is simply referred to as “SMA”. It is the subject 
of this thesis and, unless mentioned otherwise, the term “SMA” used herein refers to the 
autosomal recessive proximal from of spinal muscular atrophies. 
 With an occurring incidence in the western European population of 1 in 6,000 to 
10,000 life-births and a carrier frequency of 1:35 (Czeizel and Hamula 1989; Feldkotter 
et al. 2002; Pearn et al. 1978), SMA is the second most frequent  autosomal recessive 
disorder in humans and the leading genetic cause of infant death today (Montes et al. 
2009). 
The major characteristic hallmark of SMA is the degeneration of α-motor neurons 
in the anterior horns of the spinal cord, leading to hypotonia and muscle weakness finally 
resulting in muscle atrophy. Other neurological systems (including brain and sensory 
nerves) usually display no dysfunction and affected individuals show normal intelligence. 
Muscular weakness starts at the voluntary muscles of the proximal limbs, such as upper 
arms and legs, rather than in the distal ones, like hands or feet. The atrophy is more 
pronounced and begins earlier in the legs than in the arms. SMA is a progressive 
disease starting from muscle weakness and resulting in atrophy of the muscles. SMA 
patients show further symptoms, like tremor of the hands and an explicit decrease of 
deep reflexes. Furthermore, fasciculations of the tongue are observable in SMA patients. 
Muscle groups in the face and in the eyes are typically not involved. 
The serum level of the creatine kinase (CK) activity is a common and very sensitive 
marker of increased muscle membrane permeability. Elevated CK activity points towards 
a muscle damage (Schlattner et al. 2006). CK activity is a common diagnostic tool for 
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myocardial infarction or muscular dystrophy. While in these cases the CK activity level is 
highly increased (10-fold and more above the normal level), in SMA patients only a mild 
elevation can be detected. Therefore, a highly augmented CK amount is a criterion of 
exclusion for SMA diagnosis. 
Nowadays, one of the main diagnostic tools for SMA is electromyography (EMG). 
Electromyography is a technique for evaluating and recording the activation signal of 
muscles. With the help of an apparatus called “electromyograph” EMG is performed and 
the results are recorded in an electromyogram. By the use of this apparatus it is possible 
to detect the electrical potential generated by myoblasts in an active and in an inactive 
state. Electromyographic investigations in affected SMA patients show a typical pattern 
of denervation, normally without sensory involvement. Additionally, SMA patients reveal 
specific EMG characteristics, such as spontaneous muscle activity with fibrillations and 
fasciculations of single muscle fibers and motor units. The nerve conduction velocity 
(NCV) in SMA patients is normal or mildly reduced, but not lower than 70% compared to 
healthy individuals. 
As a guideline for the diagnosis of SMA, in 1992 the SMA Consortium defined the 
following list of major exclusion criteria for SMA (Munsat and Davies 1992): 
 
• CNS dysfunction 
• arthrogryposis 
• involvement of other neurologic systems or other organs (e.g. hearing, 
cardiac or vision) 
• sensory loss 
• eye muscle weakness 
• marked facial weakness 
• marked increase in creatine kinase (CK) activity levels.  
 
Still, in very rare SMA cases it has been observed that the disease may sometimes 
associate with arthrogryposis, CNS involvement, increased CK values or heart defects 
(Rudnik-Schoneborn et al. 1996). Nevertheless, it remains elusive, whether these 
observations are true causal associations or just random findings. 
To screen out the misdiagnosis of muscular dystrophy or other neuromuscular 
disorders and to verify the diagnosis for SMA, muscle biopsy of patients is an 
established means. These histological samples are evaluated histochemically, and may 
allow distinguishing SMA from other denervating diseases. There are two types of 
muscle fibers. Muscle fibers of the type I have a red appearance, because they contain 
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the oxygen binding protein myoglobin and they show slow fatigue since they generate 
ATP by oxidative metabolism, and therefore are suited for endurance. Due to the 
absence of myoglobin, type II fibers appear white. Besides the oxidative metabolism type 
II fibers make use of the anaerobic metabolism, hence they are faster to fatigue, but they 
are efficient for short bursts of speed and power. In a muscle biopsy from a typical 
chronic SMA patient groups of atrophic and hypertrophic fibers or fiber-type grouping are 
most often found (see Figure 1). Moreover, SMA skeletal muscle usually shows atrophic 
fibers with islands of group hypertrophy (Buchthal and Olsen 1970). Furthermore, 
evidence of skeletal muscle denervation can be observed.  
 
Figure 1 Histopathology of spinal muscular atrophy 
Motor commands generated in the cerebral cortex are transmitted through spinal cord α-motor 
neurons (red cell in spinal cord anterior horn and green arrow in (A)). The spinal cord anterior 
horn region shows an absence of motor neurons in a patient (B) compared with those in the 
healthy control (A). Skeletal muscle of a patient (D) shows hypertrophic fibers (hollow arrowhead) 
surrounded by group atrophy (green arrowhead) compared with healthy fibers with uniform 
morphology in normal infantile muscle (C). Despite the atrophy of muscle fibers in spinal muscular 
atrophy, muscle spindles (black asterisk) are not affected and become more conspicuous (D). All 
slides are stained with haematoxylin and eosin. (Taken from (Lunn and Wang 2008)) 
 
 
Besides the atrophy of both muscle fiber types, an additional distinctive feature is the 
presence of a small number of scattered hypertrophic type I fibers presumably resulting 
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from physiologic hypertrophy. Nevertheless, normal-appearing fibers may be present. 
Although the muscle biopsies of SMA patients show neither, significant necrosis, 
degeneration, regeneration, lipid accumulation, nor connective tissue proliferation, some 
of these features may sometimes occur in older chronic SMA patients, suggesting a 
secondary myopathic process. 
In the year 1995 Lefebvre and colleagues identified the SMA disease determining 
gene, called survival of motor neuron 1 gene (Lefebvre et al. 1995). Since then it has 
been possible to confirm the clinical diagnosis of SMA by molecular genetic testing. To 
verify the clinical diagnosis of SMA, the SMN1 gene on chromosome 5q is screened for 
specific mutations (deletions/gene conversions of exon 7 or exon 7 and 8). Furthermore, 
this highly important diagnostic tool may also be applied in prenatal diagnosis and carrier 
testing. The gain of knowledge regarding SMA led to the modification of the primary 
diagnostic criteria proposed by the International SMA Consortium (Munsat and Davies 
1992) by Zerres and Davies in 1999 (Zerres and Davies 1999). In 2008, Lunn and Wang 
proposed another guideline for proper SMA diagnostics shown in Figure 2. 
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1.1.1 Classification of proximal SMA 
Based on different motor functions and on the age of onset, spinal muscular atrophy has 
been divided into four clinical types: severe type I; intermediate type II; mild type III and 
adult-onset type IV as a very mild form (Munsat and Davies 1992; Zerres and Rudnik-
Schoneborn 1995). 
 
1.1.1.1 SMA type I (Werdnig-Hoffmann disease, MIM #253300) 
This type of SMA is the most severe form and is also called acute SMA. The clinical 
picture of SMA type I was first described by Werdnig in 1891 (Werdnig 1891) and 
independently by Hoffmann in 1893 (Hoffmann 1893). 
Usually type I SMA is diagnosed within the first 6 months of life. The onset of the 
disease is before the age of 6 months and death occurs within the first two years of life. 
Recent data suggest a mean age of survival of ~7 months for an SMA type I patient 
(Rudnik-Schoneborn et al. 2009, in press). In rare cases, the symptoms may begin 
prenatally (in the third trimester). Werdnig-Hoffmann disease is the most common form 
of SMA and accounts for about 50% of patients diagnosed with spinal muscular atrophy 
(Markowitz et al. 2004). Besides a generalized muscle weakness (“floppy infants”) the 
affected children suffer from hypotonia and are never able to sit unaided. The patients 
show symmetrical flaccid paralysis and no control of head movement. Typical for SMA 
type I patients is the paradoxical breathing (inward bony thorax movement with outward 
abdominal movement during inspiration) and a bell-shaped upper torso, which is due to 
their spared diaphragm, combined with weakened intercostal muscles. The bulbar 
denervation results in characteristic tongue fasciculation and weakness with poor suck 
and problems in swallowing. The increased risk of aspiration pneumonia is an important 
cause of morbidity and mortality. In 1995, it was postulated that 8% of affected children 
reach the tenth year of life (Zerres and Rudnik-Schoneborn 1995). However, that study 
might have included non SMN1-linked patients, since at that time SMN1 had not yet 
been identified.  
 
1.1.1.2 SMA type II (intermediate form, MIM #253550) 
Affected children with SMA type II show first disease symptoms after six, but before 18 
months of life. SMA type II is of intermediate severity and patients are able to sit 
independently but never learn to walk and need support to stand. Life expectancy is 
reduced, but usually children do not die before the age of two years and more than 70% 
grow older than 20 years. Surgical or orthotic intervention is required to correct the often 
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developing kyphoscoliosis. Frequent symptoms are also fine tremors with digit extension 
or hand grips. Comparable to patients with type I disease, clearing of tracheal secretions 
and coughing might become difficult because of poor bulbar function and weak 
intercostal muscles. A very frequent cause of death during adolescence is respiratory 
insufficiency. 
 
1.1.1.3 SMA type III (Kugelberg-Welander, MIM #253400) 
A less severe form of SMA was for the first time reported in the year 1956 by Kugelberg 
and Welander (Kugelberg and Welander 1956). 
 The so called juvenile SMA is quite variable in its age of onset, but generally first 
symptoms of SMA type III occur after the 18th month of life. Depending on the exact age 
of onset, SMA type III is divided into two subtypes: if first symptoms are diagnosed 
before the age of three years, the disease is called type IIIa, if the patient is older than 
three years he or she SMA bears type IIIb (Zerres and Rudnik-Schoneborn 1995). This 
juvenile form of SMA is very heterogeneous as some affected individuals may need 
wheelchair assistance in childhood, whereas others may continue to walk throughout 
their whole lives. A quiet common orthopedic feature of this progressive form is the 
development of scoliosis. 
 
1.1.1.4 SMA type IV (adult SMA, MIM #271150) 
The first symptoms of this adult form of SMA typically occur in the second or third 
decade of life (Wirth 2002). The patients are comparatively mildly affected and have a 
normal life expectancy. No respiratory problems are observed and affected individuals 
are able to walk in adult years. 
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1.2 The molecular basis of proximal spinal muscular atrophy (SMA) 
The identification of the SMA disease causing gene started in the year 1990, when 
scientists succeeded in mapping SMA patients of type I, II, and III by linkage analysis to 
a region of about 10 cM on chromosome 5q11.2 - q13.3 (Brzustowicz et al. 1990; Gilliam 
et al. 1990; Melki et al. 1990). A few years later the development of many new 
polymorphic markers enabled the researchers to narrow down the initial quite large 
interval to a critical disease region of less than 1 Mb (DiDonato et al. 1994; Melki et al. 
1993; Melki et al. 1994; Soares et al. 1993; Wirth et al. 1995; Wirth et al. 1994). This 
newly identified region contained a highly complex unstable sub-region of about 500 kb, 
which was subjected to intrachromosomal rearrangements, including gene duplications, 
gene conversions, and de novo deletions (Lefebvre et al. 1995). This complex genomic 
organization considerably hindered the researches  to construct a uniform physical map 
(Lefebvre et al. 1995; Melki et al. 1994; Roy et al. 1995a; Roy et al. 1995b; Thompson et 
al. 1993).  
Finally in the year 1995, the survival  motor neuron gene (SMN) was identified as 
the disease-causing gene by the use of a human fetal brain cDNA library (Lefebvre et al. 
1995).  
Today it is well-known that the genomic SMA region is prone to de novo 
rearrangements, including unequal crossovers, intrachromosomal rearrangements, and 
gene conversions (Melki et al. 1994; Wirth et al. 1997). In this critical 500 kb SMA 
segment five genes have been identified: the survival of motor neuron gene (SMN); the 
BIRC1 (baculoviral IAP repeat-containing 1) gene, also known as NAIP (neuronal 
apoptosis inhibitory protein); the SERF1 (small EDRK-rich factor 1) gene, also known as 
H4F5, the GTF2H2 (general transcription factor IIH) gene or p44; and the OCLN 
(occludin) gene (Lefebvre et al. 1995; Schmutz et al. 2004) (see Figure 3). This dynamic 
500 kb genomic SMA region can be present in 0 to 4 copies per chromosome 5 and is 
flanked by the single-copy genes RAD17 (proximal) and BDP1 (also known as TFNR) 
(distal) (Kelter et al. 2000; von Deimling et al. 1999).  
 
 
Figure 3 Schematic overview of the genomic SMA region on chromosome 5q13. Many genes in 
the vicinity of the SMN genes are duplicated and inverted. 
Introduction 
 
 
9 
1.2.1 The SMN gene 
Lefebvre and colleagues identified the SMA disease-determining gene called survival 
motor neuron gene (SMN) in the year 1995 (Lefebvre et al. 1995). Two copies of the 
SMN gene are located in the genomic SMA candidate region: the telomeric (SMN1) and 
the centromeric (SMN2) duplicate (Lefebvre et al. 1995). These gene copies are almost 
identical except for five silent nucleotide differences not affecting the amino acid 
sequence: one each in exon 7 (840C→T, codon 280, nt position 27141), exon 8 (nt 
position 27869) and intron 6 (nt position 27092) and another two in intron 7 (nt positions 
27289 and 27404), respectively (see Figure 4) (Burglen et al. 1996; Lefebvre et al. 
1995). To date there have several other gene variants been described, but discrimination 
between SMN1 and SMN2 has not been possible, since these variants have been found 
in both gene copies (Brahe et al. 1996; Hahnen and Wirth 1996; Monani et al. 1999).  
The SMN gene has a size of 28 kb on genomic level and consists of 9 exons (1, 
2a, 2b-8) and 8 introns with an open reading frame of 882 bp (294 codons) (Chen et al. 
1998; Lefebvre et al. 1995). The ~1.5 kb SMN transcripts are expressed in all somatic 
tissues and encode a 294 amino acid protein of 38 kDa (Lefebvre et al. 1995). The 
expression level is ~50-fold to 100-fold higher in spinal cord as compared to other 
tissues (Coovert et al. 1997; Lefebvre et al. 1997). Interestingly, the SMN protein is very 
highly conserved from yeast to man (Miguel-Aliaga et al. 1999; Paushkin et al. 2000; 
Schrank et al. 1997). On an evolutionary background, the SMN gene duplication 
occurred for the first time in primates and therefore took place after the split of primates 
from rodents, since mice and rats have only one copy namely Smn. Nevertheless, the 
gene copy SMN2 is unique to humans, since chimpanzees never carry this converted 
gene despite having multiple SMN gene copies in their genome (Rochette et al. 2001). 
Over 98% of patients with spinal muscular atrophy have a homozygous SMN1 
deletion, rearrangement, or mutation (Hahnen et al. 1995; Lefebvre et al. 1995). All these 
patients, however, retain at least one copy of SMN2, which undergoes alternative 
splicing and produces mainly a truncated mRNA isoform, which lacks exon 7 (major 
product) or exon 5, or both (see 1.2.2). In these individuals the loss of the SMN1 gene 
causes SMA, while the severity of the SMA phenotype inversely correlates with the 
number of SMN2 copies (Lefebvre et al. 1995; Wirth 2000). In very rare cases some 
individuals are protected from developing SMA, although they lack SMN1. These 
persons express the only known fully protective modifier of SMA, namely Plastin 3 
(Oprea et al. 2008). 
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Figure 4 Schematic representation of the genomic structure, nucleotide and splicing differences 
between SMN1 and SMN2. The SMN gene copies can be distinguished by 5 nucleotide 
exchanges of which only the C  T transition in exon 7 (marked in red) lies within the coding 
region. The nucleotide exchange in exon 7 is a translationally silent mutation. Therefore full-length 
SMN1 and SMN2 mRNA encode identical proteins of 294 amino acids. However, the CT 
transition affects an exonic splicing enhancer and/or silencer causing alternative splicing of SMN2 
pre-mRNA. SMN2∆7 transcripts produce a truncated and unstable protein. 
 
1.2.2 The SMN transcript 
Although the SMN1 and the SMN2 gene encode for an identical protein, they differ in 5 
nucleotide exchanges, all of which are translationally silent. SMN1 produces almost 
exclusively full length transcripts, whereas because of the C to T transition at position +6 
in exon 7 of SMN2, 90% of the SMN2 transcripts are alternatively spliced lacking exon 7 
(∆7-SMN2). Only 10% of SMN2 pre-mRNA produce full length transcripts (FL-SMN2). 
The first stop codon of the FL-transcripts is located at the end of exon 7; hence these 
transcripts are translated into a FL-SMN protein consisting of 294 amino acids. The ∆7-
SMN2 transcripts lack exon 7 and therefore encode a truncated SMN protein of only 282 
amino acids. The skipping of exon 7 leads to the use of an alternative stop codon located 
in exon 8, therefore a truncated protein is generated, which C-terminally lacks 16 amino 
acids encoded by exon 7 but instead contains four amino acids encoded by exon 8. This 
shortening of the protein reduces its oligomerization capacity and decreases its stability. 
Thus, the appropriate protein function of SMN is severely reduced (Lorson and Androphy 
2000; Lorson et al. 1998). 
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Furthermore, it has been shown that both SMN genes are able to produce three more 
transcripts. One alternative transcript is the ∆3-SMN, which lacks exon 3, another one is 
∆5-SMN lacking exon 5 and, additionally, there are SMN mRNA occurring which lack 
both, exon 5 and exon 7 (∆5,7-SMN) (Chang et al. 2001; Gennarelli et al. 1995; Singh et 
al. 2006). 
 At a closer look on the splicing function of the SMN protein, the ∆3-SMN protein 
reveals an interesting feature of the Tudor domain, which is located in exon 3 of SMN. 
Researchers have proven that the disruption of this respective domain reduces the ability 
of SMN to interact with the Sm (Smith antigen) proteins, which is essential for the 
splicing involvement of the SMN protein (Buhler et al. 1999; Mohaghegh et al. 1999; Sun 
et al. 2005) (see also protein function of SMN chapter 1.2.3.1). 
 Focusing on the SMN pre-mRNA splicing, it is necessary to mention the C to T 
transition in SMN2 exon 7 again. This particular nucleotide exchange lies directly within 
an exonic splicing enhancer (ESE) (Lorson and Androphy 2000; Lorson et al. 1999). It 
destroys a heptamer motive, which is normally (in the case of SMN1) recognized by the 
splicing factor SF2/ASF (splicing factor 2 (SF2), a positive splicing factor that is also 
known as the alternative splicing factor (ASF)) (Cartegni and Krainer 2002). The hence 
resulting alternative splicing produces a transcript lacking exon 7. A concurring 
hypothesis instead postulates that the C to T transition forms a new exonic splicing 
silencer (ESS), which recruits the splicing factor hnRNP A1, and that this leads to the 
exclusion of exon 7 (Kashima and Manley 2003). 
 The splicing pattern of the SMN2-pre-mRNA is subjected to the influence of 
different splicing factors. It has been shown in in vivo splicing experiments that the SR-
like splicing factor SFRS10 (Serine/Arginine rich splicing factor 10; formally known as 
hTra2-β1, the human homolog of transformer-2 from Drosophila melanogaster) 
specifically binds to a GA-rich region, a second ESE in the central part of SMN exon 7. 
Overexpression of SFRS10 restores the alternative splicing pattern of SMN2, so that 
80% of full length transcripts are produced (Hofmann et al. 2000). 
 Both splicing factors SF2/ASF and SFRS10 interact specifically and directly with 
exon 7 of the SMN pre-mRNA (Cartegni and Krainer 2002; Hofmann et al. 2000). 
Splicing factors like SRp30 and hnRNP-G act on the exon 7 inclusion via binding to 
SFRS10 (Bose et al. 2008; Helmken and Wirth 2000; Hofmann and Wirth 2002; Young 
et al. 2002). The splicing factor SF2/ASF is interacting with the U2 class of small nuclear 
ribonuclear protein (U2 snRNP) and its auxiliary factor (U2AF) at the branch point 
located in intron six to support removal of the intron and successful pre-mRNA splicing 
during SMN1 transcription (Cartegni and Krainer 2002). A detailed description of the 
splicing process of SMN pre-mRNA is given in Figure 5. 
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Furthermore, several chemical compounds were found to influence the splicing 
pattern of SMN2. Previously it was shown in a lymphoblastoid cell line for sodium 
butyrate to increase the FL-SMN2 level 4-fold by forcing the inclusion of exon 7 (Chang 
et al. 2001). In the following years the capability to boost full-length levels of  transcripts 
was proven in fibroblast cultures for Aclarubicin (Andreassi et al. 2001) and in our 
laboratory for valproate (Brichta et al. 2003). 
 
 
Figure 5 Pre-mRNA splicing of SMN1 and SMN2 
In SMN1, an exonic splicing enhancer (ESE), which contains the nucleotide cytosine (C) at 
position six in exon seven (Ex7+6), is recognised by splicing factor 2 or alternative splicing factor 
(SF2/ASF), which interacts (thick black arrow) with the U2 class of small nuclear ribonuclear 
protein (U2 snRNP) to remove intron six. Other splicing factors (e.g. SFRS10) determine splicing 
through interactions (thin black arrow) with ESE elements found centrally within exon seven. 
Serine and arginine (SR)-rich proteins might also exert a positive splicing effect. In SMN2, the 
ribonucleotide uridine (transcribed from thymidine) at Ex7+6 favours exon seven exclusion by 
binding to heterogeneous nuclear ribonuclear protein (hnRNP) A1, a negative splicing factor. 
Moreover, SF2/ASF no longer recognises this sequence motif. Binding of hnRNP A1 is also 
believed to prohibit U2 snRNP binding to the branch point, which results in about 90% of SMN2 
final mRNA transcripts with no exon seven. The positive splicing factors downstream (thin black 
arrow) are functioning and could account for exon 7 inclusion in about 10% of SMN2 transcripts. 
(taken from (Lunn and Wang 2008)) 
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1.2.3 The SMN protein 
The SMN protein, 38 kDa in size, consists of 294 amino acid and is found in virtually all 
cells of the human body (Carvalho et al. 1999; Lefebvre et al. 1995; Liu and Dreyfuss 
1996; Young et al. 2001; Young et al. 2000). The full-length SMN protein localizes both 
in the nucleus and the cytoplasm. Immunostaining of various cell types revealed a 
diffuse cytoplasmic distribution of SMN, while it is found in bright dot-like structures in the 
nucleus (Burlet et al. 1998; Coovert et al. 1997; Liu and Dreyfuss 1996). These SMN-
containing structures are often observed in close proximity to or completely overlapping 
with the coiled bodies [also Cajal bodies; nuclear domains that are enriched in 
spliceosomal U snRNPs (Fakan et al. 1984)], and therefore are termed gemini of coiled 
bodies (gems) (Liu and Dreyfuss 1996; Liu et al. 1997; Young et al. 2000). 
Another isoform of SMN consisting only of exons 1-3 and a part of intron 3 is only 
observed in axons (aSMN) (Setola et al. 2007).  
Since the SMN protein possesses diverse functions in many different 
environments, its functions are subsequently subdivided into a) housekeeping functions, 
b) neuron specific functions and c) muscle specific functions:  
 
1.2.3.1 Housekeeping functions of SMN 
 
o Biogenesis of snRNPs (pre-mRNA splicing) 
The so called small nuclear ribonucleoproteins (snRNPs) play an important role in every 
cell. The snRNPs are active in recognizing and removing introns from pre-mRNAs in the 
nucleus. Every snRNP is comprised of a small nuclear RNA (snRNA) and a protein part. 
The protein part is made of a number of specific proteins that are unique for each snRNP 
and the so called Sm (Smith antigen) proteins. The Sm proteins are essential for the 
splicing process. SMN plays here an important role in assembling Sm proteins onto the 
snRNAs to produce an active snRNP particle (Eggert et al. 2006; Gubitz et al. 2004; 
Pellizzoni 2007; Raker et al. 1999). Therefore, the SMN protein acts in an active complex 
in the cytoplasm of every cell. This so called “SMN complex” is composed of SMN, 
GEMIN2–8 and UNR-interacting protein (UNRIP). SMN protein itself is acting as an 
oligomer as it has been found to self-associate, and it has been suggested that 
oligomerization is crucial for SMN function (Lorson et al. 1998; Pellizzoni et al. 1999). 
The exact numbers of SMN monomers in an SMN complex is unknown, it has been 
shown to form higher-order complexes ranging from 20S to 80S and has been proven to 
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be impaired in SMN mutants of SMA patients (Lorson et al. 1998; Paushkin et al. 2002; 
Pellizzoni 2007; Pellizzoni et al. 1999). 
 
o Transcription 
The SMN protein was shown to interact with its exon 6 with mSin3a (Zou et al. 2004). 
mSin3a is a well known transcription corepressor that is involved in histone deacetylation 
and chromatin remodelling. SMN and the mSin3a protein are involved in the formation of 
a protein supra-complex exceeding 40,000 kDa in size (Zou et al. 2004). Since mSin3a 
associates with histone deacetylases and methytransferases and other proteins known 
to regulate chromatin remodelling (Yang et al. 2003), it has been postulated that SMN 
might be involved in the transcriptional repression of critical genes in motor neurons, via 
mSin3 associated histone modification enzymes (Zou et al. 2004). 
 
o Stress response 
If a cell is exposed to environmental stress such as heat shock, exposure to relevant 
chemical compounds or to UV irradiation, it starts a protective cellular process called 
“stress response“. While specific stress-induced genes are activated in response to 
stress most other genes are silenced. It has been shown that ~50% of total mRNA 
transcripts are actively recruited and dynamically sorted into cytosolic compartments 
forming the so-called stress granules (SGs) (Kedersha et al. 1999). This process has 
been shown to be dependent on the eukaryotic initiation factor (eIF) 2α and its 
phosphorylation status (Clemens 2001a, b). The SGs have been proven to serve as 
transient local storage compartment for mRNAs under stress conditions (Nover et al. 
1989). Interestingly, it has been observed that the SMN protein co-localizes and interacts 
with T-cell internal antigen-1 (TIA-1) and TIAR (TIA-1-related protein), which are known 
RNA-binding proteins that accumulate in SGs (Hua and Zhou 2004). It has been stated 
that SMN granules can be seen as stress granules (Hua and Zhou 2004). This suggests 
that SMN contributes to formation and function of SGs.  
 
o Translation regulation 
Since SMN is known to be involved in mRNA localization and transport along the axons, 
SMN is widely discussed to be involved in translational regulation. It has been shown 
that the fragile X mental retardation syndrome protein (FMRP), which plays an important 
role in transport of mRNPs and in their translation, interacts with SMN. Therefore, it has 
been discussed that SMN may have a specific function in regulating translation in 
neurons (Piazzon et al. 2008). 
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1.2.3.2 Neuron specific functions of SMN 
 
o Axonal mRNA transport 
For the C-terminal exon 7 of SMN was shown that it contains a sequence motif, which is 
responsible for the cytoplasmic localization of the SMN protein. The overexpression of 
an exon-7 deletion mutant was characterized by nuclear accumulation of SMN and 
reduced neurite outgrowth. An active transport of SMN granules to developing neurites 
and growth cones was observed, indicating an involvement of SMN in axonal transport of 
mRNA and mRNA binding proteins (Zhang et al. 2003). Recently, a novel isoform of 
SMN was identified, called a-SMN (axonal SMN). This isoform consists of exons 1-3 and 
a part of intron 3  of SMN and is exclusively found in axons of motor neurons (Setola et 
al. 2007). a-SMN, preferentially encoded by SMN1, stimulates motor neuron 
axonogenesis and induces axonal-like growth in non-neuronal cells (Setola et al. 2007). 
 
o Neurite outgrowth 
Not only the axonal isoform of SMN (a-SMN) plays an important role in neurite outgrowth 
(see chapter above), but also the selective overexpression of the SMN C-terminal 
domain has been shown to induce neurite outgrowth similar to full length protein and 
could rescue SMN knock-down effects. Furthermore, it has been stated that knock-down 
of endogenous SMN led to a significant change in the G-/F-actin ratio, indicating a role 
for SMN in actin dynamics. In regard to these observations, SMN might be involved in 
microfilament metabolism in axons of motor neurons (van Bergeijk et al. 2007). 
 Moreover, the knock-down of Smn in zebrafish embryos has been shown to lead to 
an earlier branching of axons, underlining the important role of Smn in motor axon–
specific pathfinding and in motor axon development (McWhorter et al. 2003). 
Overexpression of the recently identified protective modifier of SMA, Plastin-3, has been 
observed to rescue this axonal phenotype by restoring the axonal length of motor axons 
(Oprea et al. 2008).  
 
o Neuromuscular junction formation 
Neuromuscular junctions (NMJ) are the synapses of the axon terminal of a motor neuron 
with the motor endplate of a muscle. The neurotransmitter acetylcholine passes the 
signal through the neuromuscular junction to the motor endplate. In an SMA mouse 
model in which Smn protein levels are severely reduced, the maturation of the NMJs was 
shown to be seriously impaired. Reduced Smn level has been shown to lead to an 
impairment of the maturation of acetylcholine receptor (AChR) clusters into pretzel-like 
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structures. Furthermore, pre-synaptic defects, such as poor terminal arborization have 
been observed. The described NMJ malformations have been postulated to lead to 
functional deficits at the NMJ characterized by intermittent neurotransmission failures 
(Kariya et al. 2008). Moreover, a recent publication indicated a severely disturbed 
synaptic vesicle release at NMJs in an SMA-like mouse model (Kong et al. 2009). 
 
 
1.2.3.3 Muscle specific functions of SMN 
 
o Myoblast fusion, sarcomeric Z-disc localization 
Although SMA is a neuromuscular disease affecting primarily the motor neurons and, as 
a secondary effect, the muscles leading to atrophy, features like scattered hypertrophic 
type I fibers, significant necrosis, lipid accumulation or connective tissue proliferation, are 
rarely found in older SMA patients, suggesting a secondary myopathic process. 
 Therefore, several studies searched for a muscle specific role of SMN. Indeed, 
some functions may be specific for this tissue, but these findings are still subject to 
discussions. One work has proven that the knock-down of Smn in myoblasts led to 
severe defects in myoblast fusion and an abnormal myotube morphology (Shafey et al. 
2005). Another publication revealed that the whole Smn protein complex is localized to 
the sarcomeric Z-disc and is a direct target of calpain-3-mediated proteolytic cleavage 
(Walker et al. 2008). 
 Noteworthily, the hypothesis that SMA might be caused by a muscle specific 
reduction of SMN was rebutted by the finding that neuronal specific expression of SMN 
in a Smn knock-out mouse rescues the phenotype, whereas the muscle specific 
expression does not (Gavrilina et al. 2008a). 
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1.3 SMA animal models 
Since humans are the only known species carrying an SMN2 gene copy, all animals 
used to model SMA have only one endogenous Smn gene that is equivalent to SMN1. 
Supporting the importance of SMN, in all organisms, loss of Smn leads to lethality. 
Nevertheless, the levels of maternal Smn (Smn derived from the mother’s Smn gene as 
opposed to the embryo’s) defines the time point of lethality. In Smn knock-out mice for 
example, there is only a minimal amount of maternal Smn leading to an early embryonic 
lethality (Schrank et al. 1997). In contrast to mice, in the egg-laying animal D. 
melanogaster death occurs later, when the maternal Smn level drops below a crucial 
point (Chan et al. 2003). The resulting hypothesis that loss of SMN in a specific tissue in 
conditional Smn mutants results in the death of that tissue was proven by different 
approaches (see chapter 1.3.1.3) (Cifuentes-Diaz et al. 2001; Frugier et al. 2000; Vitte et 
al. 2004). 
1.3.1 SMA mouse models 
To analyze the pathomechanism of SMA, many different SMA mouse models have been 
generated over the past years. Mice carry only one Smn gene, which is equivalent to the 
human SMN1, and lack another copy comparable to the human SMN2 (DiDonato et al. 
1999; DiDonato et al. 1997; Viollet et al. 1997). In the following chapters, different SMA 
mouse models will be highlighted. 
1.3.1.1 Classic knock-out of murine Smn 
Already in 1997, Schrank and co-workers described the first classical knock-out of the 
murine Smn gene. The researches disrupted exons 2-4 of the Smn gene and observed 
early embryonic lethality before implantation between day E2.5 and E3.5. The analyzed 
blastocysts and morulae have revealed a disorganized, multicystic structure with 
extensive cellular degeneration (Schrank et al. 1997). 
 In the year 2000, the group of Li genetically replaced a 1.6 kb fragment of the Smn 
gene including exon 7 with a HPRT (hypoxanthine phosphoribosyltransferase) cassette 
and observed normal embryos at E3.5 but not at E6.5, indicating an essential role of 
Smn in the embryonic development (Hsieh-Li et al. 2000). 
 Heterozygous Smn+/--mice showed no symptomatic muscle atrophy, but a ~50% 
reduction of the Smn protein level and a resulting degeneration of the α-motor neurons 
after 6 months of life (Jablonka et al. 2000). 
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1.3.1.2 SMN2 transgenic mice modeling an SMA phenotype 
Since the homozygous ubiquitous knock-out of the endogenous Smn gene leads to early 
embryonic lethality, researchers tried to mimic SMA in mice by additionally integrating 
copies of the human SMN2 gene. In the year 2000, two independent groups managed to 
generate an SMA-like phenotype in mice. Monani and co-workers integrated a 34 kb 
large BamHI fragment of human SMN2, isolated from a cosmid clone into the mouse 
genome. Mice with an Smn-/-;SMN2tg/tg genotype represent an SMA-like phenotype, with 
degeneration of α-motor neurons and resulting muscle atrophy. Comparable to SMA 
patients, the severity of the disease correlates inversely with the SMN2 copy number. 
While Smn-/-;SMN2tg/tg-mice, carrying one SMN2 copy per integrate, die between 1-8 
days, Smn-/-;SMN2tg/tg-mice with 8-16 SMN2 copies show a complete rescue of the 
phenotype (Monani et al. 2000). Hsieh-Li and co-workers integrated a BAC clone 
containing the human SMN2 gene into the murine DNA. The resulting Smn-/-;SMN2tg/tg-
mice carry 4 SMN2 copies (two per integrate), are fertile and live for about one year 
(Hsieh-Li et al. 2000). Smn-/-;SMN2tg/wt-mice show a severe form of SMA and survive for 
about 9.9 days (own observation). 
 Another mouse model resembling a milder form of SMA (SMA type III mice) is 
based on the already mentioned Monani-SMA mouse model. In a study by Arthur 
Burghes´ laboratory, researchers have introduced a transgene carrying a missense 
(A2G) mutation in exon 1 of the SMN gene into the severe SMA genetic background. 
Smn-/-;SMN2tg/tg;SMNA2Gtg/wt-mice exhibited many of the clinical and pathological 
characteristics of type III (mild) SMA, suggesting a stabilization-capacity of the truncated 
SMN protein for the low expressed full-length SMN protein amount. These mice suffer 
from motor neuron degeneration and its associated effects. They include evidence of 
motor axon degeneration, loss and sprouting, muscle atrophy, and abnormal EMG 
patterns (Monani et al. 2003). Moreover, researchers could recently show that a 
previously human SMN1 mutation (SMN(A111G)) (Sun et al. 2005), an allele capable of 
snRNP assembly, can rescue mice that lack Smn and contain either one or two copies of 
SMN2 (SMA mice). However, the SMNA111G transgene has been proven not to be able to 
rescue the SMA phenotype alone. Moreover, the normal survival of SMNA111G-high-
expressing Smn-/-;SMN2tg/tg;SMNA111Gtg/wt-mice has directly been correlated with snRNP 
assembly activity in spinal cord and the correction of snRNA levels (Workman et al. 
2009). 
  Furthermore, the transgene expression of the truncated SMN2∆7 cDNA on a Smn-/-
;SMN2tg/tg background was observed to increase the lifespan of SMA-like animals from 5 
to 14 days. This was an in vivo proof that the SMN∆7-protein has the capability to 
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associate with the SMN-protein and to stabilize the whole SMN-complex and that 
SMN∆7 has no detrimental effect on the SMA animals (Le et al. 2005). 
1.3.1.3 Conditional Smn knock-out mice 
To investigate tissue specific functions of Smn, several Cre/LoxP mediated conditional 
knock-out strains were generated. 
 With the help of a neuron-specific enolase promoter driven Cre-recombinase 
(NSE-Cre) Frugier and colleagues disrupted the endogenous Smn in neurons of mice. 
Profound motor axon but no cell body loss and muscle paralysis of neurologic origin was 
detected, the mean age of these SMA-like animals was 25 days (Frugier et al. 2000). 
 The important role of Smn in the skeletal musculature was proven by the finding 
that an α-skeletal actin promoter (HSA-Cre) driven Cre, causing a muscle specific 
deletion of Smn exon 7, which leads to muscle paralysis after 3 weeks, resulting in a 
progressive myopathy and finally death after a mean age of 33 days (Cifuentes-Diaz et 
al. 2001). 
 A liver specific deletion of Smn exon 7 led to massive iron overload in the liver of 
E16 mice, dramatic liver atrophy, dysfunction and lack of regeneration, culminating in 
late embryonic lethality (Vitte et al. 2004).  
 Neuron specific overexpression driven by a prion promoter could rescue the SMA 
phenotype in a severe SMA mouse model (genotype: Smn-/-;SMN2tg/tg , mean survival 5 
days), whereas the muscle specific expression (HAS promoter) could not (Gavrilina et al. 
2008a). This reflects the finding that SMA results from SMN depletion-mediated 
degeneration of motor neurons and is not caused by a primary muscular defect. 
1.3.2 Further SMA animal models 
The essential housekeeping function of Smn was highlighted by the finding that loss of 
Smn by gene disruption in a relatively simple organism like Schizosaccharomyces 
pombe is lethal (Owen et al. 2000; Paushkin et al. 2000). 
 RNA interference (RNAi) and knock-out experiments in the nematode (roundworm) 
Caenorhabditis elegans led to embryonic lethality and developmental defects or to 
movement defects with later knock-down of Smn in adult animals (Burt et al. 2006; 
Miguel-Aliaga et al. 1999). 
In the genetic model organism Drosophila melanogaster it was shown that 
mutations of Smn which disrupt its self-organization and which therefore can be 
considered equivalent to null alleles, lead to larval lethality or embryonic lethality if 
maternal Smn was removed (Chan et al. 2003). A mutation that causes loss of Smn  in 
the adult thorax of the fly led to loss of ability to fly and jump (Rajendra et al. 2007), 
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whereas different small interfering RNA knock-down approaches of Smn resulted in 
lethality at different stages, depending on different knockdown attempts (Chang et al. 
2008). 
Antisense morpholino knock-down of Smn in Zebrafish (Danio rerio) resulted in 
abnormal axon patterning and death (McWhorter et al. 2003). 
1.4 SMA therapy 
To date, there is no cure for SMA available. Symptomatic treatment like physical therapy 
to maintain joint mobility and to decrease the incidence of contractures and respiratory 
drainage are very important. Due to the gain of knowledge about the molecular basis of 
SMA, its underlying pathomechanism is well understood. Thus, the development of 
therapeutic approaches underwent a boost in the past years. A major aim is to prevent 
potential SMA patients from developing the disease. Besides so-called non-targeted 
strategies, which aim at the development of neuroprotective or neurotrophic agents that 
are able to protect α-motor neurons from degeneration, the unique feature of SMA, that 
every patient possesses at least one SMN2 copy-gene, capable of ameliorating the 
phenotype, is a further target of a prospective therapy. 
 An overview of the therapeutic approaches for SMA, which have been 
established until now is given in Figure 6. 
 
Figure 6 Strategies for potential spinal muscular atrophy therapy 
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 On DNA level, mainly four approaches for SMA therapy are imaginable. The 
growing field of stem cell research might one day make embryonic stem cell transfer of 
healthy donor cells a concrete opportunity (Andreassi et al. 2001; Ebert et al. 2009; 
Zhang et al. 2001). Furthermore, introduction of an SMN1 gene copy by gene therapy 
into the α-motor neurons could prevent neuronal degeneration. Since recently the SMA 
modifying factor Plastin 3 has been identified, a potential activation of this factor might 
also be a prospective therapeutic approach (Oprea et al. 2008). One variant, which takes 
advantage from the clinical benefit that SMA patients retain SMN2 copies, is to activate 
the expression of SMN2 by transcriptional activation, for example by the use of histone 
deacetylase inhibitors (Brichta et al. 2003; Garbes et al. 2009; Riessland et al. 2006) 
(see chapter 1.5.6). 
 On pre-mRNA-level, the correction of the SMN2 transcript splicing is the main 
attempt to produce higher amounts of full-length SMN2. The inclusion of SMN2 exon 7 
would lead to the production of fully functional SMN protein (Andreassi et al. 2001; Ebert 
et al. 2009; Zhang et al. 2001). 
 One discussed intervention on mRNA level is skipping of the stop codon in exon 8 
of the ∆7-SMN2 transcripts, which leads to the synthesis of a protein containing 
additional amino acids at the C-terminus, which could increase stability and 
oligomerization ability of the ∆7-SMN2 protein. Additionally, activation of the translation 
machinery would lead to higher amounts of ∆7-SMN2, which is known to stabilize the 
low-level FL-SMN2 protein (Mattis et al. 2006; Wolstencroft et al. 2005). 
 Another idea is to elevate the activity or to biochemically stabilize the functional 
FL-SMN2 protein remaining in SMA patients to improve the efficacy of processes 
catalyzed by SMN, e.g. the assembly of snRNPs and axonal mRNA trafficking (Chang et 
al. 2004; Garbes et al. 2009). 
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1.5 Epigenetic chromatin modifications 
The deoxyribonucleic acid (DNA), which comprises the genetic material and possesses 
the long-term storage function of information, exists in the nucleus as a complex with 
proteins, the so called chromatin. The DNA is tightly packed in the chromatin. The DNA-
double helix which has a diameter of 2 nm is in ~200 bp (base pairs) wrapped around a 
histone-octamere; this resembles the 10 nm fiber. If a histone H1 attaches to this fiber, 
the DNA becomes more densely packed and the 30 nm fiber is built. The 30 nm fiber is 
in turn attached to a protein matrix, which forms a further condensed chromatin structure 
(overview of the DNA packaging is given in Figure 7). 
 
 
Figure 7 Eukaryotic packaging of DNA in the nucleus. DNA is associated with histone and non-
histone proteins to form a highly folded, complex structure called chromatin (Felsenfeld and 
Groudine 2003). 
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 The already mentioned histone proteins play a crucial role in the DNA packaging 
process. Histones are basic proteins which exist in mainly five different types in each 
animal or plant cell: H1, H2A, H2B, H3 and H4. In principle, each histone resembles a 
similar structure. Histones possess a central globular domain and a flexible 
aminoterminal and frequently a carboxyterminal tail. A characteristic feature of the 
histone amino acid-sequence is its high frequency of the basic amino acids lysine and 
arginine. Histones H2A and H2B form dimers with themselves, which in turn assemble 
with a tetramer consisting of two H3 and two H4 proteins, resulting in the formation of a 
histone-octamer. Because of its negatively charged phosphate-backbone, the DNA 
attaches tightly to the histone-octamers and forms a so-called nucleosome. When the 
nucleosome assembles with the histone H1 the above described 30 nm fiber is formed 
(Gruss and Knippers 1996; Kornberg and Klug 1981; Kornberg and Lorch 1999). 
 There is a series of posttranslational modifications of histones such as 
phosphorylation, methylation, ubiquitylation or acetylation, which generate the dynamic 
state of chromatin. In the following, the histone-acetylation will be described in more 
detail. Specific enzymes, the histone acetyltransferases (HAT), are able to attach acetyl-
groups derived from acetyl-coenzyme A to up to four lysine-residues of the histones 
H2A, H2B, H3 and H4. The acetyl-group is transferred to the positively charged ε-amino 
group of the side chain of lysine residues of histone tails. Thus, the charge is neutralized 
and the affinity of the DNA to the histones is severely reduced. Hence the chromatin 
packaging is loosened and the DNA is accessible for protein factors involved in 
transcription, replication, recombination or repair processes (Eberharter and Becker 
2002; Kornberg and Lorch 1999). The antagonists of the histone acetyltransferases 
(HAT), which activate transcription are the histone deacetylases (HDAC), which remove 
the acetyl-groups from lysine groups of the histones and therefore repress the gene 
transcription (see Figure 8). 
 
 
Figure 8 The antagonistic functions of histone acetyltransferases and histone deacetylases 
(adapted from (Graul et al. 2007)). 
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Based on their sequence homology to yeast orthologues Rpd3 (reduced potassium 
dependency 3), HdaI (histone deacetylase A) and Sir2 (Silent mating type Information 
Regulation-2), respectively, mammalian HDACs are grouped into class I, class II, class 
III and class IV (de Ruijter et al. 2003; Gregoretti et al. 2004). The so-called ‘‘classical” 
HDACs  comprise 11 family members of class I, II, and IV (see Figure 9), whereas class 
III members are named sirtuins (Gregoretti et al. 2004). The sirtuins and the classical 
HDACs mainly differ in their catalytic mechanisms. While classical HDACs are Zn2+-
dependent enzymes harboring a catalytic pocket with a Zn2+ ion at its base, sirtuins have 
a different mechanism of action requiring NAD+ as an essential cofactor (de Ruijter et al. 
2003).  
As previously described, high HDAC activity is associated with condensed, 
transcriptionally inactive chromatin. In addition to this epigenetic function of HDACs, it 
has recently been recognized that certain HDACs also exhibit important cytoplasmatic 
function by controlling the acetylation status and function of numerous cytoplasmatic 
proteins and transcription factors. Thus, the more precise term for these respective 
enzymes would be ‘‘lysine deacetylases” to indicate that their substrates are not 
restricted to histone proteins (Yang and Seto 2008). 
Since HDACs and the chemical inhibition of these enzymes are the major topic of 
this work, the different classes of classical HDACs will be discussed in detail in the 
following. 
 
1.5.1 Class I histone deacetylases 
Class I includes HDACs 1, 2, 3, and 8. These enzymes are related to yeast deacetylase 
RPD3 (reduced potassium dependency 3) and show homologous catalytic sites. HDAC1, 
2 and 3 are known to be part of multiprotein nuclear complexes that are involved in 
transcriptional repression. HDAC1 and 2 are observed to be components of the co-rest 
complex, which inactivates the expression of neuronal genes in non-neuronal tissues 
(Huang et al. 1999). Since HDAC3 was found within the N-COR and SMRT repressor 
complex, this family member is clearly involved in controlling gene expression (Wen et 
al. 2000). So far class I member HDAC8 has not been found to be a component of any 
repressor complex, although it possesses similar biological attributes (e.g. domain 
organization etc.) suggesting a particular function for this class I HDAC. The selective 
inhibition of HDAC8 was recently shown to induce apoptosis in T-cell lymphoma or 
leukemia cell lines and to induce neuronal differentiation, inhibition of proliferation, and 
decreased clonogenic growth in neuroblastoma cells (Balasubramanian et al. 2008; 
Krennhrubec et al. 2007). 
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1.5.2 Class IIA histone deacetylases 
Class IIA HDACs possess only one catalytic domain, whereas family members from 
class IIB possess two. Class IIA consists of the family members HDAC4, 5, 7, 9, which 
typically incorporate a large, functionally important N-terminal domain, which is involved 
in nuclear-cytoplasmic shuttling and specific DNA-binding. Each HDAC from class IIA 
contains three conserved 14-3-3 binding sites, additionally the endogenous nuclear 
import and export signals control the cellular trafficking of these HDACs. If the 14-3-3 
proteins bind to these respective HDACs, their cytoplasmatic retention or nuclear export 
is phosphorylation dependently stimulated. This process in turn can regulate the activity 
of transcription factors like the myocyte enhancing factor-2 (MEF2) (Yang and Seto 
2008). 
1.5.3 Class IIB histone deacetylases 
As already mentioned in contrast to the class IIA enzymes, HDACs of class IIB carry two 
tandem deacetylase domains and a C-terminal zinc finger. The two members of class IIB 
are HDAC6 and HDAC10. Interestingly, HDAC6 seems to play important roles in 
deacetylating cytoplasmic targets such as α-tubulin (Hubbert et al. 2002) or heat shock 
protein 90 (HSP90) (Kovacs et al. 2005). Involved in these functions it was shown that 
HDAC6 can influence cell adhesion, motility and chaperone function. Besides its 
deacetylase activity, HDAC6 may function by binding to ubiquitin via its zinc finger 
domain and therefore regulate aggresome function, autophagy, heat shock factor-1 
(HSF-1) and the function of platelet derived growth factor (PDGF) (Kawaguchi et al. 
2003; Pandey et al. 2007). Although HDAC10 is structurally closely related to HDAC6, 
there is not much known about its function. 
1.5.4 Class IV histone deacetylase 
The only family member of class IV is HDAC11. This HDAC is structurally related to 
discussed classes, class I and II. Very little is known about its expression profile and its 
cellular function.  
 
1.5.5 Histone acetyltransferases (HATs) 
Compared with the HDACs, proteins with histone acetyltransferase (HAT) activity show a 
higher diversity (Carrozza et al. 2003; Roth et al. 2001). Like the deacetylation function 
of HDACs, which is not restricted to histones, also some HATs are able to acetylate non-
histone proteins (Kouzarides 2000; Sterner and Berger 2000). This finding was first 
described in 1997 when p53 was found to be acetylated at specific lysine residues in its 
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C-terminus (Gu and Roeder 1997). On the other hand, not all of the proteins which 
possess lysine acetyltransferase activity are able to acetylate histones (Yang 2004), 
therefore those enzymes are more generally termed lysine acetyltransferases (LATs). 
The classification of HATs led to the subdivision into the following families: Hat1, 
Gcn5/PCAF, p300/CBP, MYST, p160, CIITA, ATFII; TAFII250, TFIIIC, Elp3, CDY, TFIIB, 
MCM3AP, Eco1, and ARD1 (Yang 2004). Nevertheless, the vast majority of proteins 
known to be modified by LATs are histones and transcriptional regulators. However, 
many different cellular proteins have been shown to be acetylated by LATs, these 
substrates include the signaling regulator Smad7 (Gronroos et al. 2002), DNA metabolic 
enzymes (Hasan et al. 2001; Tini et al. 2002), and α-tubulin (Doenecke and Gallwitz 
1982). Since HATs may act in different mulitprotein-complexes the mode of LAT function 
is quite complex and not completely understood (Yang 2004). 
 
1.5.6 Histone deacetylase inhibitors 
Since the activity of HDACs in general reduces the transcription rate, it is evident that the 
inhibition of HDACs could up-regulate the transcription level. Inhibition of HDACs would 
lead to acetylation of histones, thus the affinity of the DNA to the histones is reduced and 
the chromatin structure loosened up and so-called ATP-dependent chromatin 
remodelling complexes have access to the DNA. These protein complexes uncover 
promoter regions of the DNA, at which the transcription finally starts (Eberharter and 
Becker 2002). 
It was shown that some chemical compounds are capable of inhibiting the activity 
of HDACs. Thus, these compounds were named histone deacetylase inhibitors (HDACi). 
Since it was proven that HDACis are indeed able to up-regulate the transcription level 
(Strahl and Allis 2000), and that HATs and HDACs play an important role in the dynamic 
regulation of genes which are involved in cell proliferation and differentiation (Glass and 
Rosenfeld 2000; Kouzarides 2000), efforts were increased in finding new HDACis as 
potential therapeutics for genetic disorders (Pazin and Kadonaga 1997). But complete 
understanding of the mechanism which controls the transcriptional changes after HDAC 
inhibition remains still elusive. Whereas the inhibition of HDACs in a cell based 
transcription assay, by trichostatin A (TSA), only 2% of the 340 investigated genes were 
found to be differentially regulated (Van Lint et al. 1996), a more recent microarray 
approach revealed that transcription of up to 22% of genes can be altered by other pan-
HDAC inhibitors (Peart et al. 2005). The complexity of the HDACi dependent 
transcription control was underlined by subsequent studies which showed that the 
inhibition of HDAC enzymes can differentially serve to up- or down regulation of 
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expression patterns with little predictive value. Hence, these experimental results 
suggest that HDAC inhibition may up-regulate the expression of other regulatory 
enzymes and co-factors, which subsequently behave as activators or repressors of gene 
activity. 
 Some of the substances which have histone deacetylase properties are 
categorized in the following (Marks et al. 2000): 
 
 1) Short-chain fatty acids: - Phenylbutyrate (PB) 
      - Sodium Butyrate (SB) 
      - Valproic acid (VPA) 
 2) Hydroxamates:  - Trichostatin A (TSA) 
      - Suberoylanilide hydroxamic acid (SAHA) 
      - Suberic bishydroxamic acid (SBHA) 
      - m-carboxycinnamic acid bishydroxamide (CBHA) 
      - PCI-34051 (HDAC8 specific) 
      - LBH589 (Panobinostat) 
 3) Bezamides:   - M344 
      - MS-275 
 4) Cyclic tetrapeptides:  - Trapoxin A 
- Apicidin 
 5) Bicyclic tetrapeptide  - Depsipeptide (FK228) 
 
 
The HDACis bind in the catalytic pocket of the respective HDACs and thereby inhibit 
their function.  
In 2001, the first publication of an HDACi treatment study for a prospective SMA 
therapy was issued. The researchers made use of the unique feature of SMA, namely 
the presence of the modifying gene copy SMN2, and targeted its expression by HDACi 
treatment. Hence, the treatment of Epstein-Barr-Virus transformed lymphoblastoid cell 
lines derived from SMA type I, II, and III patients with sodium butyrate indeed revealed 
increased full-length SMN2 transcript and SMN protein levels (Chang et al. 2001). 
Moreover, in an in vivo model, when sodium butyrate was administered to pregnant 
mothers of SMA transgenic mice (Smn-/-; SMN2tg), it improved survival in their offspring. 
Since this first study suggested that HDAC inhibitors might be able to exert an effect on 
SMN2 expression, many attempts to up-regulate the SMN2 expression and to revert the 
splicing pattern of SMN2 followed. 
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It was shown that also the well-known epilepsy drug valproic acid (VPA) is able to 
up-regulate the FL-SMN2 transcription level and protein level in fibroblasts derived from 
SMA patients (Brichta et al. 2003). Comparable results were published on the second-
generation HDACi Suberoylanilide hydroxamic acid (SAHA), which revealed a favourable 
effect on SMN2 protein levels and expression levels in cell lines and in rat hippocampal 
slices (Hahnen et al. 2006c). 
 
 
Figure 9 Inhibitory profile of pan- and class-selective HDAC inhibitors (taken from (Witt et al. 
2009)) 
 
Since sodium butyrate and SAHA are so called pan-HDACis (“pan-“: Greek πᾶν, pan, “of 
everything“, “involving members“ of a group) and VPA predominantly inhibits 
unspecifically all HDAC members from HDAC family I, the expression of many genes 
may be regulated by their functions. Thus, it is quite obvious that pan-HDAC treatment in 
patients leads to frequent unfavorable side effects (e.g. for VPA known side effects are 
GI intolerance, sedation, tremor, asymptomatic reduction in platelet count, severe 
hepatic dysfunction, hemorrhagic pancreatitis, and agranulocytosis. Other serious side 
effects include neural-tube defects with first-trimester exposure and death from 
overdose. Platelet dysfunction, coagulopathies, and edema occur infrequently. Increased 
appetite, weight gain, and transient hair loss may occur (reviewed in (Gerstner et al. 
2008))). Furthermore, a clinical trial has recently shown that SMA patients respond 
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differentially to VPA treatment. It was observed that, for yet unknown reasons, only one 
third of VPA treated SMA patients responded by an up-regulation of SMN expression, 
whereas one third responded by a down-regulation and the last third revealed no change 
in the SMN expression level (Brichta et al. 2006a). 
The two previously described facts support the urgent need for more HDACi which 
are capable in up-regulating the SMN2 expression in SMA patients. Moreover, the 
identification of a specific HDAC which regulates the SMN2 expression might reduce 
common side effects of pan-HDACis in a prospective SMA therapy. The development of 
HDAC isoenzyme specific inhibitors is currently ongoing and of wide interest. For an 
overview of the specificity of the respective compounds, see Figure 9.
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2 Aims 
Proximal spinal muscular atrophy is the leading genetic cause of death in early 
childhood. Until now, no cure is available. The survival motor neuron gene 1 (SMN1) is 
the disease determining gene. While the disease gene SMN1 produces full length 
transcripts only (FL-SMN), the majority of transcripts derived from the copy gene SMN2 
lack exon 7 due to alternative splicing. Even though the amount of SMN2-derived FL-
SMN protein is not sufficient to countervail the loss of SMN1 and to prevent disease 
onset, SMN2 has shown to be the main disease modifying gene. Due to its disease 
modifying property, which could be confirmed using transgenic models, SMN2 became 
an interesting therapeutic target. 
 
Since transcriptional SMN2 activation or modulation of its splicing pattern to 
increase FL-SMN levels is likely to slow down disease progression, the main aim of this 
was to identify chemical compounds, namely histone deacetylase inhibitors (HDACis), to 
act in this way.  
 
In the first place, this work was concentrated on the in vitro investigation of newly 
identified second generation HDAC inhibitors. To evaluate if the new compounds are 
able to exert an effect on the human SMN2 gene in vitro, it was made use of a treatment-
assay, based on cell lines derived from SMA patients. Potential effects of the HDACis 
should be characterized in detail by analysis of SMN2 RNA and protein levels in the 
treated cell lines. 
 
Moreover the identification of the respective histone deacetylase, which controls 
the expression of SMN2 was another aspired goal of this work. The potential 
identification of a specific HDAC would raise the question for a respective specific 
inhibitor, which then should also be assessed. 
 
Finally, since our group has previously shown that the FDA-approved drug 
suberoylanilide hydroxamic acid (SAHA) is a potent and non-toxic candidate drug for 
SMA treatment, this work focussed on the in vivo characterization of this compound. 
Therefore two different SMA-mouse models were chosen and treated with SAHA. After 
finding the best treatment regimen for these animals, different outcome measurements, 
like survival time, motor abilities, SMN expression levels and histological changes in 
tissues such as motor neurons, neuromuscular junctions and muscles should be 
evaluated.  
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3 Materials and Methods 
3.1 Fibroblasts derived from SMA patients 
For all human fibroblast cell lines used in this work, a genetic analysis was carried out 
and informed written consent was given by the respective subjects or their legal 
guardians. All SMA type I, II, and III patients who donated human material fulfilled the 
diagnostic criteria for SMA (Munsat and Davies 1992) and carry homozygous deletions 
of SMN1 as determined by routine molecular diagnostic testing. The number of genomic 
SMN2 copies (SMA type I, II, and III patients; see Table 1) was determined in DNA 
isolated from an EDTA blood sample, which has been collected from the respective 
donor (for details regarding the quantitative analysis of SMN1 and SMN2 copies, see 
also chapter 3.11.11). 
 
Table 1 Human fibroblast cell lines derived from SMA patients, used in this work. 
Name of the cell line SMA type SMN1 gene copies SMN2 gene copies 
ML12 III - 3 
ML16 I - 3 
ML17 I - 2 
ML20 II - 2 
 
 
3.2 Mouse inbred strains 
Two different SMA model mouse inbred strains were used in this project: 1.) FVB.Cg-
Tg(SMN2)2Hung Smn1tm1Hung/J, subsequently entitled SMAH mouse model (purchased 
from Jackson´s Laboratory; Stock Number: 005058) In this mouse model the Smn gene 
was disrupted by the deletion of a 1.6-kb fragment at the Smn locus, including Smn exon 
7. The SMN2 transgene of this mouse model is located in a 115 kb large integrated 
BAC-clone-fragment (derived from clone C7). Importantly, the SMAH mice carry 2 SMN2 
copies per integrate. 2.) FVB.Cg-Tg(SMN2)89Ahmb Smn1tm1Msd/J (kindly provided from 
the group of Michael Sendtner (Würzburg); available at Jackson´s Laboratory, 
Stock Number: 005024), subsequently abbreviated as SMAB mouse model. In this 
mouse model the Smn gene was disrupted by the insertion of the targeting vector into 
exon 2 of the Smn gene. The SMN2 transgene of this mouse model is located in a 35.5 
kb large integrated PAC-clone-fragment (derived from clone 215P15). Importantly, the 
used SMAB mice carry 1 SMN2 copies per integrate. As a wild-type strain, the inbred 
strain FVB/NJ (Jackson´s Laboratory, Stock Number: 001800) was used.
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The SMAH mice were housed in micro-isolation chambers in the mouse facilty of 
the Institute of Genetics, Cologne. Breeding pairs consisted of one mouse that was 
homozygous for the transgene and the knock-out (SMN2tg/tg; Smn-/-) allele and the other 
mouse was heterozygous for the knock-out (Smn-/+) allele, which resulted in pups that 
display the SMA phenotype and control littermates. All mice were humanely euthanized 
according to protocols set forth by the “Landesamt für Natur, Umwelt und 
Verbraucherschutz NRW”.  
The animal breeding and all mouse experiments were approved by the local animal 
protection committee. The animal experiment application form was confirmed. All in vivo 
experiments were performed under the reference number 9.93.2.10.31.07.292. 
The SMAB mice were kept under the same conditions, but in the “Franz-Penzoldt-
Zentrum” in Erlangen. The reference number for the animal experiments performed in 
Erlangen was: 621-2531.31-18/05. 
3.3 Cell lines derived from SMA patients 
In the institute for Human Genetics in Cologne, the laboratory of Professor Dr. Brunhilde 
Wirth has access to a collection of more than 100 primary fibroblast cell lines derived 
from SMA patients, SMA carriers and controls. All fibroblast lines were obtained from 
skin biopsies. Confirmed consent is available and was approved by the local ethnic 
committee.  
 
3.4 Equipment and Chemicals 
Centrifuges:  
Allegra X22-R, Beckman Coulter 
5415 D, Eppendorf 
5415 R, Eppendorf 
 
Microplate reader: 
Safire2, Tecan 
 
Ultrasonic waterbath: 
 Bioruptor, Diagenode 
 
Heating block:  
HTMR-133, HLC 
 
Spectrophotometer:  
BioPhotometer, Eppendorf 
NanoDrop ND-1000, Peqlab 
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Cuvettes:  
UV-Vette, Eppendorf 
 
Thermocycler: 
GeneAmp 9600, Perkin Elmer 
GeneAmp 9700, Applied Biosystems 
 
Realtime thermocycler: 
 LightCycler 1.5, Roche 
 Taqman 7500, Applied Biosystems 
 
 
Agarose gel electrophoresis chamber: 
SGE-020-02, CBS Scientific 
 
pH meter:  
pH Level 1, inoLab 
 
SDS gel electrophoresis chamber: 
Mini-Protean 3 Cell, Biorad 
 
Tissue culture hood: 
Hera Safe, Heraeus 
 
Microscopes: 
Leica DMIL (inverted microscope for cell culture), Leica 
Leica TCS-SP (confocal microscope), Leica 
Axioplan 2 imaging microscop, Zeiss 
 
Power supplies: 
PowerPac 1000, Biorad 
PowerPac HC, Biorad 
High Voltage Power Pac P30, Biometra 
 
Shaker:  
3015, GFL 
VS.R23, Grant BOEKEL 
 
Imaging systems:  
Chemidoc XRS, Biorad 
Gel Doc 2000, Biorad 
 
Western Blot transfer chamber: 
Mini Trans-Blot Cell, Biorad 
 
Autoradiography cassette: 
Developer Cassette 18x24cm, Siemens 
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Developer machine:  
CURIX 60, Agfa 
 
Imaging system: 
ChemiDoc XRS, Biorad 
 
Incubator: 
Hera Cell 150, Heraeus 
 
Vibratome: 
 Vibratome® Series 1000, Pelco 
 
Infiltration System 
 Infiltrationsautomat Leica TP 1020, Leica 
 
Transfection apparatus 
 Nucleofector, Lonza 
 
Neubauer counting chamber, Optik-Labor 
 
Concentrator 5301, Eppendorf 
 
3.4.1 Chemicals 
Whenever possible, only chemicals with the purity grade “pro analysis” were used for the 
experiments described in this work. All standard chemicals and organic solvents were 
purchased from the following companies: Roche Molecular Biochemicals, Mannheim; 
Invitrogen, Niederlande, BV, Leek (Netherlands); Merk, Darmstadt; MWG, Ebersberg; 
Amersham, Freiburg; Diagenode Liège (Belgium); Promega, Mannheim; Sigma Chemie, 
Taufkirchen; Serva, Heidelberg; Stratagene, La Jolla (USA); Applichem, Darmstadt; 
Roth, Karlsruhe. For RNA isolation and analysis, only chemicals free of RNases have 
been used. 
 
3.4.2 Kits 
Custom Superscript ds-cDNA synthesis Kit, Invitrogen 
ChargeSwitch® gDNA Mini Tissue Kit, Invitrogen 
LowCell# ChIP kit, Diagenode 
Qiaex II Gel Extraction Kit, Qiagen 
QuantiTect Rev. Transcription Kit, Qiagen 
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QIAshredder, Qiagen 
RNase-Free DNase Set, Qiagen 
Quant-iT™ RiboGreen® RNA Assay Kit, Invitrogen 
Quant-iT™ PicoGreen® dsDNA Assay Kit, Invitrogen 
QIAquick PCR Purification Kit, Qiagen 
RNeasy MinElute Cleanup Kit, Qiagen 
EndoFree Plasmid Maxi Kit, Qiagen 
RNeasy Mini Kit, Qiagen 
SuperScript First-Strand Synthesis System for RT-PCR Kit, Invitrogen 
SuperSignal West Pico Chemiluminiscent Substrate Kit, Pierce 
Power SYBR® Green PCR Master Mix, Applied Biosystems 
LightCycler® FastStart DNA Master SYBR Green I, Roche 
Basic Nucleofector® Kit for Primary Mammalian Fibroblasts, Lonza 
3.4.3 Reagents, enzymes and additional supplies for cell culture procedures 
 
3.4.3.1 Reagents 
Oligo d(T) primers, # SP230, Operon 
100 bp DNA Ladder, # 15628-050, Invitrogen 
1 kb DNA Ladder, # 15615-016, Invitrogen 
Precision Plus Protein All Blue Standards, # 161-0373, Bio-Rad 
Dimethylsulfate, # D5279-05, Sigma 
Hydroypropyl-β-cyclodextran (HP-β-CD), AppliChem 
DAPI, # H-1200, Vector Laboratories Inc 
Thiazolyl blue tetrazolium bromide (MTT), Sigma  
M344 (4-Dimethylamino-N-(6-hydroxycarbamoylhexyl)-benzamide), Axxora 
SAHA, synthesized by D. Zlotos, Intitue for Pharmakology University Bonn 
FK228, kindly provided by Gloucester Pharmaceuticals 
PCI-34051, kindly provided by J.J. Buggy, AXYS Pharmaceuticals, San Francisco 
Amphotericin B, Gibco 
Dulbecco´s Modified Eagle Medium, Gibco (Invitrogen) 
Dimethylsulfoxide, Sigma 
Deoxycholacid, Sigma 
Milk powder (Instant Nonfat Dry Milk), Stop&Shop 
Fetal Calf Serum, Biochrom AG 
IGEPAL, Sigma 
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2-Propanol, Roth 
Sodiumchloride, AppliChem 
PBS: Phophate buffered saline Dulbecco, Gibco (Invitrogen) 
PenStrep (Penicillin Streptomycin), Roche 
Trypsin-EDTA soultion (1x), Sigma 
Sodiumdodecylsulfate (SDS), AppliChem 
Acrylamide: Acrylamide/Bisacrylamide 29:1 (30%), Biorad 
Ammoniumpersulfat, AppliChem 
Bromphenolblue, AppliChem 
Bovine Serum Albumin, Sigma 
SuperSignal West Pico Chemiluminescent Substrate, Pierce 
Coomassie Brilliantblau R-250, AppliChem 
Ethanol, Roth 
Gycerin 99%, AppliChem 
Glycin, AppliChem 
Methanol, Roth 
Ponceau S, Sigma 
Precision Plus Protein All Blue Standard, Biorad 
Stripping Puffer: Restore Western Blot Stripping Buffer, Pierce 
TEMED: N,N,N’,N’ – Tetramethyl-Ethylendiamin, AppliChem 
Tris: Tris-(hydroxymethyl)-Aminomethan, Roth 
Tris-Base: Tris-(hydroxymethyl)-Aminomethan, Sigma 
Tween 20: Polysorbat 20, Caelo 
β-Mercaptoethanol, AppliChem 
 
3.4.3.2 Enzymes 
RQ1 RNase-Free DNase, # M6101, Promega  
Taq DNA Polymerase Recombinant, cat. # 10342020, Invitrogen 
3.4.3.3 Additional materials for cell culture procedures 
DharmaFECTTM 1 Transfection Reagent, T-2001-03, Dharmacon 
DharmaFECTTM 4 Transfection Reagent, T-2004-03, Dharmacon 
DMSO, # D2650, Sigma 
OPTIMEM® I, # 31985, Invitrogen 
Disposable Filter Unit 0.45 µm FP30/0.45 CA-S, # 10462100, Whatman 
Disposable Filter Unit 0.2 µm FP30/0.2 CA-S, # 10462200, Whatman 
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3.4.3.4 Additional materials for laboratory mouse in vivo procedures 
Animal feeding needles 24x1’’, Harvard Apparatus 
BD Micro-Fine + U-40 Insulin syringe, BD Medical 
Hydroxypropyl-β-cyclodextrin, AppliChem 
3.4.3.5 Purchased human cDNA clones 
ORF clone of human HDAC8 #RC208390, OriGene 
clone of human HDAC2 #SC110918, OriGene 
clone of human HDAC11 #SC123846, OriGene 
3.5 Antibodies 
3.5.1 Primary antibodies 
α-SMN, monoclonal IgG1, # S55920, (BD Transduction Laboratories) 
α-β-tubulin, monoclonal IgG1, # T4026, (Sigma) 
α-β-actin, monoclonal IgG2a, (Sigma) 
c-MYC (9E11), Mouse Monoclonal Antibody – UNCONJ (Invitrogen) 
anti-SF2/ASF, monoclonal mouse (kindly provided by A. Krainer, Cold Spring Harbor 
Laboratories) 
anti β-Actin, monoclonal mouse (Sigma)  
anti-SRp20, monoclonal mouse (Santa Cruz) 
anti-SMN, monoclonal mouse (BD Transduction Laboratories) 
anti-Htra2-β1, polyclonal rabbit  
anti-cMYC, monoclonal mouse (Invitrogen) 
anti-HDAC2 (Santa Cruz) 
anti-HDAC8 polyclonal rabbit (MBL) 
anti-acetyl Histone H3 K9, monoclonal mouse (Upstate) 
anti-β-Tubulin, (Sigma) 
anti-H3K9ac polyclonal rabbit (Diagenode) 
α-bungarotoxin labeled with rhodamine (Invitrogen) 
anti-Neurofilament M (145kDa) rabbit  
anti-GADD45α monoclonal mouse (Abnova) 
3.5.2 Secondary antibodies 
Horseradish peroxidase conjugated goat anti-mouse IgG, # 115-035-000, Dianova 
Horseradish peroxidase conjugated goat anti-rabbit IgG, # 31460, Pierce  
donkey anti-rabbit Cy2 (Dianova) 
Materials and Methods 
 
 
38 
3.6 Solutions and Media 
3.6.1 Frequently used buffers and solutions 
Ammonium Persulfate (APS) solution (10%): for 10 ml: 
APS        1.0 g 
deionized H2O       to a final volume of 10 ml  
store at -20°C 
 
Blocking solution (6%):     for 100 ml: 
Nonfat dry milk      6 g 
TBS Tween buffer     to a final volume of 100 ml 
 
Bradford solution:     for 1l: 
Coomassie Brilliant Blue G250   100 mg 
H3PO4 (85%)      100 ml 
Ethanol (95%)      50 ml 
deionized H2O      to a final volume of 1 l 
store at 4°C 
 
Diethylpyrocarbonate (DEPC) treated H2O: for 1 l: 
DEPC       1 ml 
deionized H2O      to a final volume of 1 l 
mix overnight and autoclave 
(other solutions can be treated with DEPC 
in a similar way, except for Tris solutions) 
 
DNA loading buffer (10 x):    for 50 ml: 
100 mM EDTA (pH 7.2-8.5)    10 ml 0.5 M EDTA (pH 7.2-8.5) 
1% SDS       2.5 ml 20% SDS 
50% Glycerol      28.7 ml 87% Glycerol 
0.1% Bromphenol Blue    0.05 g 
deionized H2O      to a final volume of 50 ml 
 
dNTP mix:       for 1 ml: 
dNTP (100 mM)      12.5 µl of each dNTP (total volume: 50 µl) 
deionized H2O      to a final volume of 1000 µl 
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Electrophoresis buffer (10 x):   for 1 l: 
Tris-Base       30.29 g 
Glycine       144.13 g 
SDS        10.0 g 
deionized H2O      to a final volume of 1 l 
 
Ethidium bromide solution (1%):   for 100 ml: 
Ethidium bromide     1.0 g 
deionized H2O      to a final volume of 100 ml 
store at 4°C in the dark 
 
Laemmli buffer for SDS PAGE (2x):  for 100 ml: 
Tris-Base       0.757 g 
Glycerol       20 ml 
Bromphenol Blue     10 mg 
SDS        6 g 
(prior to use: β-Mercaptoethanol   10 ml) 
deionized H2O      to a final volume of 90 ml without        
β-Mercaptoethanol, store at RT 
(100 ml with β-Mercaptoethanol, store at 4°C and use not longer than 2 weeks) 
 
Lysis buffer (pH 7.4):     for 500 ml: 
155 mM NH4Cl      77.5 ml 1 M NH4Cl 
10 mM KHCO3      5 ml 1 M KHCO3 
0.1 mM EDTA      100 µl 0.5 M EDTA 
deionized H2O      400 ml 
adjust pH to 7.4 with HCl 
deionized H2O      to a final volume of 500 ml 
store at 4°C 
 
PCR buffer (10 x):     for 500 ml: 
500 mM KCl      250 ml 1 M KCl 
100 mM Tris-HCl (pH 8.3)    50 ml 1 M Tris (pH 8.3) 
15 mM MgCl2      7.5 ml 1 M MgCl2 
0.1% gelatin      0.5 g gelatin 
deionized water      to a final volume of 500 ml 
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adjust to pH 8.3, sterile filtration 
 
Phosphate buffered saline (PBS) (10 x):  for 1000 ml: 
NaCl        80.0 g 
KCl        2.0 g 
Na2HPO4       14.4 g 
KH2PO4 (pH 7.3)     2.4 g 
deionized H2O      to a volume of 800 ml 
adjust pH to 7.4 
deionized H2O      to a final volume of 1000 ml, autoclave 
 
Ponceau solution:     for 100 ml: 
0.5% Ponceau S      0.5 g 
1% Acetic acid glacial     1 ml 
deionized H2O      to a final volume of 100 ml 
 
RIPA buffer:      for 50 ml: 
150 mM NaCl      1.5 ml 5 M NaCl 
1% IGEPAL      5 ml 10% IGEPAL 
0.5% DOC (Deoxycholic acid)   2.5 ml 10% DOC 
0.1% SDS (Sodium Dodecyl Sulfate)  0.5 ml 10% SDS 
50 mM Tris (pH 8.6)     2.5 ml 1 M Tris (pH 8.6) 
deionized H2O deionized H2O   to a final volume of 50 ml 
 
RT mix:       for 1000 µl: 
5 x buffer (supplied with reverse transcriptase) 400 µl 
DTT (100 mM)      200 µl 
dNTP (100 mM)      25 µl of each dNTP (total volume: 100 µl) 
DEPC treated deionized H2O   300 µl 
 
Separation gel for SDS PAGE 12%:  for 1 gel: 
deionized H2O      1.7 ml 
acrylamide-bisacrylamide mix (29:1, 30%) 2.0 ml 
Tris (1.5M, pH 8.8)     1.3 ml 
SDS (10%)       0.05 ml 
APS (10%)       0.05 ml 
TEMED       0.002 ml 
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Sodium Dodecyl Sulfate (SDS) solution 10%: for 100 ml: 
SDS        10.0 g 
deionized H2O      to a final volume of 100 ml 
dilute at 65°C, store at room temperature 
 
Stacking gel for SDS PAGE:    for 1 gel: 
deionized H2O      0.68 ml 
acrylamide-bisacrylamide mix (29:1, 30%) 0.17 ml 
Tris (1 M, pH 6.8)     0.13 ml 
SDS (10%)       0.01 ml 
APS (10%)       0.01 ml 
TEMED       0.001 ml 
 
TBE buffer (5 x):      for 1 l: 
445 mM Tris base     54 g Tris base 
445 mM Borate      27.5 g Boric acid 
10 mM EDTA      20 ml 0.5 M EDTA (pH 8.0) 
deionized H2O      to a final volume of 1000 ml 
 
TBS Tween buffer:     for 5 l: 
20 mM Tris       12.1 g Tris 
137 mM NaCl      40.0 g NaCl 
0.5% Tween 20      25 ml Tween 20 
deionized H2O deionized H2O   to a final volume of 5 l 
adjust to pH 7.56 
 
TE-4 buffer:       for 100 ml: 
Tris (1 M, pH 8.0)     1 ml 
EDTA (0.5 M, pH 8.0)     20 µl 
deionized H2O      to a final volume of 100 ml 
 
Transfer buffer:      for 5 l: 
Tris-Base       12.1 g 
Glycine       56.3 g 
Methanol       1000 ml 
deionized H2O      to a final volume of 5 l 
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Tris-HCl (1 M, pH 6.8):     for 400 ml: 
Tris-HCl       60.0 g 
deionized H2O      to a final volume of 400 ml 
adjust pH to 6.8 with concentrated HCl 
 
Tris-HCl (1.5 M, pH 8.8):    for 400 ml: 
Tris-HCl       90.5 g 
deionized H2O      to a final volume of 400 ml 
adjust pH       to 8.8 with concentrated HCl 
 
3.6.2 Media for eukaryotic cell and tissue culture procedures 
Medium for human fibroblasts: for 556.4 ml: 
D-MEM with 4500 mg/l Glucose, L-Glutamine, 
Pyruvate (#41966-029, Invitrogen) 500.0 ml 
Fetal calf serum (Biochrom) 50.0 ml 
Penicillin-Streptomycin (Invitrogen) 5.0 ml 
Amphotericin B (PromoCell) 1.4 ml of a stock with the concentration 250 µg/ml 
 
Media for siRNA transfection of human fibroblasts: 
OptiMEM I (#31985-047, Invitrogen) 
 
PBS Dulbecco w/o Ca2+, Mg2+ low endotoxin (Biochrom AG) 
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3.7 Primers and siRNAs 
All primer were individually designed and purchased from the company Metabion. Every 
primer was delivered in lyophilized form and subsequently diluted in deionized, 
autoclaved H2O to achieve primer stock solutions with a concentration of 100 pmol/µl. 
Stock solutions were stored at -20°C and served for the preparation of working solutions 
with the concentration 10 pmol/µl. 
 
 
Table 2 Overview over the pre-designed primer assays used in quantitative real-time PCR 
experiments in Taqman (Applied Biosystems). * = this primer pair was not used for quantification 
of recombinant expression of HDAC8, because it is located in the 3’ UTR region. 
Transcript QuantiTect Primer Assay 
(Qiagen) 
Catalogue # Amplicon 
length  
Actin, beta Mm_Actb_2_SG QT01136772 77 bp  
ACTIN, beta Hs_ACTB_2_SG QT01680476 104 bp  
SMN1/SMN2 Hs_SMN2_2_SG QT01673679 97 bp  
HDAC1 Hs_HDAC1_1_SG  QT00015239 140 bp  
HDAC2 Hs_HDAC2_1_SG  QT00001890 127 bp  
HDAC3 Hs_HDAC3_1_SG QT00093730 100 bp  
HDAC4 Hs_HDAC4_1_SG QT00005810 86 bp  
HDAC5 Hs_HDAC5_1_SG QT00060585 145 bp  
HDAC6 Hs_HDAC6_1_SG QT00002709 64 bp 
HDAC7 Hs_HDAC7_1_SG QT00031822 121 bp  
HDAC8 Hs_HDAC8_1_SG * QT00049630 91 bp  
HDAC9 Hs_HDAC9_1_SG QT00039333 92 bp 
HDAC10 Hs_HDAC10_1_SG QT00007252 161 bp  
HDAC11 Hs_HDAC11_2_SG QT01674617 65 bp  
 
 
Table 3 siRNA assays used in the respective experiments 
Target Transcript Name of the siRNA assay Catalogue # 
HDAC1 Hs_HDAC1_6 HP SI02663472 Qiagen 
HDAC2 Hs_HDAC2_1 HP SI00434952 Qiagen 
HDAC3 Hs_HDAC3_1 HP SI00057316 Qiagen 
HDAC4 Hs_HDAC4_3 HP SI00083951 Qiagen 
HDAC5 Hs_HDAC5_1 HP SI00077714 Qiagen 
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HDAC6 Hs_HDAC6_5 HP SI02663808 Qiagen 
HDAC7 Hs_HDAC7A_5 HP SI02777719 Qiagen  
HDAC8 Hs_HDAC8_2 HP SI00122066 Qiagen 
HDAC9 Hs_HDAC9_1 HP SI00148372 Qiagen 
HDAC10 Hs_HDAC10_1 HP SI00141736 Qiagen 
HDAC11 Hs_HDAC11_5 HP SI03039085 Qiagen 
siTOX  
 
Transfection Control Dharmacon (siRNA to check 
transfection efficiency) 
D-001500-01-05 
AllStars Negative 
Control siRNA 
Non-Targeting siRNA Qiagen (control siRNA) 
1027280 
 
 
Table 4 Specifically designed primer for  genotyping 
 
 
Primer # Name Gene/Transcript Sequence (5’ to 3’) Annealing 
temperature 
Amplicon 
size [bp] 
3370 Hung WT fw Wt Smn ATA ACA CCA CCA 
CTC TTA CTC 
3371 Hung KO fw  Smn KO  GTA GCC GTG ATG 
CCA TTG TCA 
3372 Hung WT_KO 
rev 
Wt Smn AGC CTG AAG AAC 
GAG ATC AGC 
55°C KO=950 WT=1050 
3373 HungSMA_mou
se_tgSMN2_fw_
1F 
transgenic 5'-UTR of 
SMN2 
ACT GCA ACC TCC 
TGG GTT CAA GTG 
3374 HungSMA_mou
se_tgSMN2_rev
_1B 
transgenic 5'UTR of 
SMN2 
CAG TTC GAG ACC 
AGC CTG ACC AAT 
58°C 172 
3375 HungSMA_mou
se_tgSMN2_fw_
2F 
10kb upstream of the 
SMN2 coding region 
(transgene) 
CGA ATC ACT TGA 
GGG CAG GAG TTT 
G 
3376 HungSMA_mou
se_tgSMN2_rev
_2B 
10kb upstream of the 
SMN2 coding region 
AAC TGG TGG ACA 
TGG CTG TTC ATT G 
58°C 479 
3377 HungSMA_mou
se_tgSMN2_fw_
3F 
centromeric NAIP 
region of the BAC 
clone (transgene) 
AAA CCA GTC GGG 
CAC AAT ACC TAG C 
3378 HungSMA_mou
se_tgSMN2_rev
_3B 
centromeric region of 
the BAC clone 
(transgene) 
TAT GCT GAT TGA 
AGG GAG GGG TGC 
58°C 720 
2649 m_smn forw Smn CCG GGA TAT TGG 
GAT TGT AG 
2650 m_smn rev Smn TTC TTT TGG CTT 
TTA TTC TTC TTG 
55°C 782 
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Table 5 Specifically designed primer for copy number determination and expression studies 
Prim
er # 
Name Gene/Transcript Sequence (5’ to 3’) Annealing 
temperature 
Amplicon 
size [bp] 
1449 SMN Ex 5 for SMN-FL_∆7 CCA CCA CCC CAC TTA 
CTA TCA 
1450 SMN Ex 6/8 rev SMN-∆7 GCT CTA TGC CAG CAT 
TTC CAT A 
3054 SMN_Ex7/8_rev
1 
SMN-FL GCT CTA TGC CAG CAT 
TTC TCC T 
FL-SMN=62°C 
∆7-SMN=61°C 
FL-SMN=236 
∆7-SMN=182 
3887 hum_HDAC8_f
w 
HDAC8 TGA CGG AAT GTG CAA 
AGT AGC 
3888 hum_HDAC8_re
v 
HDAC8 ATA TTC CCA GGA CAG 
CAT CAT T 
53°C 107 
2952 Intron4 fw hum SMN2 AAA TGC TCA AGA GGT 
AAG GAT ACA A 
2953 Intron2b rev 
hum 
SMN2 GAA GTT AAA TCT CAA 
CAT TTT AAA T 
55°C 111 
158(e
h) 
ApoB fwd ApoB CAC GTG GGC TCC AGC 
ATT 
159(e
h) 
ApoB rev ApoB TCA CCA GTC ATT TCT 
GCC TTT G 
55°C 73 
 
All siRNAs were pre-designed by the respective company. The siRNAs purchased from 
Qiagen were delivered in lyophilized form. To obtain a 20 µM stock solution, 250 µl 
siRNA Suspension Buffer (Qiagen) were added to 5 nmol siRNA. Subsequently, the 
dilution was incubated at 90°C for 1 min and at 37°C for another 60 min according to the 
manufacturer’s protocol to disrupt higher aggregates. 
Stocks were stored at -20°C and further diluted with siRNA Suspension Buffer to 
obtain 1 µM working dilutions prior to use. 
The siRNAs purchased from Dharmacon were also delivered in lyophilized form 
and dissolved in 1 x siRNA Buffer (Dharmacon) to obtain a stock dilution of 20 µM. 
Stocks were stored at -20°C. Prior to transfection of fibroblasts, stocks were further 
diluted with siRNA Buffer to obtain working dilutions with a concentration of 1 µM. 
3.8 Software, internet programs, and databases 
Microsoft® Office Professional Edition 2003, Microsoft Corporation (word processing, 
data analysis and preparation of presentations)  
Adobe Photoshop 8.0.1, Adobe Systems Inc. (image editing) 
EndNote 9, Thomson ResearchSoft (organization of references) 
SigmaPlot 9.0, Systat Software, Inc. (creation of graphs) 
OneDScan, Scanalytics (densitometric analysis of PAA gels and western blots) 
Quantity One 4.5.1, Biorad (scanning and densitometric analysis of gels and western 
blots) 
Editseq/PrimerSelect/SeqBuilder, DNASTAR Inc. (DNA/protein sequence analysis, 
primer selection) 
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LightCycler Software, Roche (documentation/analysis of real-time PCR data) 
Sequence Detection Software, Applied Biosystems (documentation/analysis of real-time 
PCR data) 
Multi-Analyst Version 1.1, Biorad (scanning and densitometric analysis of gels and 
western blots) 
XFluor4SafireII software, Tecan (analysis of absorption/fluorescence using microtiter 
plates) 
AxioVision Rel.4.7 computer software (Zeiss) 
 
NCBI, www.ncbi.nlm.nih.gov 
Genecards, www.genecards.org 
ENSEMBL, www.ensembl.org 
UCSC Genome Browser, www.genome.ucsc.edu/cgi-bin/hgGateway 
Medline, www.ncbi.nlm.gov/PubMed 
OMIM, www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM 
Gene Expression Atlas database, expression.gnf.org 
3.9 Cell culture procedures 
Whenever cell culture work was performed it was done under sterile conditions in order 
to avoid any contaminations with fungi or bacteria. Sterile conditions were guaranteed by 
the use of a laminar flow tissue culture hood and sterile solutions and materials. 
Additionally, always amphotericin B and penicillin and streptomycin were added to 
culture media. Both, human and murine embryonic fibroblasts were grown in the same 
culture medium. 
3.9.1 Cell culture of primary fibroblasts derived from SMA patients 
All used fibroblast cell lines were grown as adherent cultures in D-MEM medium 
containing 10% FCS, amphotericin B and penicillin and streptomycin (for detailed 
medium description see chapter 3.6.2). Fibroblasts were grown as monolayer in tissue 
culture flask of either 25 cm² or 75 cm² surfaces and kept in a sterile cell incubator at 
normal cultivation growing conditions of an atmosphere with 5% CO2 at 37°C. Humidity 
in the incubator was warranted by evaporation of water from a special water reservoir. 
Depending on the cell division rate of the respective fibroblast line the medium was 
either changed by default once or twice a week or when a cell line showed a very rapid 
growth or metabolism, the metabolic products changed the pH within the medium so that 
the indicator in the standard D-MEM turned the color from red to yellow indicating the 
necessity of a medium change. Each time a cell line was grown ~70-80% confluent, the 
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cells were splitted into new flasks, following the subsequent steps. First, the fibroblast 
monolayer was washed with PBS (w/o Ca2+, Mg2+), then Trypsin-EDTA was added to the 
cells and incubated for 5 minutes in the cell incubator. After that the trypsinization was 
stopped by addition of fresh culture medium and cells were split into several new flasks. 
To keep the growth of the cells dense but not confluent, cells were split, depending on 
the division rate of the respective cell line from one 75 cm² flask in two to three new 75 
cm² flasks. 
For the longtime storage of the fibroblasts, cells were first pelleted after 
trypsinization in a centrifugation step for 8 min at 1200 rpm at 4°C. Then the pellet was 
resuspended in a sterile-filtered solution of FCS (90%) and DMSO (10%). The 
resuspended cells in the freezing medium were stored over night at -80°C and then 
transferred to -196°C liquid nitrogen and kept there for longtime storage. At any time, 
these aliquots can be thawn again and cells can be brought back to culture conditions. 
3.9.2 Stimulation of primary fibroblast cell lines with chemical substances 
To treat fibroblasts with the respective chemical compound, the monolayer was first 
grown to a maximum confluency of 80% then the cells were trypsinized and after cell 
concentration determination, a homogenous mixture of 2x105 fibroblasts in 8 ml medium 
was transferred onto 10 cm² petri dishes. In order to let the cells attach to the petri dish 
ground, the cells were pre-incubated for at least 4 h. For each experiment one dish 
served as a control and was treated only with the respective drug solvent (DMSO). To 
exclude passage specific effects, every HDACi treatment experiment was always 
repeated at least twice with different passages of the respective fibroblast cell line and 
the final results are given as mean ± SEM. 
 
Substance Concentrations treatment time period 
M344 0.5, 5, 10, 30, 50, 100 µM 64 h 
SAHA 0.1, 1, 5, 10, 50 µM 48 h 
FK228 10, 50, 100, 250, 500 nM 64h (human), 48h (murine) 
PCI-34051 1, 5, 10, 25, 50, 100 µM 6 h 
 
3.9.3 MTT assay 
Thiazolyl blue tetrazolium bromide (MTT) is converted into violet formazan crystals by 
living cells, but not by dead cells. The absorption maxima of MTT and formazan are 
different. Thus, MTT can be added to cell cultures treated with a respective chemical 
substance (e.g. HDAC inhibitor), and subsequent photometric measurement of the newly 
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synthesized formazan can give evidence of cell survival under drug treatment and the 
cytotoxicity of the drug (Mosmann 1983). 
Some 8000 fibroblasts in 250 µl medium in each well of a 96-well plate were treated with 
the different concentrations of the respective HDACi as described above in the 
respective experiments and incubated for 64 h at 5% CO2 and 37°C. For each 
concentration eight wells were used, to avoid major errors. For the mock even sixteen 
wells were included. After incubation the old medium was removed and replaced by 225 
µl fresh medium and 25 µl MTT-stock-solution (50 mg MTT (Sigma) in 10 ml PBS 
(Gibco)). Again the cells were incubated for 3 h, to start the crystal-production. After 
replacing the old medium by 100 µl iso-stock (50 ml Isopropanol (100%) + 165 µl HCl 
37%) the photometric absorption was measured in a plate-reader (Tecan). The 
absorption gives evidence for the cell-viability after the respective HDACi treatment. All 
resulting data are given as mean values (± SEM).  
3.9.4 Transient transfection of primary human fibroblasts 
In order to knock down the expression of a specific gene small interfering RNAs (siRNA) 
were used. The siRNA stocks (chapter 3.7) were first diluted to a final concentration of 1 
µM in siRNA suspension buffer. The lipofection substance Dharmafect 1 (Dharmacon) 
was used for all siRNA transfection experiments. The transfection experiments were 
performed according to the manufacturer´s protocol. Beside the siRNA regarding the 
respective target gene, siTOX (Dharmacon) siRNA served as a transfection control and 
AllStars Negative Control siRNA (Qiagen) served as a negative control. All cells 
transfected with siTOX induced apoptosis. Subsequently to the respective incubation 
time, cells were harvested for RNA (see 3.11.5) or protein isolation (see 3.12.2). Every 
knock-down experiment was performed in triplicates. 
 Since primary fibroblasts are not easy to transfect with plasmids in order to over-
express the respective cloned gene (for used plasmid see 3.4.3.5), the method of 
electroporation was used. With the help of the Nucleofector (Lonza) it is possible to 
transfect plasmid directly into the nucleus of fibroblasts (see internet-page: 
http://www.lonzabio.com/technology/nucleofector/ as reference). The Basic 
Nucleofector® Kit for Primary Mammalian Fibroblasts (Lonza) was used to transfect SMA 
fibroblast cell lines, following its manual.  
In summary, fibroblasts were trypsinized, counted, and a volume containing the 
required amount of cells was centrifuged at 1200 rpm for 10 min. For each single 
transfection reaction, a number of 0.5 x 106 cells were used. The cell pellet was 
suspended in Nucleofector Solution (100 µl for each 0.5 x 106 cells), and after addition of 
2 µg pmaxGFP expression vector (Lonza), which served as a transfection control, for 
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each 0.5 x 106 cells, aliquots of 100 µl were transferred to cuvettes and electropored with 
the program U21. After electroporation in cuvettes, aliquots were added to 1.5 ml of 
culture medium, which was pre-warmed in 6-well plates and incubated in the cell 
incubator for the respective time-period.  
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3.10 Animal breeding and characterization of SMA-like mice 
3.10.1 Animal breeding 
All mice used in this thesis were housed in micro-isolation chambers in the mouse facilty 
of the Institute of Genetics, Cologne or in the Franz-Penzoldt-Zentrum in Erlangen, 
respectively (SMAB). In order to generate SMAH-like mice, breeding pairs consisted of 
one mouse that was homozygous for the human SMN2 transgene and the Smn knock-
out (SMN2tg/tg; Smn-/-) allele and the other mouse was heterozygous for the knock-out 
(Smn-/+) allele, which resulted in pups that all were heterozygous for the transgene and 
to 50% either homozygous or heterozygous for the knock-out allele. The Smn-/-;SMN2tg/wt 
mice develop a severe SMA-like phenotype, whereas the Smn+/-;SMN2tg/wt develop 
normal and were used as contol littermates. The normal rhythm of light and dark periods 
was set to 12h-12h intervals. Animal bedding, cages, water and feed was regularly 
changed every week by the animal keepers. When the mice reached an age of three 
weeks, tail-tips were taken for genotyping and ear-tags were set. SMA-like animals and 
their respective littermates were marked soon after birth by a water-resistant marker 
labelling on the chest. Genotyping of SMA-like animals was performed after death. 
3.10.2 Motor ability test and determination of weight progression of mice 
To measure the motor ability of SMA-like mice and their respective littermates, the so-
called tube test was performed (El-Khodor et al. 2008). The great advantage of the tube 
test is that it can be performed with neonates. To perform a tube test, first the whole litter 
was taken together with some bedding into an adequate vessel to separate it from the 
mother. Next, each pup was placed one by one headfirst into a vertical 50 ml reaction 
tube. The pups were placed into the tube in that way that they could hold themselves by 
their muscular strength of their hind limbs (see Figure 10). If a mouse was able to hold 
itself for a while (>20 sec.) and if the hind limbs were spread, it was scored to the highest 
tube score of 4. Depending on the spreading of the hind limbs, each mouse was rated 
from 4 (best score wide spreading) to 1 (bad score, hind limbs in a clasped position). A 
mouse was rated with the worst score of 0 when it was not able to hold onto the tube. 
The tube test was performed daily starting from P0 in the morning between 9:00 h and 
10:30 h a.m. 
 Additionally, the weight of each mouse was determined in parallel. Therefore, the 
upright 50 ml plastic reaction tube was placed onto a balance. During the time when a 
mouse was performing a tube test, its weight was noted. Thus, the weighing was 
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performed like the tube test daily starting from P0 in the morning between 9:00 h and 
10:30 h a.m. 
 
 
 
 
Figure 10 The tube test and the scoring criteria for tube score. Mice were suspended by their 
hind limbs from the lip of a standard 50 ml plastic centrifuge tube. The posture adopted was 
scored according to the following criteria: score of 4 indicates normal hind-limb separation with tail 
raised (A); score of 3, weakness is apparent and hind limbs are closer together but they seldom 
touch each other (B); score of 2, hind limbs are close to each other and often touching (C); score 
of 1, weakness apparent and the hind limbs are almost always in a clasped position (D) with the 
tail raised (E); a score of 0 indicates constant clasping of the hind limbs (D) with the tail lowered 
(F) or failure to hold onto the tube. (Taken from (El-Khodor et al. 2008)). 
 
3.10.3 Treatment of mice with test substances 
Three different methods of application were chosen to treat the SMA-like mice and their 
littermates with the test substances. First, in the case of SMAB mice, which were 
observed to be severely affected, the mother animals were treated with 200 mg/kg/day of 
SAHA. Therefore, 1.33g of SAHA was solved in 1L water (supplemented with 18g 
hydroypropyl-β-cyclodextran (HP-β-CD)). This respective solution was given to the 
mother mouse instead of normal drinking water. Thus, given the fact that a 20g mouse 
drinks 3 ml water per day, this dosage equals 200 mg SAHA per kg body weight per day. 
However, the expected SMA-like pups were then treated with SAHA by suckling of the 
mother milk. 
The second method used to apply the test substance to the SMA-like mice, was a 
direct subcutaneous injection of the respective substance. Each treatment concentration 
was diluted in that way that one injection of 12.5 µl of the solution into the neck of the 
mouse equalled the respective mg/kg dosage (e.g. 25 mg/kg SAHA). 
The third application method was the oral treatment. Therefore, each mouse was 
fed with 12.5 µl of the substance with the respective concentration. To feed a mouse, it 
was held at the neck and the tip of a blunt-ended syringe was placed into its mouth and 
Motor strength   
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12.5 µl of the treatment solution was slowly released. It was always paid attention to the 
swallowing behaviour of each mouse. The speed of application was accordingly adapted. 
Individual treatment methods, the subcutaneous and the oral treatment were performed 
twice daily. The first treatment took place in the morning after the performance of the 
tube test and the weighing (see chapter 3.10.2) between 9:00 h and 10:30 h a.m. The 
second treatment was performed between 17:00 h and 18:30 h. 
3.10.4 Generation of murine embryonic fibroblasts 
Primary embryonic fibroblasts were obtained from E13.5 old embryos. The mice with the 
relevant genotype were bred and it was checked for pregnancy according to the 
presence of a vaginal plug. 13 days after the plug-check, plug-positive mice were 
sacrificed. Subsequently, the embryos were removed from the uterus and washed in 
PBS under sterile conditions. Additionally, head, heart and liver were removed and the 
head was used for subsequent verification of the expected genotype. Each embryo was 
homogenized by pressing it with the help of a 10 ml syringe plunger through a cell sieve. 
The sieve was then rinsed with 10 ml MEF-medium and the flow-through was collected 
in a 50 ml reaction tube. The lysate was centrifuged for 5 min at 1200 rpm. The 
supernatant was discarded and the pellet was resuspended in 6 ml MEF-medium and 
plated out onto 6 cm dishes. At the following day the medium was exchanged to get rid 
of cell debris. 
 
Table 6 Murine embryonic fibroblast cell lines used in this thesis 
Name of the cell 
line 
genotype SMA inbred 
strain 
Inbred strain SMN2 gene copies 
MEF14 SMN2tg/tg; Smn-/- 
SMA-Burghes 
(SMAB) C57BL/6 2 
MEF5 SMN2tg/tg; Smn-/- 
SMA-Hung 
(SMAH) FVB/N 4 (2 per integrate) 
 
3.10.5 Preparation of mouse organs 
For the preparation of mouse organs, the respective mouse was sacrificed by 
decapitation either at day P5 or P10. Subsequently, the mouse was fixed onto a 
operating table and its body was opened by abdominal incision.  
 For the subsequent RNA or protein preparation of organs (see chapters 3.11.4 and 
3.12.1), whole liver, brain, the gastrocnemius muscle and spinal cord was removed. 
While liver, muscle and brain were simply withdrawn, spinal cord was rinsed out of the 
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spinal canal with PBS. All organs were immediately snap-frozen and stored in liquid 
nitrogen.  
 For subsequent histological experiments, biopsies from the gastrocnemius muscle 
and the rectus femoris muscle were taken as well as the whole spine including the spinal 
cord. All organs for histological stains were immediately stored and fixed in 4% 
paraformaldehyde at 4°C. For the proceeding of histochemistry see chapter 3.13. 
 
3.11 Molecular biology methods 
3.11.1 Isolation of genomic DNA 
To isolate clean and intact genomic DNA from both, tail-tip biopsies and fibroblast cell 
lines, always the ChargeSwitch® gDNA Mini Tissue Kit (Invitrogen) was used according 
to the manufacturer´s protocol. With the help of magnetic beads this kit provides a fast 
and extensive cleanup of genomic DNA even from tissues like tail-tips. The very clean 
genomic DNA is essential for the sensitive genomic quantitative real-time PCR. 
3.11.2 Photometric determination of the DNA concentration 
A NanoDrop ND-1000 Spectrophotometer (Peqlab) was used to determine the DNA 
concentration. Therefore, a 1.5 µl DNA sample was pipetted onto the end of a fiber optic 
cable and a second fiber optic cable was brought into contact with the liquid. Absorption 
was measured at wavelengths of 260 nm and 280 nm utilizing a pathlength of 0.2 mm, 
and the DNA concentration and purity was calculated by the software. The ratio of the 
measured absorption at the wavelength of 260 nm and 280 nm gives the grade of purity 
of the DNA. The ratio is recommended to range between 1.8 and 2.0. Higher values 
suggest contamination with RNA, while lower values point to contamination with proteins 
or ethanol. Measurements were performed in triplicates and the concentration calculated 
as mean of the single values.  
3.11.3 Fluorimetric determination of the DNA concentration 
For highly sensitive methods, like gene copy number determination, it is necessary to 
have very pure DNA and to know the exact concentration of it. To avoid any misleading 
concentration measurements due to RNA contaminations, the Quant-iT™ PicoGreen® 
dsDNA reagent (Invitrogen) was used according to the manufacturer´s protocol. With this 
kit and the help of a microplate reader it is possible to determine the exact DNA 
concentration. 
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3.11.4 Isolation of total RNA from mouse organs 
To isolate total RNA from mouse organ biopsies the RNeasy Kit (Qiagen) and the 
QIAshredder (Qiagen) were used according to the manufacturer’s protocols. For the 
isolation of total RNA out of fatty organs like brain or spinal cord, some preparative steps 
with Qiazol® according to the manufacturer´s protocol were included before starting with 
the RNeasy protocol. Always the optional DNase I digest was carried out using the 
RNase-Free DNase kit (Qiagen) according to the protocol included in the RNeasy kit. 
3.11.5 Isolation of total RNA from primary fibroblast cell cultures 
The isolation of total RNA from fibroblasts was carried out by the operating protocol of 
the used RNeasy Mini kit. Prior to the first cell lysis step, which was performed directly 
on the petri dishes, the medium was removed from the monolayer. 
3.11.6 Determination of the RNA concentration 
The standard method to quantify the RNA concentration is the measurement of the 
photometric absorbance at a wavelength of 260 nm (A260). Since at 260 nm also 
proteins, free nucleotides and DNA contribute to the absorbance signal, the pure 
photometric determination of the RNA is not very exact. To avoid misleading results, it 
was made use of a dye called RiboGreen®, which is fluorescent if it is specifically bound 
to RNA molecules and therefore helps to determine the exact RNA concentration. 
Furthermore the Quant-iT™ RiboGreen® RNA Assay Kit (Invitrogen) not only prevents to 
interpret contaminated RNA solutions, but also it aids to measure very low RNA 
concentration very exactly. 
3.11.7 Photometric RNA concentration analysis 
Similar to the DNA concentration determination, a NanoDrop ND-1000 
Spectrophotometer (Peqlab) was used to determine the RNA concentration. Therefore, a 
1.5 µl RNA sample was pipetted onto the end of a fiber optic cable and a second fiber 
optic cable was brought into contact with the liquid. Absorption was measured at 
wavelengths of 260 nm and 280 nm utilizing a pathlength of 0.2 mm, and the RNA 
concentration and purity was calculated by the software. The ratio of the measured 
absorption at the wavelength of 260 nm and 280 nm gives the grade of purity of the 
DNA. The ratio is recommended to range between 1.8 and 2.1. Higher values suggest 
contamination with degraded RNA or free nucleotides, whereas lower values point to 
contamination with proteins. Measurements were performed in triplicates and the 
concentration calculated as mean of the single values.  
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3.11.8 Fluorimetric RNA concentration analysis with RiboGreen® dye 
Whenever RNA expression of treated fibroblasts or murine tissues was investigated, the 
expression of the transcript of interest was normalized to the total RNA amount. For this 
purpose, it was crucial to know the exact total RNA concentration. To ensure the 
knowledge of the exact RNA concentration, the Quant-iT™ RiboGreen® RNA Assay Kit 
(Invitrogen) was used according to the manufacturer´s protocol. This kit utilizes the 
feature that RiboGreen is non-fluorescent when free in solution, but when it is bound to 
RNA, the fluorescence of the dye increases more than 1000fold. The assay was set up 
in 96-well plates (Black, flat bottom, medium binding, #655076, Greiner bio-one). 
Fluorescence of the RNA-RiboGreen®-complexes was determined on a TECAN Safire2 
monochromator-based microplate reader (Tecan). All RNA stocks were analyzed in 
triplicates and the concentration calculated as mean value of these measurements. 
3.11.9 Reverse transcription (cDNA synthesis) 
All RNA expression experiments are based on the mRNA expression, but actually not 
directly RNA is measured by realtime-PCR attempts, but so called cDNA molecules are 
the templates for expression analysis. Do generate double-stranded complementary 
DNA (cDNA), the reverse transcription is the biomolecular technique of choice. It is taken 
advantage of the fact that most mRNA molecules possess a 3’ poly-A-tail, and oligo-dT 
primers are used as starter molecules for the reverse transcriptase. The whole cDNA 
synthesis method was performed with the QuantiTect Rev. Transcription Kit (Qiagen) 
and oligo-dT primers (Operon). 
3.11.10 Polymerase chain reaction (PCR) 
One of the most commonly used biological technique worldwide is the polymerase chain 
reaction (PCR), which allows the enzymatic amplification of specific single-stranded DNA 
regions (Mullis and Faloona 1987). This technique utilizes the capacity of a DNA-
dependent DNA polymerase to synthesize copies from a denatured, single-stranded 
DNA template, starting from sequence specific oligonucleotides (primers). The primers 
specifically hybridize to the complementary sequence in the DNA template and are 
elongated at their free 3’-hydroxy group. The program of cycles including repeated DNA 
denaturation, primer hybridization, and DNA synthesis is performed in a thermocycler. To 
sustain the maintenance of a functioning DNA-polymerase, the thermo stable Taq-
polymerase (from Thermophilus aquaticus) (Invitrogen) was used. 
 The standard PCR conditions, which were used, if not mentioned otherwise are:  
10 min at 95oC denaturation followed by 34 cycles of 30 sec at 95oC, 30 sec at annealing 
temperature shown in table 4, 30 sec at 72oC. The final extension step was at 72oC for 
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10 min. The PCR products were resolved on an 1-2 % agarose gel (see chapter 
3.11.14). For the used primers see chapter 3.7. 
 
Table 7 Components used for a standard PCR 
Component Volume/reaction ( µl) 
Master mix 
Sterile water    
1.25 mM dNTP 
10xPCR Buffer 
25mM MgCl2 
Primer for 
Primer rev 
(Betain 1M) 
Taq polymerase 
Template  
50 ng genomic DNA 
Total volume 
 
variable  
4 
2.5 
1 
1 
1 
(5µl)* 
0.3 
 
variable* 
25 
* Betain was only added to SMAB genotyping PCR 
 
 
3.11.11 Analysis of the number of transgenic SMN2 copies by 
quantitative real-time PCR 
Since SMN2 is the main modifier of SMA, the knowledge of the exact transgene SMN2 
copy number in SMA model mice, is of crucial importance. The real-time PCR based 
copy number determination of SMN2 transgenes is newly developed method and 
therefore the details are presented in the “results”-part of this work (see 4.3.1.1). 
3.11.12 Analysis of gene expression by quantitative real-time PCR 
Quantitative real-time PCR of transcript levels in fibroblasts total RNA was extracted 
from every 10 cm cell culture dish using the RNeasy Kit (Qiagen) and QIAshredder 
according to the manufacturer’s protocols. DNase digest was included by use of the 
RNase-Free Dnase I set (Qiagen). Exact concentration of isolated RNA was precisely 
determined on a TECAN Safire² microplate reader using the RiboGreen® RNA 
quantitation kit (Molecular Probes). After reverse transcription of RNA into cDNA as 
described elsewhere (chapter 3.11.9), quantitative real-time PCR was performed on a 
LightCycler 1.5 instrument using Fast Start DNA Master SYBR Green I (Roche). Primers 
were chosen to bind in SMN exon 5 (5’-CCA CCA CCC CAC TTA CTA TCA-3’) (primer 
#1449) and SMN exon 7/8 (5’-ATC AAG AAG AGT TAC CCA TTC CA-3’) (primer #3054) 
for amplification of FL transcripts, and in SMN exon 5 (5’-CCA CCA CCC CAC TTA CTA 
TCA-3’) (primer #1449) and at the SMN exon6/exon8 border (5’-GCT CTA TGC CAG 
CAT TTC CAT A-3’) (primer #1450) in order to amplify truncated ∆7 transcripts. The 
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quantification program was followed by a melting step to detect the melting points for 
every PCR product. Analysis of the PCR curves was performed with the second 
derivative maximum method of the LightCycler software. All sample measurements were 
repeated at least three times and results are given as mean ± SEM. 
3.11.13 Analysis of gene expression by one-step reverse transcription - 
quantitative real-time PCR 
It is possible to perform the reverse transcription of RNA into cDNA followed by 
quantitative real-time PCR using cDNA as template in one and the same tube. To do so, 
a specific amount of RNA is incubated with all reagents required for reverse transcription 
(including the reverse transcriptase) and all reagents required for subsequent PCR 
(including the DNA-dependent DNA polymerase). The reaction mix is incubated at 
conditions, which allow the reverse transcriptase to become active and to synthesize 
cDNA. Then, by heating up the reaction mix, the reverse transcriptase is inactivated. 
Thereafter, the DNA-dependent DNA polymerase is activated and the quantitative real-
time PCR takes place. One-step reverse transcription - quantitative real-time PCR is less 
time-consuming than separate reactions and minimizes pipette steps. 
One-step reverse transcription - quantitative real-time PCR was performed on RNA 
samples derived from fibroblasts, which were previously transfected either with siRNA 
against different HDAC or with plasmids containing either HDAC2, HDAC8, HDAC11 or 
GFP as a control. The used OneStep RT-PCR Kit (Qiagen) is designed for sensitive one-
step RT-PCR using any RNA template. For all quantified transcripts (except HDAC8, see  
Table 4) the pre-designed real-time QuantiTect Primer Assays (Qiagen) were chosen. 
  Analysis of the real-time raw data and normalization of SMN data with β-actin data 
for each sample was performed using the Sequence Detection Software, version 1.7 
(Applied Biosystems). All sample measurements were repeated at least twice and results 
are given as mean ± standard error of the mean (SEM). 
3.11.14 Agarose gel electrophoresis for separation of DNA fragments 
The phosphate groups of the sugar-phosphate-backbone of DNA molecules are 
negatively charged. This attribute is used in the gel electrophoresis of DNA fragments. 
Depending on the fragment size, DNA molecules migrate at different speeds through the 
agarose gel matrix pores to the positively charged electric pole. The shorter fragments 
will more easily fit through the pores of the gel and migrate faster, while larger ones will 
have more difficulty and thus migrate slower. Additionally, the speed of migration 
depends on the current applied to the gel and the size of the pores of the gel. To 
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separate DNA fragments, which have different size, gel electrophoresis can be 
performed.  
Not only for the genotyping of mice, but also to control the right size of PCR 
amplicons from newly established real-time PCR assays, agarose gel electrophoresis 
was performed. The routinely used agarose concentration of the gels was 1.5 %. 1.5 g of 
agarose (Sigma) was dissolved in 100 ml TBE buffer by boiling in a microwave. After a 
short cool-down step, 5 µl ethidium bromide solution (1%, AppliChem) was added and 
mixed. Thereafter, the liquid gel was poured into an appropriate gel tray and equipped 
with a comb. After solidifying of the agarose gel, the whole tray was transferred to a gel 
electrophoresis chamber. The gel was covered with a layer of TBE buffer, PCR samples 
were supplemented with DNA loading buffer and pipetted into the gel slots. DNA 
fragment separation was carried out at 75 V for ~30 min. To estimate the length of the 
PCR products a 100 bp DNA ladder (Invitrogen) was run together with the samples in an 
extra lane on the gel. The ethidium bromide-DNA fragments were visualized with UV 
light (wavelength 254 nm) on a ChemiDoc XRS Imaging system (Biorad). 
 
 
3.12 Proteinbiochemical and immunological methods 
3.12.1 Extraction of proteins from mouse organs 
After the respective laboratory mouse was humanely sacrificed - either by decapitation 
(young mice) or by gasification on dry ice (adult mice) - its body was opened and quickly 
the organs of interest were removed. The freshly prepared organs were either used 
directly for protein or RNA (see chapter 3.11.4) extraction or snap frozen in liquid 
nitrogen. 
To extract protein from mouse organs, about 300 mg of the respective organ was 
transferred into 150 µl of RIPA buffer (Sigma) and thoroughly homogenized using a T-10 
Basic Ultra Turrax Homogeniser (IKA). All steps were performed on ice to avoid 
enzymatic degradation of RNA or proteins. To get rid of debris and DNA contamination 
the homogeneous organ solution was transferred into a centrifuge and spin down at 
12,000 rpm at 4°C for 20 min. After centrifugation the protein containing supernatant was 
transferred into a new reaction tube. The proteins were either used directly for 
subsequent experiments or stored at -80°C. 
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3.12.2 Extraction of proteins from primary fibroblast cell cultures 
To harvest protein from fibroblast cell lines, the D-MEM culture medium was removed, 
and cells were washed twice in 1 x PBS buffer (without Ca2+, Mg2+). To lyse the 
fibroblasts, 50 µl RIPA buffer (Sigma) was added directly on a 10 cm petri dish. To 
complete the lysis, dishes were kept on ice for 20 min. Thereafter, to get rid of debris and 
DNA contamination the homogeneous cell solution was transferred into a 1.5 ml reaction 
tube and then into a centrifuge and spin down at 12,000 rpm at 4°C for 20 min. After 
centrifugation the protein containing supernatant was transferred into a new reaction 
tube. The proteins were either used directly for subsequent experiments or stored at -
80°C. 
3.12.3 Protein contents determined according to the Bradford method 
To quantify the protein concentration, it was made use of the method developed by 
Bradford (Bradford 1976). This technique utilizes the Bradford-dye capacity to bind 
proteins. If bound to protein, the dye shits it absorption maximum from 470 nm to 595 
nm.  
To determine the protein concentration 2 µl of each protein sample to be analyzed 
was incubated in 500 µl Bradford solution for 10 min on room temperature. Then the 
absorption of the samples was measured at a wavelength of 595 nm. With the help of a 
standard curve, which was prepared from bovine serum albumin (BSA) and which was 
previously programmed into the spectrophotometer the protein concentrations of the 
unknown samples were calculated. 
3.12.4 Discontinuous denaturing polyacrylamide gel electrophoresis (SDS-
PAGE) 
To separate proteins according to their molecular weight, it is necessary to linearize the 
proteins by the use of the anionic detergent SDS (sodium dodecylsulfate). Since SDS 
applies a negative charge to the linearized protein, its endogenous charge is masked 
and all proteins in a protein solution are separated by their molecular weight (Laemmli 
1970). 
In a first step, the 12% PAA separation gel was prepared between two glass plates 
(distance 0.5 mm). 70% ethanol was added on top of the gel until solidification. After 
polymerization, the ethanol was removed and the stacking PAA gel was added on top of 
the separation gel between the two glass plates. The stacking gel contains less PAA 
than the separation gel, which results in larger gel pores. Moreover, the stacking gel is 
prepared with a Tris-buffer that differs from the Tris-buffer used for the separation gel in 
its concentration and pH. The main function of the stacking gel is to focus all of the 
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proteins into a single sharp band shortly after penetration into the gel. Proteins are then 
resolved in the separation gel, which possesses much smaller pores. As soon as an 
electric current is applied across the gel, the negatively charged proteins start to migrate. 
Short proteins will more easily fit through the pores in the gel, while larger ones will have 
more difficulty and migrate slower. The usage of a system with discontinuous buffers and 
gel pores enhances the sharpness of the protein bands. Before 7.5 µg of each protein 
sample were transferred into the slots of the PAA gel, samples were supplemented with 
Laemmli buffer and boiled at 95°C for 5 min to enhance denaturation. In a separate lane, 
marker proteins of known molecular weight were run (Precision Plus Protein All Blue 
Standards, Biorad) to estimate the molecular weight of the unknown proteins in the 
samples. Gel electrophoresis was performed at 50-120 V in an electrophoresis chamber 
using 1 x electrophoresis buffer. 
3.12.5 Transfer of proteins to nitrocellulose membrane by wet blotting 
(Western blot) 
To observe or to quantify protein expression, the method of Western blotting was 
utilized. As a first step to make proteins available for antibody detection, they were 
moved from within the SDS gel onto a nitrocellulose membrane [Protran BA 83 
Cellulosenitrat (E), Whatman]. Prior to use, the membrane was equilibrated in transfer 
buffer, after that placed face-to-face on the gel, and a gel sandwich was prepared 
together with two fiber pads and two filter pads all soaked in transfer buffer. This gel 
sandwich was put into a cassette, which then was placed into a transfer module of a Mini 
Trans-Blot Cell (Biorad). Wet blotting was carried out at a current of 30 V overnight at 
4°C. Thus, due to the incubation with SDS negatively charged proteins moved onto the 
membrane and adhered there, while maintaining the size specific organization they had 
within the gel. As a result of this blotting process, proteins were exposed on a thin 
surface layer for detection. 
3.12.6 Ponceau staining of proteins on nitrocellulose membranes 
To control the correct protein transfer after wet blotting over night, the nitrocellulose 
membrane was stained in a Ponceau solution for 30 s. The Ponceau dye staines the 
positively charged amino acid side chains red. For a good transfer, a homogenous 
protein band pattern is expected, but also air bubbles could be detected, making the 
whole blot useless. To go on with the immunostaining of the membrane (see chapter 
3.12.7), the membrane was washed in TBS-Tween buffer several times to remove 
Ponceau dye again. 
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3.12.7 Immunostaining of membranes with antibodies and detection of 
signals with chemiluminescence reagent 
After the wet blot protein transfer, all proteins are bound unspecifically to the 
nitrocellulose membrane. To avoid background signals due to unspecific interactions of 
the respective antibodies with the nitrocellulose membrane, the membrane was blocked 
in 6% blocking solution containing non-fat dry milk in TBS Tween buffer for 3 h (after 
Ponceau staining). This was followed directly by the incubation with the respective 
primary antibody against the target protein of interest (see  
Table 8). Therefore, the primary antibody was diluted in 5 ml 1-2% non-fat dry milk in 
TBS Tween in a 50 ml reaction tube and after that incubated with the nitrocellulose 
membrane for the respective incubation time on a roller shaker at 4°C. To remove the 
unbound primary antibody rests, the membrane was washed subsequently for 5 x 5 min 
in TBS Tween. Then the secondary antibody, which binds specifically to the primary 
antibody and is linked to a reporter enzyme, the horseradish peroxidase, is incubated 
together with the membrane as described for the primary antibody. After a second 
washing step, dectection of the samples that are labeled and bound to the protein of 
interest was performed via chemiluminescent detection. For this purpose Western blots 
were incubated with 8 ml SuperSignal® West Pico Chemiluminescent Substrate (Pierce) 
for 5 min. This is a substrate, which will fluoresce when exposed to horseradish 
peroxidase on the secondary antibody. The light was then detected by photographic film 
(Hyperfilm ECL, Amersham) and the image analyzed by densitometry to evaluate the 
relative amount of protein staining and to quantify the results in terms of optical density.  
 
Table 8 Antibody conditions used for Western blot analysis 
Antibody Dilution and incubation time 
anti β-Actin, monoclonal mouse (Sigma) 1:20,000 for 1 h 
anti-SF2/ASF, monoclonal mouse 
(kindly provided by A. Krainer, 
Cold Spring Harbor Laboratories) 
1:200 overnight 
anti-SRp20, monoclonal mouse (Santa Cruz) 1:100 for 24 h 
anti-SMN, monoclonal mouse (BD 
Transduction Laboratories) 1:3,000 for 1 h 
anti-Htra2-β1, polyclonal rabbit 1:1,000 for 2h 
anti-cMYC, monoclonal mouse (Invitrogen) 1:1,000 for 1h 
anti-HDAC2 (Santa Cruz) 1:1,000 overnight 
anti-HDAC8 polyclonal rabbit (MBL) 1:1,000 for 2h 
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anti-acetyl Histone H3 K9, monoclonal mouse 
(Upstate) 1:1,000 for 2h 
anti-β-Tubulin, (Sigma) 1:2,000 for 1h 
anti-GADD45α monoclonal mouse (Abnova) 1:1,000 overnight 
 
3.12.8 Chromatin Immunoprecipitation 
Chromatin Immunoprecipitation (ChIP) gives a picture of the protein-DNA interactions 
that occur inside the nucleus of living cells or tissues. Here ChIP was used to determine 
the histone 3 acetylation status of lysine residue 9 (acetyl-H3K9). After treating cells with 
HDACis, the DNA-protein complexes were crosslinked and therefore fixed by applying 
formaldehyde to the cells. After crosslinking, the cells were lysed and the DNA was 
sheared into pieces 0.2-1 kb in length by sonication. Then anti-acetyl-H3K9 antibody-
based immunoprecipitation was performed. After the protein-DNA complexes were 
pulled-down, the cross-linking was reversed and the amount of eluted DNA was 
quantified by real-time PCR. From the quantitative real-time PCR, conclusions may be 
drawn to the histone acetylation status of the respective genomic region. The same 
procedure was repeated with the use of an anti-HDAC8 antibody in order to assess the 
amount of HDAC8 protein bound to the SMN2 promoter region. A more detailed 
describtion is given in the following: 
After protein-DNA cross-linking with formaldehyde (300,000 fibroblast cells in 500 µl PBS 
+ 12.5 µl 36.5% formaldehyde for 8 min at room temperature), cells were washed in PBS 
(2 x 0.5 ml ice-cold PBS) and pelleted (10 min at 470 x g at 4°C). The cell-pellet was 
resuspended in cell lysis buffer (130 µl buffer B (Diagenode) for 5 min on ice). To shear 
the chromatin into 500-1,000 bp long fragments, the cell lysate was sonicated using the 
Bioruptor (Diagenode) with the following parameters: 12 cycles of 30 sec “on” and 30 sec 
“off” each at “high” power. 
Chromatin Immunoprecipitation (ChIP) was performed by using the LowCell# ChIP 
Kit™ (Diagenode) according the manufacturer’s protocol. With the help of protein A-
coated paramagnetic beads respective antibodies were labeled in a first step and 
afterwards used for chromatin pull-down. After the cleanup of DNA, DNA concentration 
was fluorometrically measured by use of the Quant-iT™PicoGreen® dsDNA kit 
(Invitrogen), according to the manufacturer’s manual.  
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Table 9 Antibody conditions for ChIP experiments 
Antibody 
amount for 300,000 cells and 
incubation time 
anti-H3K9ac polyclonal rabbit (Diagenode) 2 µg overnight 
anti-HDAC8 polyclonal rabbit (MBL) 2 µg overnight 
anti-acetyl Histone H3 K9, monoclonal mouse 
(Upstate) 2 µg overnight 
 
For the quantification of the DNA amount of the SMN2 promoter region, which was 
eluted from the respective ChIP experiment, a real-time PCR in the Taqman apparatus 
was performed. Therefore the PowerSYBR green master mix (2x) from Applied 
Biosystems was used. The mentioned master mix contains Taq-polymerase and SYBR-
green, which is needed for a quantitative real-time PCR. The exact compound and 
conditions for the SMN2 promoter real-time PCR are given in the subsequent tables. 
 
Table 10 Compunds for the SMN2 promoter real-time PCR 
Mastermix for Real-Time 25µl  
SYBR-MM [2x] 12.5 µl 
Primer 1 [10 pmol] 0.5 µl 
Primer 2 [10 pmol] 0.5 µl 
DNA (20ng) e.g. 3.5 µl 
H2O 8 µl 
 
 
Table 11 Conditions for real-time SMN2 promoter PCR 
 
temperature time Mode 
1x 50° C 2 min Activation of Taq 
1x 95° C 10 min Denaturation 
95° C 15 sec Denaturation 
60° C 45 sec Annealing 40x 
70° C 45 sec Taq activity/ fluorescent measurement 
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3.13 Histochemistry 
Before whole mouse organs or biopsies were embedded in paraffin, they were fixed in 
2% paraformaldehyd (PFA) over night and afterwards dehydrated with the help of an 
infiltration machine (Leica). Embedded samples were cut with the help of microtome 
(Leica) into 8 µm thick sections. 
3.13.1 Nissl staining 
Cresyl violet is a basic dye, which stains cell bodies and nuclei. Cross sections of the 
spine of mice were stained with the Nissl staining method in order to visualize cell bodies 
and nuclei of neurons, using the following steps: 
 
1. depariffinization in Xylol     3 min 
2. rehydration in a downward ethanol series 
 100% ethanol     3 min 
 96% ethanol     3 min 
 70% ethanol     3 min 
 50% ethanol     3 min 
 PBS       5 min 
3. staining in Cresyl Violet acetate   10 min 
4. wash in aquabidest.     
5. wash in high diluted acetic acid (2-3 drops acetic acid in 100 ml H2O) 
6. wash in aquabidest. 
 
After the last washing step was finished, the sections were mounted in Vectashield 
mounting medium. 
3.13.2 Hematoxylin and eosin staining 
The hematoxylin and eosin (H&E) staining method involves application of the basic dye 
hematoxylin, which colors basophilic structures blue-purple, whereas the alcohol-based 
acidic eosin Y colors eosinophilic structures bright pink. The cellular basophilic structures 
contain nucleic acids, such as the ribosomes and the chromatin-rich cell nucleus, and 
the cytoplasmatic regions rich in RNA. Structures which contain intracellular or 
extracellular protein and most of the cytoplasm are stained by eosin. H&E staining was 
used for muscle overview stainings. Subsequently a detailed H&E staining protocol is 
given: 
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1. deparaffinization in Xylol     30 min 
2. rehydration in a downward ethanol series 
 100% ethanol     1 min 
96% ethanol     1 min 
70% ethanol     1 min 
 PBS       1 min 
 Water      1 min 
3. staining in hematoxylin    6 min 
4. short wash in water       
5. wash in water      15min 
6. short wash in aquabidest. 
7. staining in eosin     1 min 
8. short wash in water     6-7 times 
9. 70% ethanol      1 min 
10. 96% ethanol      1 min 
11. 100% ethanol     1 min 
12. Xylol       1 min 
13. embedding in Entellan 
 
 
3.13.3 Immunohistochemistry 
For preparation, muscle biopsies from the gastrocnemius muscle were embedded in 4% 
low melting agarose (Cambrex). In order to perform immunostainings of the 
neuromuscular junctions, always relatively thick (200 µm) vibratome sections were 
prepared. To visualize neuromuscular junctions (NMJ) anti-Neurofilament M antibody 
(Millipore), which recognizes the neurofilaments and tetramethylrhodamin-labelled α-
bungarotoxin (α-BTX) (Invitrogen), which binds to acetylcholine receptors in the NMJs, 
were used, following the below-mentioned protocol. 
 
Table 12 Stepwise protocol for immunostaining of neuromuscular junctions. Used material and 
respective conditions. 
Substances Conditions 
Day 1  
Washing: in PBS  3 x 5 min 
Blocking: in 4%BSA in PBS  1 h 
Staining: anti-Neurofilament M (145kDa) rabbit 1:350 dilution 
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in 2% BSA/PBS/1%Triton X overnight (wet board) at 4°C 
  Day 2  
Washing: in PBS  3 x 5 min 
Staining: donkey anti-rabbit Cy2 (Dianova) 
and α-BTX 
in 2% BSA/PBS/1%Triton X 
1:40 dilution 
1:500 dilution 
For 4 h (wet board) at 4°C 
Washing: in PBS  3 x 5 min 
Mounting Medium w/o : Mounting medium with Dapi 1:4 dilution 
  
 
 
3.13.4 Analysis of the motor neuron, NMJ and muscle stainings 
o Motor neuron count 
After the whole spine (including bones and spinal cord) was cut into 8 µm cross section 
and stained with Nissl-staining (as previously described in chapter 3.13.1), the cross 
sections from the lumbar region were analyzed under the light microscope. To avoid 
counting the same motor neurons several times, not subsequent sections, but every third 
or fourth section was analyzed. The obvious shape and size of the motor neurons and 
their specific localization in the anterior horns of the spinal cord, allowed a restricted and 
specific motor neuron count. The motor neurons of 20 cross sections each derived from 
3 SAHA treated P5 SMA, 3 untreated P5 SMA, 3 SAHA treated P5 heterozygous, and 3 
untreated P5 heterozygous animals were counted. The same was repeated for P10 
mice. The motor neurons were counted by eye and subsequently evaluated. 
 
o NMJ evaluation 
Immunohistologically labeled neuromuscular junctions (NMJs) were visualized under a 
fluorescence microscope. Two-channel pictures (red: α-BTX, green: neurofilament M) 
were taken from NMJs. The surface area of each NMJ was measured with the help of 
AxioVision Rel.4.7 computer software (Zeiss). 100 NMJs were measured for each 
respective animal. The muscle biopsies for the NMJ stainings derived from 3 SAHA 
treated P10 SMA, 3 untreated P10 SMA, 3 SAHA treated P10 heterozygous, and 3 
untreated P10 heterozygous animals. The NMJ evaluation was subsequently analyzed 
by the use of statistic software (MS Excel, SigmaPlot). 
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o Muscle fiber evaluation 
The musculus rectus femoris was stained with the H&E staining method. Under a light 
microscope an overview of the muscle structure was clearly visible. Comparable to the 
NMJ evaluation, the surface area of each muscle fiber was measured with the help of 
AxioVision Rel.4.7 computer software (Zeiss). 100 muscle fibers were measured for 
each respective animal. The muscle biopsies for the muscle fiber stainings derived from 
3 SAHA treated P10 SMA, 3 untreated P10 SMA, 3 SAHA treated P10 heterozygous, 
and 3 untreated P10 heterozygous animals. The muscle fiber evaluation was 
subsequently analyzed by the use of statistic software (MS Excel, SigmaPlot). 
 
3.14 Statistical methods 
Whenever the significance of the RNA expression levels after HDACi treatment as well 
as the changed protein levels were tested, it was done by the use of a directional 
student’s t-test for uncorrelated samples. This significance test was performed for both, 
cell-derived protein and RNA levels after in vitro treatment and tissue-derived protein and 
RNA levels after in vivo treatment. In all cases, three levels of statistical significance 
were distinguished: p<0.05, p<0.01, and p<0.001. 
 To evaluate the significant variance in the number of born SMAB mice compared to 
the expected number of SMA mice, a chi-square (χ²) test was performed. 
 A Wilcoxon-rank-sum test was performed in order to determine the significance in 
the increase of survival (the shift of the Kaplan-Meier curves) of the SMA mice after 
SAHA treatment. 
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4 Results 
In 96% of all patients with proximal spinal muscular atrophy (SMA) the homozygous loss 
of the survival motor neuron gene 1 (SMN1) is either caused by a deletion or a gene 
conversion of SMN1 into its almost identical copy gene SMN2 (Wirth et al. 1999). The 
absence of the SMN1 gene causes the degeneration of the α-motor neurons in the 
anterior horns of the spinal cord and thereby causes a progressing atrophy of the 
voluntary muscles. All SMA patients retain at least one copy of the SMN2 gene, which is 
the main modifying gene of SMA. This is reflected by the fact that the disease severity 
inversely correlates with the SMN2 copy number (Brahe 2000; Burghes 1997; Feldkotter 
et al. 2002). The SMN2 gene is incapable to produce enough full-length SMN2 
mRNA/protein; only ~10% of all SMN2 transcripts are spliced correctly, including all 
exons, whereas ~90% of the SMN2 transcripts lack exon 7 (Gennarelli et al. 1995; 
Lefebvre et al. 1995; Lorson et al. 1999).  
For a potential SMA therapy the main target is the SMN2 copy gene. Different 
strategies in modifying the SMN2-derived SMN protein level are possible. Two main 
policies are the elevation of the expression level of SMN2 and the correction of the 
splicing of the SMN2 pre-mRNA. The attempt that we performed was the epigenetic 
modification of the SMN2 gene by means of histone deacetylase inhibitors (HDACi). In 
our laboratory we could prove that the FDA approved drug valproic acid (VPA), which 
functions as an HDACi, is able to up-regulate SMN expression in vitro and in vivo in SMA 
carriers and patients (Brichta et al. 2003; Brichta et al. 2006a). Recently, the favorable 
effect of VPA for a potential SMA therapy was further underlined by the in vivo findings in 
an SMA mouse model (Tsai et al. 2008a).  
However, there is still a need for new potential SMA neurotherapeutics, since a 
clinical trial showed that VPA is able to increase SMN levels in only one third of SMA 
patients, whereas one third did not respond to the regimen and one third of patients even 
showed a down-regulation of the SMN expression (Brichta et al. 2006b). The results 
from a recent open label trial of VPA in 42 subjects with SMA revealed that this HDACi 
was well-tolerated, but no significant positive effect on the SMA progression has been 
observed. Nevertheless, weight gain and carnitine depletion has been found to be 
significant adverse effects (Swoboda et al. 2009). We focused our search for HDACi first 
on new substances from different chemical groups: the benzamide M344, the peptide 
depsipeptide (FK228) and the hydroxamic acid suberoylanilide hydroxamic acid (SAHA). 
The goal was the identification of new potential SMA therapeutics. Moreover, the broad 
range of undesirable side effects of unspecific pan-HDACis leads us to concentrate our 
search on a specific HDAC which regulates SMN2 expression and a respective HDACi. 
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4.1 In vitro experiments with histone deacetylase (HDAC) inhibitors in 
fibroblast cell lines derived from SMA patients and SMA mouse 
models 
4.1.1 Treatment of SMA fibroblast cultures with M344 
M344 (IUPAC name: 4-(Diethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide) has 
1999 been synthesized as an amide analogue of trichostatin A (TSA) by Jung et al.(Jung 
et al. 1999). It has been shown that M344 is a potent histone deacetylase inhibitor 
(HDACi) (IC50 = 100 nM), which induces terminal cell differentiation and causes an 
increase in hyperacetylated histone H4 and H3 (Jung et al. 1999; Takai et al. 2006). 
M344 has been proven to be an antiproliferative agent, which is able to suppress the 
growth of human endometrial and ovarian cancer cells by inducing cell cycle arrest and 
apoptosis (Takai et al. 2006). Because of its high potency in inhibiting HDACs, M344 
was chosen for in vitro testing in SMA patient derived fibroblast cells, with regard to 
investigate M344´s potency in up-regulating the SMN2 expression. 
 
 
 
Figure 11 Chemical structure of the benzamide M344 
 
In our laboratory, a collection of more than 100 primary fibroblast cell lines derived from 
epidermal skin biopsies of SMA patients, carriers and controls, is available. The rapid 
growth and the stable reproduction rate turn these fibroblasts into an important tool for in 
vitro testing of potential SMA neurotherapeutics. Cell lines from SMA type I (ML17; 2 
SMN2 copies), type II (ML20; 2 SMN2 copies) and type III (ML12; 3 SMN2 copies) 
patients were chosen to perform in vitro tests with M344. As preliminary work the optimal 
time period for M344 treatment was assessed by SMN protein level quantification (via 
western blotting) after 12, 24, 32, 48, 64, 80 and 96 h (M. Rießland, Diploma Thesis). For 
M344 treatment the optimal and most effective treatment period was 64 h and therefore 
chosen for all subsequent experiments. 
4.1.1.1 Impact on SMN2 RNA levels 
In order to quantify the transcript amounts, first whole RNA of treated and untreated 
fibroblast cultures was precisely measured on a microplate reader using the RiboGreen® 
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dye. After that an exact amount of 150 ng was reverse transcribed. To avoid misleading 
results from the risk of altered housekeeper gene expression after HDACi treatment, the 
SMN2 mRNA levels to the total RNA amount. 
To assess whether M344 has an impact on the expression level of SMN2, the total 
amount of both SMN2 transcripts, FL-SMN2 and ∆7-SMN2, was quantified. The 
diagrammatic presentation of the quantified mean values for FL-SMN2 and ∆7-SMN2 is 
shown in Figure 12 a and b, respectively. In all three different cell lines a more than 1.6-
fold up-regulation of the full-length transcript was observed after the treatment with 30 
µM of M344 compared to the mock-treated cells (Figure 12). Interestingly, this elevation 
was not observed on the ∆7-SMN2 levels. Whereas in ML20 the ∆7-SMN2 remained 
nearly unchanged, in ML12 and ML17 a significant down-regulation starting from M344 
concentrations of 5 µM was noticed. After treatment with 50 µM M344 the ∆7-SMN2 level 
in ML12 went down to ~64% compared to the mock treated expression level. An even 
higher effect was found in ML17, where the ∆7-SMN2 amount decreased to ~56% after 
treatment with 5 µM M344 (Figure 12b). This data suggests that not only the basic 
expression level of SMN2 can be elevated by M344 treatment, but that also the splicing 
pattern of the SMN2 pre-mRNA is reversed by its regimen. This reversion is clearly 
shown in Figure 12c. For each cell line in nearly every concentration of M344 a 
significant increase of the FL-SMN2/∆7-SMN2 ratio points towards the strong reversion 
of the splicing pattern. This reversion of the splicing pattern would be another beneficial 
effect of M344 in terms of looking for a future potential SMA neurotherapeutic agent. 
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Figure 12 Up-regulation of SMN2 mRNA in fibroblasts derived from SMA patients treated with 
increasing concentrations of M344 (0.5–100 µM) for 64h. Quantitative real-time PCR results are 
summarized as bar graphs. a Mean values (± SEM) for FL-SMN2 relative to total RNA amount in 
cell lines ML12, ML17 and ML20. b Mean values (± SEM) for ∆7-SMN2 relative to total RNA 
amount in cell lines ML12, ML17 and ML20. ∆7-SMN2 levels were nearly unchanged or even 
reduced, suggesting an efficient reversion of the splicing pattern contributing to the significantly 
increased FL-SMN2 levels. c Increasing FL-SMN2/∆7-SMN2 ratios in all cell lines, pointing out 
the strong reversion of the splicing pattern (* p < 0.05; ** p < 0.01; *** p < 0.001). 
 
4.1.1.2 SMN and splicing factor protein level change under M344 
To assess the impact of M344 on protein level, semiquantitative Western blotting was 
applied using β-Tubulin as internal control. All experiments were carried out in triplicates, 
using at least three different passages of the respective fibroblast cell line.  
Whole protein extracts were first measured by the Bradford method; equal 
amounts of protein (7.5 µg) were loaded onto SDS PAGE gel and after electrophoresis, 
blotted on nitrocellulose membranes. The signal-intensity of the subsequently performed 
immunostainings was densitometrically quantified.  
On protein level every tested fibroblast line responded to the 64 h M344 treatment 
in an up-regulation of the SMN protein level. The SMN protein amounts were significantly 
and dose-dependently up-regulated, reaching maximum values in the respective cell line 
ranging between 3- and 7-fold at concentrations of 30 to 50 µM (Figure 13 a and b). 
Importantly, a significant augmentation of SMN up to 1.5- to 3-fold could already be 
noticed at a very low concentration of only 5 µM M344. 
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Figure 13 Increase of SMN and alteration of splicing factor protein levels in fibroblast cell lines 
from SMA patients after treatment with increasing concentrations of M344 (0.5–100 µM) for 64 h. 
a Western blots loaded with equal protein amounts were simultaneously stained with anti-β-
tubulin, anti-SFRS10, anti-SF2/ASF, anti-SRp20 and anti-SMN. The pictures show representative 
Western blot analyses of cell cultures ML12, ML17 and ML20. b Mean SMN protein levels (± 
SEM) in ML12, ML17 and ML20 relative to β-tubulin (* p < 0.05; ** p < 0.01; *** p < 0.001) 
 
Since it was noticed that M344 is able to reverse the splicing pattern of SMN2 pre-
mRNA, the question arose, if the splicing factor which is mainly involved in SMN2 
splicing correction, namely SFRS10, could be expressed differentially under M344 
treatment. For that purpose quantitative Western blot analyses were performed, 
including the SR-like splicing factor SFRS10 (Hofmann et al. 2000), the SR splicing 
factor SF2/ASF, which is known to be involved in SMN pre-mRNA splicing (Cartegni and 
Krainer 2002) and the SR splicing factor SRp20, which was excluded to act in that way 
(Hofmann et al. 2000).  
Whereas SF2/ASF protein levels were subjected to big fluctuations below and 
above baseline (Figure 14 a), SFRS10 showed a clear up-regulation in two of the three 
cell lines, while a slight down-regulation was observed for the remaining one at 50 and 
100 µM M344 (Figure 14b). 
Strikingly, both SFRS10 and SRp20 protein levels were augmented in a significant 
manner at the respective M344 concentrations. ML12 turned out to have a 3-fold 
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increase of SFRS10 at 30 µM M344 and ML17 even showed a 4.3-fold elevated 
expression at 50 µM. ML20 revealed only a very weak dose-dependent response. 
Nevertheless, even ML20 reached a highly significant increase of SFRS10 protein at 10 
µM of M344 (Figure 14c). 
The response to M344 treatment in SRp20 protein expression varied drastically 
inter-individually. ML12 showed a 4-fold increase starting from 10 µM M344 and its 
maximum elevation at 50 µM M344 culminated in a 7-fold protein concentration. In 
contrast to ML12, ML20 reached its maximum SRp20 expression of only 200% at 30 µM 
M344. 
To draw a conclusion from these protein-expression data, M344 has a high impact 
not only on transcriptional activation of SMN2 but also it is able to reverse the SMN2 pre-
mRNA splicing pattern via up-regulation of the mainly involved splicing factor SFRS10. 
Furthermore, the HDAC inhibitory function of M344 leads to the expression elevation of 
the SMN2 unrelated splicing factor SRp20, indicating an unspecific impact of M344 on 
this protein. 
   
 
Figure 14 Regulation of the splicing factors a SF2/ASF, b SFRS10 and c SRp20 in the human 
SMA fibroblast lines ML12, ML17 and ML20 treated with increasing amounts of M344 for 64 h. 
SFRS10 and SRp20 protein levels are clearly elevated, while SF2/ASF is subject to expression 
fluctuations or nearly unchanged (* p < 0.05; ** p < 0.01; *** p < 0.001). 
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4.1.1.3 Change of the number of gems 
The SMN protein is localized in subnuclear structures called gems (Liu and Dreyfuss 
1996). Since the SMN protein level is strongly elevated under the M344 treatment, the 
next point to be investigated was the subcellular localization of SMN. To follow up the 
hypothesis that M344 is able to augment the number of gems, these structures were 
visualized by SMN immunofluorescence staining and counted. The nuclei were 
counterstained with 4′,6-Diamidino-2-phenylindol (DAPI). The number of gems per 100 
cells was compared between the mock (DMSO) and the M344 (10 µM was chosen as a 
mean dosage, which showed remarkable responses in the respective cell lines) treated 
fibroblasts. M344 treatment revealed for each cell line a significant elevation of the 
number of gems per 100 cells (Figure 15a). Moreover, it was observed that the 
percentage of cells without gems decreased, whereas the percentage of cells with a low 
number of nuclear gems (one or two gems) remarkably increased, whereas only a few 
cells with a higher number of gems was found (Figure 15b). This suggests that the 
number of gems increased not only in cells, which prior to the M344 treatment contained 
gems, but that a great proportion of the monitored cells produced gems de novo.  
Strikingly, a clear correlation between the degree of SMN protein amount up-
regulation and the elevation of nuclear gem was found for every cell line. On protein level 
ML12 revealed the weakest increase after M344 stimulation of about 3-fold (Figure 13b), 
the same range of increase was observed on gem level (~3.3-fold). The highest impact 
in SMN protein expression was observed for ML20 (~7-fold) (Figure 13b). Consistent 
with this result, the highest increase (~30-fold Figure 15a) of observed gems was also 
found here. The intermediate up-regulation of SMN (~4.3-fold) in ML17 was reflected on 
gem level, where a significant 5.4-fold increase was found (Figure 15a). 
Noteworthy, for all tested cell lines it could be stated that the respective line, which 
contained in an untreated state relatively low amounts of gems showed the highest 
response in up-regulating gem numbers. 
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Figure 15 a Inter-individual comparison of the gem number/100 cells in untreated and M344-
treated cell lines. For each cell line, a clear response on M344 treatment resulting in a significant 
elevation of the number of gems was observed (* p < 0.05; ** p < 0.01; *** p < 0.001). b Pie 
charts representing the percentages of cells without or with a certain number of gems in untreated 
or M344-treated fibroblasts. c Representative microscopy images of nuclear gems (marked with 
white arrows) from every treated cell line. Gems were stained with anti-SMN-FITC antibody, 
whereas the nuclei in blue were counterstained with DAPI. White bar = 10µm. 
 
c 
b 
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4.1.1.4 Cytotoxicity of M344 in SMA fibroblasts 
Because it has to be considered that pan-HDAC inhibitors like M344 may have many 
unfavorable side effects in cell treatment, an MTT (thiazolyl blue tetrazolium bromide) 
assay was performed, which determines the viability of cells (Mosmann 1983). 
The decrease of the fluorometric absorption of the formazan crystals, which are 
produced by living cells out of the MTT substrate, reached a significant level compared 
to mock treated cells at concentrations of M334 starting from 50 µM (Figure 16). This in 
turn indicates an increased cytotoxicity of M344 for fibroblasts for the concentrations 50 
and 100 µM.  
However, since M344 showed a high impact on SMN expression (3- to 6-fold up-
regulation) at already considerably lower concentrations (5-30 µM), this substance could 
still be considered as a potential SMA therapeutic agent. 
To date M344 is not FDA approved and so it remains elusive whether this HDACi might 
be used in a prospective SMA therapy. Until then M344 remains an experimental drug 
and we did not imply M344 for in vivo testing. 
 
 
 
Figure 16 MTT cell viability assay in ML12 demonstrating Cytotoxicity of M344 at concentrations 
higher than 30 µM, implicating increasing cell death of cultured SMA fibroblasts at these M344 
amounts (treatment time 64 h) (*** p < 0.001)  
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4.1.2 Treatment of SMA fibroblast cultures with FK228 (Depsipeptide)  
Chromobacterium violaceum is producing the HDAC inhibitor FK228 (formerly named 
FR901228), also known as depsipeptide. FK228 is a very potent pan-HDACi, which 
predominantly inhibits HDAC class I (Furumai et al. 2002). Depsipeptide shows a potent 
in vivo antitumor activity against both human tumor xenografts and murine tumors (Ueda 
et al. 1994a; Ueda et al. 1994b). Gloucester Pharmaceuticals, Inc. holds the patent for 
FK228 and started recently several phase 2 clinical trails for different cancer entities 
(www.gloucesterpharma.com). This company graciously provided us with a limited 
amount of FK228 for a small in vitro testing setup. 
 
Figure 17 Chemical structure of FK228 (Depsipeptide) 
 
Two human SMA type I fibroblast cell lines (ML16 3 SMN2 copies and ML17; 2 
SMN2 copies) and one murine (MEF14, derived from an embryo SMAB mouse strain 
(Monani et al. 2000), carrying the genotype Smn-/- SMN2tg/tg) fibroblast cell line were 
tested for SMN2 expression changes after FK228 treatment. Because of the limited 
amount of FK228, the numbers of gems were quantified only in the human cell lines. 
As preliminary work the optimal time period for FK228 treatment was assessed by 
SMN protein level quantification after 12, 24, 32, 48, 64, 80 and 96 h (data not shown). 
For FK228 treatment the optimal and most effective treatment period was 48 h for the 
murine fibroblast line and 64 h for the human cell lines and therefore chosen for all 
subsequent experiments. 
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4.1.2.1 Impact on SMN2 RNA levels 
To answer the question whether FK228 has an effect on the expression level of SMN2, 
the total amount of both SMN2 transcripts, FL-SMN2 and ∆7-SMN2, was quantified. As 
mentioned earlier, since HDACi may influence the expression of housekeeping genes, 
total RNA amount was taken as internal control. Therefore, the RNA derived from FK228 
treated and untreated fibroblast cultures were precisely measured with the help of a 
microplate reader using the RiboGreen® dye. Subsequently exactly 150 ng RNA were 
reverse transcribed.  
Using real-time RT PCR, it was shown that the RNA expression levels of the full 
length SMN (FL-SMN) are elevated by FK228 treatment in SMA-fibroblast cells. FK228 
is a very potent HDACi, indicated by its high effect on the SMN expression level starting 
at low nanomolar doses. In the murine cell line MEF14 a significant increase of FL-SMN 
to over 170% was observed at only 10 nM FK228. Generally, every treated cell line 
responded positively to the FK228 regimen. The FL-SMN level was up-regulated to 
~300% in ML17 at 50 and 100 nM, to ~140% in ML16 and MEF14 to 185% at 100 nM 
see Figure 18). This respective figure shows the diagrammatic presentation of the 
quantified mean values for FL-SMN2, ∆7-SMN2 and the ratio between both, respectively. 
The most pronounced response revealed the cell line ML17 (SMA type I), with a 3-fold 
elevation of the FL-SMN level at relatively low FK228 concentrations of 50 and 100 nM. 
The inter-individual differences of human SMA fibroblast cell lines become very clear, 
comparing the FL-SMN expression change after FK228 treatment of ML16 and ML17. 
Although both cell lines were derived from type I SMA patients, ML16 responded at none 
of the FK228 concentrations in a significant manner, although this cell line showed  weak 
elevated FL-SMN levels (Figure 18a), however to only ~140%. The murine SMA cell line 
(MEF14), presented a significant augmentation of the FL-SMN level at nearly all 
concentrations with a maximum increase to 185% at 100 nM. These data indicate that 
human SMN2 is activated by FK228 also in a heterologous background, such as the 
mouse. 
Strikingly, for all investigated cell lines the ∆7-SMN2 level declined concordantly 
with FK228-treatment. In ML16 the decrease of the ∆7-SMN2 amount reached 
significance already at a concentration of 10 nM FK228. Moreover, at a concentration of 
500 nM the ∆7-level dropped to ~44%. For ML17 the amount of the ∆7-SMN2 transcripts 
remained nearly unchanged at all concentrations, except at the highest concentration of 
500 nM, where it revealed significantly reduced levels (~43%). The murine SMA 
fibroblast cell line showed a comparable reaction to the FK228 regimen on ∆7-SMN2 
level. An obvious decline of the ∆7-SMN2 transcript level was observed, starting to be 
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significant at a FK228 concentration of 50 nM. A severe reduction of the ∆7-SMN2 
amount to ~42% was detectable at the highest concentration of 500 nM FK228. 
The up-reglation of FL-SMN2 on one side and the down-regulation of ∆7-SMN2 on 
the other side resulted in an elevation of the FL-SMN2/∆7SMN2 ratio. Nearly in all cell 
lines and at every concentration of FK228 a significant increase of this ratio was 
observed (Figure 18c).  
Taken together, the positive shift in FL-SMN2 and the decline on ∆7-SMN2 level 
obviously suggests an impact on the splicing of the SMN2 pre-mRNA. This influence 
might be direct or indirect, by the up-regulation of a respective splicing factor, which 
reverses ∆7-SMN2 towards FL-SMN2 transcripts. However, the decline of both FL-
SMN2 and ∆7-SMN2 transcripts observed for the highest FK228 concentrations at 250 
nM and 500 nM suggests a certain cytotoxicity of FK228. The cytotoxicity will therefore 
be analyzed in chapter 4.1.2.4. 
 
 
Figure 18 Up-regulation of SMN2 mRNA in fibroblasts derived from SMA patients and on murine 
embryonic fibroblast line (MEF14) derived from a SMA mouse (Smn-/-;SMN2tg/tg) treated with 
increasing concentrations of FK228 (10–500 nM). Quantitative real-time PCR results are 
summarized as bar graphs. a Mean values (± SEM) for FL-SMN2 relative to total RNA amount b 
Mean values (± SEM) for ∆7-SMN2 relative to total RNA. ∆7-SMN2 levels were nearly unchanged 
or even clearly reduced, suggesting an efficient reversion of the splicing pattern contributing to the 
significantly increased FL-SMN2 levels. c Increasing FL-SMN2/∆7-SMN2 ratios in all cell lines, 
pointing out the reversion of the splicing pattern (* p < 0.05; ** p < 0.01; *** p < 0.001). 
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4.1.2.2 SMN and SFRS10 protein level change under FK228  
To assess the impact of FK228 on the protein level of SMN, quantitative Western blots 
were performed. Since it was evident from the preceding RNA expression experiments 
that FK228 might influence the splicing of SMN2, the protein expression of the main 
splicing factor of SMN2, namely SFRS10, which is known to be capable to reverse the 
splicing pattern, quantitative Western blots of this factor was also performed. 
 In all three different tested cell lines, FK228 had a significant impact on the SMN 
protein level. Comparably to the previous observations regarding the elevation of the FL-
SMN2 transcript level, human ML17 and the murine MEF14 revealed the highest 
increase in SMN protein level (Figure 19).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19 Increase of SMN and alteration of SFRS10 protein levels in fibroblast cell lines from 
SMA patients and SMA mouse model after treatment with increasing concentrations of FK228 
(10–500 nM) for 64 h (48h for murine fibroblasts). a, b, c Western blots loaded with equal protein 
amounts were simultaneously stained with anti-β-Actin , anti-SFRS10 and anti-SMN. The pictures 
show representative Western blot analyses of cell cultures ML16, ML17 and Mef14.  
d Mean SMN protein levels (± SEM) in ML16, ML17 and MEF14 relative to β-Actin e Mean 
SFRS10 protein levels (± SEM) in ML16, ML17 and MEF14 relative to β-Actin (* p < 0.05; ** p < 
0.01; *** p < 0.001)  
e 
d
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The human fibroblast line ML16 responded with an up-regulation of the SMN protein 
amount to maximum level of ~180% at a FK228 concentration of 250 nM. ML16 already 
revealed a significant augmentation to ~122% at the lowest FK228 concentration of 10 
nM. Moreover, 50 nM of FK228 elevated SMN protein levels to ~179% compared to the 
mock-treated cells. The other human cell line ML17 responded to the FK228 regimen 
with a far higher elevation of SMN protein. 250 nM FK228 led to the maximum up-
regulation of SMN protein amount of more than 4-fold. Interestingly, starting at the lowest 
concentration of 10 nM FK228, ML17 reacted in a significant increase of SMN to more 
than 175%. The murine fibroblast line revealed a 4.4-fold up-regulation of SMN at 250 
nM. Here, the highest significant increase to ~347% was detected at a concentration of 
500 nM FK228. 
 The most important splicing factor of the SMN2 transcript is SFRS10. This factor 
was subjected to quantitative Western blot analysis, in order to explain the reason for the 
reversion of the splicing pattern (see chapter 4.1.2.1). Strikingly, all tested cell lines 
responded to FK228 treatment in an elevation of SFRS10. The ML17 and MEF14 
revealed a high up-regulation of SFRS10 (ML17; 213% at 500 nM FK228; MEF14; 256% 
at 250 nM), the cell line ML16 responded to low FK228 concentrations in a decline of 
SFRS10 levels. Starting at 100 nM FK228 ML16 showed also a SFRS10 augmentation, 
reaching 147% at 500 nM FK228. 
 Taken these results together, it is obvious that FK228 mediated up-regulation of 
the SFRS10 level results in a shift of the splicing pattern towards SMN2 exon 7 inclusion. 
The ratio of FL-SMN to ∆7-SMN strongly correlates with the SFRS10 protein level. This 
is observable for every tested cell line. 
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4.1.2.3 Change of the number of gems  
It is well known that SMN proteins form nuclear aggregates, called gems. The respective 
number of these gems most likely reflects the amount of functioning SMN protein in the 
cell. Therefore, immunochemistry-stainings in human SMA fibroblasts was performed. 
Unfortunately the limited amount of the test substance FK228, restricted the treatment 
for the immunochemistry experiments to only the two human cell lines ML16 and ML17. 
Nevertheless, comparable to the already reported expression results, ML16 
reacted in a weak but significant increase of gems from 5.16±2.13 gems/100 nuclei to 
22.8±1.51 gems/100nuclei, whereas ML17 revealed a ~6-fold up-regulation in gem 
numbers (from 7.23±3.5 gems/100 nuclei to 45.87±4.59 gems/100nuclei). 
Additionally, the 50 nM FK228-treatment was observed to increase the percentage 
of cells with a low number of nuclear gems (one or two gems) remarkably, whereas the 
cell number without gems decreased. This means that the number of gems increased 
most likely not only in cells, which prior to the FK228 treatment contained gems, but that 
the treated cells produced new gems.  
These findings suggest that the elevation seen on RNA and protein level is 
reflected in the amount of subnuclear gems. 
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Figure 20 a Inter-individual comparison of the gem number/100 cells in untreated and FK228-
treated cell lines. For each cell line, a clear response on FK228 [50 nM] treatment resulting in a 
significant elevation of the number of gems was observed (*** p < 0.001). b Pie charts 
representing the percentages of cells without or with a certain number of gems in untreated or 
FK228-treated fibroblasts. c Representative microscopy images of nuclear gems (marked with 
white arrows) from every treated cell line. Gems were stained with anti-SMN-FITC antibody, 
whereas the nuclei in blue were counterstained with DAPI. White bar = 10µm. 
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4.1.2.4 Cytotoxicity of FK228 in SMA fibroblasts 
To test for cytotoxicity of FK228, a cell viability test, the so-called MTT-assay was 
applied. After treating the cells with FK228, the capability of the cell to convert MTT 
(thiazolyl blue tetrazolium bromide) into formazan crystals was assessed, which 
determines the viability of cells (Mosmann 1983). 
The test for cytotoxicity revealed an unfavorable effect of the fibroblast lines. The 
test substance FK228 is known to be a very potent HDACi, starting to be efficient at low 
nanomolar concentrations. However, virtually all treatment concentrations of FK228 
showed a negative effect on cell survival, making a future use of FK228 as a potential 
SMA neurotherapeutic drug questionable. Because of the observed high in vitro 
cytotoxicity, FK228 was not chosen to be tested for a future animal trail. Still, the in vitro 
data helped to gain insight into the SMN2 activation via HDACi treatment, since FK228 
was shown to activate SMN2 even on a heterologous background, such as the mouse. 
 
 
 
Figure 21 MTT cell viability assay in ML16 demonstrating cytotoxicity of FK228 at concentrations 
starting from 10 µM, implicating increasing cell death of cultured SMA fibroblasts at these FK228 
amounts (treatment time 64 h) (*** p < 0.001)  
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4.2 Identification of the specific histone deacetylase (HDAC) regulating the 
expression of SMN2 
With regard to a prospective SMA therapy, it would be crucial to identify an applicable 
drug, which bears only a passable amount of unfavorable side effects. Since pan-HDACi, 
such as VPA, FK228, M344, or SAHA unspecifically inhibit virtually all classes of 
HDACs, they most probably influence a wide variety of genes. This assumption is 
supported by the previously described results that the expression of up to 22% of genes 
can be altered by HDAC inhibitors (Peart et al. 2005). Thus, several side effects by the 
unspecific up-regulation of genes are consequently expected. At least for the long-term 
used HDACi VPA a number of unfavorable side effects have been described (reviewed 
in (Gerstner et al. 2008)). 
 
4.2.1 Effects of histone deacetylase (HDAC) knock-down experiments on 
SMN2 expression 
To identify the specific HDAC, which is able to regulate the SMN2 expression, a siRNA 
knock-down approach was applied. Therefore, to find the HDAC specifically regulating 
the SMN2 gene the SMN1 deleted SMA patient fibroblast line ML17 was selected. ML17 
was subjected to siRNA knock-down approaches. Each HDAC was knocked down one 
after the other. The knock-down (KD) efficiency was controlled by real-time PCR 
(appendix Figure 56). After the knock-down of each HDAC, the whole protein extracts 
were first measured by the Bradford method; equal amounts of protein (7.5 µg) were 
loaded onto SDS PAGE gel and after electrophoresis, semi-quantitative Western blotting 
was applied using β-Actin as internal control. These experiments were carried out in 
triplicates. 
 Beside inter-individual fluctuations of the SMN protein level, exclusively the knock-
down of HDAC8 resulted in a significant up-regulation of the SMN level (Figure 22 and 
Figure 23). After the quantification of three independent knock-down experiments of all 
Zn2+-dependent classical HDAC from class I, II and IV, solely HDAC8 KD revealed a 
SMN protein elevation to ~150% (p<0.05), suggesting a specific role of HDAC8 in SMN2 
regulation (Figure 23). 
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Figure 22 Representative Western blots of β-Actin and SMN protein after 48h knock-down of 
each classical HDAC (classes I,II,IV) in SMA-fibroblast cell line ML17. After knock-down of 
HDAC8, SMN protein level was significantly elevated. 
 
 
 
 
 
 
 
Figure 23 SMN protein quantification (relative to β-Actin) after 48h knock-down of each classical 
HDAC (classes I,II,IV). After knock-down of HDAC8, SMN protein level was significantly elevated. 
Quantification of triplicate knock-down in SMA fibroblast cell line ML17. 
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4.2.2 Chromatin immunoprecipitation of HDAC8 in the promoter region of 
SMN2 
Since the knock-down of HDAC8 was found to up-regulate the expression of SMN 
protein, the question was addressed whether the HDAC8 protein is bound to the 
promoter region of SMN2. Therefore the previously characterized promoter region of 
SMN2 (Kernochan et al. 2005) has been investigated. The SMN1-deleted SMA patient 
derived fibroblast line ML17 was chosen to perform a chromatin immunoprecipitation 
(ChIP) experiment. To do so, all proteins bound to the respective promoter region were 
cross-linked to the DNA by the addition of paraformaldehyde. After this step the DNA 
was sheared by sonication and the respective protein-DNA complexes were 
immunoprecipitated with the help of an anti-HDAC8 antibody. After reversion of the 
cross-linking and elution of the DNA from the HDAC8 proteins, a quantitative real-time 
PCR was performed with specific primers amplifying the respective SMN2 promoter 
regions (Figure 24). 
 The quantification of the SMN2 promoter DNA fragments, which were bound by 
HDAC8 proteins revealed definitive binding in comparison to unspecific binding 
(represented by the unspecific IgG antibody ChIP-experiment). The amount of HDAC8, 
which was bound to the ~2500 bp upstream of the transcription initiation site located 
human SMN2 promoter region 1 (HuSP1), was 3-fold higher than the HDAC8 level, 
which was bound to HuSP3 and HuSP4, which are located in the close vicinity to the 
transcription start site (TSS). Moreover, HuSp2 (~1200 bp upstream TSS) revealed a 2-
fold higher binding of HDAC8 compared to HuSP3 and HuSP4 (Figure 25). 
 To summarize, these findings indicate that HDAC8 is natively bound to the SMN2 
promoter in SMA patient derived fibroblasts. Moreover, it was obvious that the amount of 
HDAC8 was increasing with the distance to the transcription initiations site. 
  
 
 
Figure 24 Schematic overview of the location of primer sets, which were spaced at ~500–1000 bp 
intervals. The arrow indicates the transcription initiation site taken from (Kernochan et al. 2005) 
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Figure 25 Diagrammatic representation of the ChIP-based quantification of the amount of 
HDAC8-protein bound to the respective SMN2 promoter region. Measured in triplicates in SMA-
fibroblast line ML17. IgG served as unspecific background binding control. (*** p < 0.001) 
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4.2.3 HDAC overexpression experiments in SMA fibroblasts and the effect 
on SMN2 expression 
Since it was found that HDAC8 knock-down is capable to up-regulate SMN2 expression 
and that HDAC8 protein is bound in the promoter region of SMN2, the next topic to 
investigate whether the up-regulation of HDAC8 may consequently down-regulate the 
SMN2 expression. Thus, to overexpress HDAC8, ML17 was transfected with an 
expression vector containing the myc-tagged cDNA of human HDAC8. 
 24h after transfection of the plasmid containing the myc-tagged cDNA of human 
HDAC8, the quantification of the subsequent semi-quantitative Western blot revealed a 
HDAC8 concentration dependent down-regulation of the SMN protein amount. 
Compared to the transfection of 4 µg GFP-tagged control plasmid, the expression of the 
transfected HDAC8 increased concentration dependently. A clear inverse correlation of 
the SMN protein level and the HDAC8 expression was observed. While the GFP-plasmid 
transfected cells showed 0% expression of myc-HDAC8, the expression raised from 
~20% (2µg HDAC8 plasmid) over ~50% (4µg HDAC8 plasmid) to ~140% (8µg HDAC8 
plasmid). However, the amount of SMN protein dropped concordantly with the elevation 
of HDAC8. The ~140% overexpression of HDAC8 led to the decline of SMN protein level 
to ~50% compared to the GFP-transfected cells. 
 Taken together these results strongly suggest that HDAC8 is able to regulate the 
SMN2 expression. The amount of overexpressed HDAC8 reflects the level of SMN 
protein decrease, since both values correlate inversely. 
 
 
 
 
 
 
 
 
 
Figure 26 Overexpression of HDAC8 down-regulates the SMN protein level. GFP (control 
plasmid) and HDAC8 (myc-tagged) overexpression for 24h in ML17. a) Picture of Western Blot. b) 
diagrammatic representation of overexpression results.  
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4.2.4 Treatment of SMA fibroblasts with the HDAC8 specific inhibitor PCI-
34051 
 
Figure 27 Chemical structure of PCI-34051 
 
Since the previous HDAC knock-down and overexpression experiments (chapter 4.2.1 
and 4.2.3) suggested that HDAC8 is regulating the SMN2 expression, the possibility to 
chemically inhibit the specific function of HDAC8 raised. Hence, recently a novel 
HDAC8-specific inhibitor has been developed (Balasubramanian et al. 2008). It has been 
stated that HDAC8-specific inhibitor namely PCI-34051 has a >200-fold selectivity over 
the other HDAC isoforms. Moreover, PCI-34051 has been shown to induce caspase-
dependent apoptosis in cell lines derived from T-cell lymphomas or leukemias 
(Balasubramanian et al. 2008). Additionally it has been proven that high HDAC8 
expression was associated with poor prognostic markers and poor overall survival in 
patients with neuroblastoma. However, the treatment of neuroblastoma cell lines as well 
as short-term-culture neuroblastoma cells with with PCI-34051 was proven to inhibit cell 
proliferation and clone formation and to induce differentiation (Oehme et al. 2009). Since 
the in vitro functionality of PCI-34051 has extensively been proven and the previous 
findings suggested the HDAC8 mediated down-regulation of SMN2, PCI-34051 was 
applied for testing in SMA fibroblasts.  
4.2.4.1 Impact on SMN2 RNA levels 
To investigate the impact of PCI-34051 on the SMN2 expression, the total amount of 
both SMN2 transcripts, FL-SMN2 and ∆7-SMN2, was quantified. Again the total RNA 
amount was taken as internal control. After the dye-based precise measurement of the 
RNA concentration, exactly 150 ng RNA were reverse transcribed. After the most 
efficient treatment time was determined via a time-course experiment, the RNA was 
prepared after 6 h of PCI-34051 treatment. 
 The chosen SMA patient fibroblast line and the murine SMA-like fibroblast line 
revealed no increase of SMN2 transcripts. A very weak up-regulation was observed for 
the human cell line, where FL-SMN2 level increased to 120%. However, this 
augmentation did not reach statistical significance. Furthermore, no obvious impact of 
PCI-34051 treatment on the ∆7-SMN2 was observed.  
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 Taken together, the HDAC8-specific inhibitor is not capable to elevate the SMN2 
transcript level in a significant manner. Neither the FL-SMN2 nor the ∆7-SMN2 level was 
significantly elevated by PCI-34051 treatment.  
 
 
Figure 28 SMN2 mRNA expression in fibroblasts derived from a SMA patient (ML17) and one 
murine embryonic fibroblast line (MEF14) derived from a SMA mouse (Smn-/-;SMN2tg/tg) treated 
with increasing concentrations of PCI-34051 (1–50 µM). Quantitative real-time PCR results are 
summarized as bar graphs. a Mean values (± SEM) for FL-SMN2 relative to total RNA amount b 
Mean values (± SEM) for ∆7-SMN2 relative to total RNA. c No obvious change in FL-SMN2/∆7-
SMN2 ratios in all cell lines, revealed no impact on the splicing pattern. None of the observed 
regulations was significant. 
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4.2.4.2 SMN and SFRS10 protein level change under PCI-34051 
In order to check whether the HDAC8-specific inhibitor PCI-34051 is capable to up-
regulate the SMN protein expression, semi-quantitative Western blots were performed, 
with β-Actin as internal control. Additionally the effect of PCI-34051 on the SFRS10 
protein level was assessed, since this protein is known to be the major splicing factor to 
restore the SMN2 splicing (Hofmann et al. 2000). 
 The quantification of the SMN protein levels derived from the treated cell lines 
ML17 (human) and MEF5 (murine) revealed only a limited capacity of PCI-34051 to 
elevate the SMN protein amount. While the human fibroblast line ML17 responded 
positively to PCI-34051 treatment, the murine cell line however revealed no obvious 
change in the SMN protein level. ML17 showed an up-regulation of SMN to ~150% at all 
tested concentrations. The highest significant elevation of the SMN level under PCI-
34051 treatment was to ~185% at a concentration of 30 µM. However, the SFRS10 
protein level was not noticed to be significantly elevated. MEF5 revealed no response to 
PCI-34051 on Sfrs10 level, whereas ML17 responded in a weak up-regulation to a 
maximum level of 147% (at 10 µM PCI-34051) (Figure 29). Small individual fluctuations 
of the SFRS10 expression resulted in a failure of the weak increase to reach statistical 
significance. 
 To summarize the protein expression data of ML17 and MEF5 under PCI-34051 
treatment, it is noteworthy that this HDAC8-specific inhibitor is able to augment the SMN 
protein level in the human SMA patient derived fibroblast line to a mean elevation to 
~150%. This is of particular interest, because the knock-down experiments of HDAC8 
resulted in exactly the same degree of SMN protein augmentation (Figure 23). 
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Figure 29 Impact of PCI-34051 on SMN and SFRS10 protein levels in fibroblast cell lines from 
SMA patient and SMA mouse model after treatment with increasing concentrations of PCI-34051 
(1–50 µM) for 6 h a, b Western blots loaded with equal protein amounts were simultaneously 
stained with anti-β-Actin , anti-SFRS10 and anti-SMN. The pictures show representative Western 
blot analyses of cell cultures ML17 and MEF5. c Mean SMN protein levels (± SEM) in ML17 and 
MEF5 relative to β-Actin d Mean SFRS10 protein levels (± SEM) in ML17 and MEF5 relative to β-
Actin (* p < 0.05)  
 
 
c d 
Results 
 
 
94 
4.2.4.3 Cytotoxicity of PCI-34051 in SMA fibroblasts  
A MTT-assay, which is a cell-viability test, was performed to assess PCI-34051 for 
cytotoxic effects. After treating ML17 for 6h with PCI-34051, a MTT-assay was 
performed. 
 At none of the applied treatment concentration the SMA patient derived fibroblast 
line ML17 showed any signs of cytotoxicity (Figure 30). This favorable in vitro toxicity 
profile of PCI-34051 suggests a possibly good tolerance in prospective in vivo studies. 
Hence, the HDAC8-specific HDACi PCI-34051 might be a good candidate for further in 
vivo trails. 
 
 
Figure 30 MTT cell viability assay in ML17 demonstrating virtually no cytotoxicity of PCI34051, 
implicating a good tolerance by the fibroblasts at the used PCI34051 amounts (treatment time 6h) 
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4.3 In vivo treatment of SMA mouse models with the histone deacetylase 
(HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) 
 
4.3.1 SAHA treatment of the SMAB mouse model 
 
Figure 31 Chemical structure of suberoylanilide hydroxamic acid (SAHA) 
 
Suberoylanilide hydroxamic acid (SAHA, Figure 31) or vorinostat (marketing name 
Zolinza) is a histone deacetylase inhibitor (HDACi), which inhibits virtually all classical 
HDACs (Hahnen et al. 2008). SAHA was the first HDACi approved (in 2006) by the U.S. 
Food and Drug Administration (FDA) for the treatment of cutaneous T cell lymphoma 
(CTCL) (www.merck.com/finance/annualreport/ar2006/pipeline.html). SAHA has been 
shown to reduce glioma progression in vivo (Eyupoglu et al. 2005). A recent study has 
been shown that SAHA re-activates human immunodeficiency virus (HIV) replication in 
peripheral blood mononuclear cells from individuals treated effectively with highly active 
antiretroviral therapy (HAART) indicating to have both an in vitro and in vivo effects 
against latently HIV infected T-cells (Contreras et al. 2009). Moreover, it has been 
proven that the oral therapy with SAHA ameliorates motor deficits in a mouse model of 
Huntington's disease (Hockly et al. 2003). Additionally, in the same study it has been 
clearly shown that SAHA crosses the blood-brain barrier, which is essential for 
prospective SMA therapy (Hockly et al. 2003).  
Strikingly, our group could previously show that SAHA is able to up-regulate SMN 
on protein and RNA level in vitro in cell culture and ex vivo using cultured hippocampal 
brain slices derived from rat and human (Hahnen et al. 2006a), therefore, this drug was 
chosen for an in vivo attempt to ameliorate the SMA phenotype in SMA-like mice. 
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4.3.1.1 Determination of the transgene copy-number in the SMAB mouse model  
In order to determine the exact number of SMN2 transgenes, we developed a novel real-
time PCR method. Similar to humans (Burghes 1997; Feldkotter et al. 2002), also in 
mice the number of SMN2 transgenes influences the SMA phenotype. Since there are 
multiple mouse models for SMA with the genotype Smn-/-; SMN2tg/tg carrying one to 
several SMN2 integrates per allele (Hsieh-Li et al. 2000; Monani et al. 2000), it is 
absolutely crucial to know the respective copy number of the human transgene to 
compare phenotypes. The exact knowledge about the SMN2 copy number is all-
important in therapeutical approaches. 
Quantitative Southern blotting is a very time consuming and complicated method to 
assess the transgene number and is rather inexact. 
Real-time PCR is the method of choice to quantify gene copy numbers. Previously 
several groups have been able to quantify transgene copy numbers in plants (Prior et al. 
2006), zebrafish (Ji et al. 2005) or mice (Martins and Krawetz 2004). These groups relied 
on external probes to exactly quantify their real-time PCRs. To avoid the sometimes very 
high costs and the effort to design labelled probes, we designed exactly matching primer 
pairs, in order to use PowerSYBR© green alone to quantify the gene copy numbers with 
the Taqman method. 
In our attempt to determine the SMN2 copy numbers, Smn+/-;SMN2tg/+ mice were 
crossbred with FVB wild-type mice. Mouse tail-tip-DNA was highly purified using a 
magnetic bead system from Invitrogen (Material and methods part 3.11.1). After 
qualitative PCR of the transgene, using the endogenous single-copy murine gene 
apoliprotein b (ApoB) (Bilbao et al. 2003) as internal control, the dCt (delta Cycle 
Threshold) value of SMN2tg and ApoB was determined with the Taqman and 
PowerSYBR© green method. For each SMN2tg positive sample the dCt showed the 
same value, indicating that every mouse was heterozygous for the transgene, as 
expected. These DNAs were pooled and served as reference for later transgene copy 
determinations. Each significant ddCt (delta delta Cycle Threshold) value of ~1 was 
assigned as homozygous mouse carrying two copies of the human transgene. For a 
better understanding, the data of the different Ct (Cycle Threshold) values are marked in 
a typical real-time PCR run results in Figure 32 below.  
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Figure 32 Overview of the values taken from the real-time PCR runs, as a basis for computer 
based calculations. The exponential amplification curves (red for ApoB and blue for SMN2) cross 
the threshold line (in green) at the respective Ct value (Cycle Threshold). The difference between 
the Ct values of ApoB and SMN2 build the delta Ct value of both (dCt). Thus, the difference of two 
dCt values derived from individual DNA samples build the ddCt value (delta delta Cycle 
Threshold).  
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Production of pool-DNA 
Fourteen highly purified mouse tail-tip-DNA derived from offspring genotyped positive for 
the human transgene of FVB wildtype mice crossed with Smn+/-;SMN2tg/tg mice was in 
two steps diluted to 5 ng/µl. Ten nanograms of these DNA samples were pooled in order 
to produce a “single-copy” internal reference of the human transgene. With both, the 
samples and the DNA-pool a quantitative real-time PCR was performed. Afterwards 
each dCt value (relating to the endogenous single-copy murine gene apoliprotein b 
(ApoB)) of the single heterozygous DNAs was compared to dCt value of the pool-DNA. 
In Figure 33 the diagrammatic presentation of the single DNAs in comparison to the 
pooled DNA is shown. 
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Figure 33 Diagrammatic compairison of the real-time PCR measured ddCt values (SMN2 in 
relation to ApoB) of the different genomic DNAs of heterozygous SMAB mice serving as pool-
DNA. All ddCt-values are given in relation to the ddCt value of the pool-DNA. 
. 
 
Quantification of SMN2 copies in homozygous and heterozygous SMAB mice 
Each mouse tail tip DNA derived from the offspring of SMN2tg/wt crossed with SMN2tg/wt 
animals was first qualitatively genotyped via normal PCR. With the 84 transgene-positive 
samples, a quantitative real-time PCR was performed, using ApoB as internal control 
and the pool-DNA as reference. As expected, 28 of 84 mice showed 2 SMN2 copies and 
are thus homozygous for the transgene. According to Mendelian inheritance, one fourth 
(25%) of the mice carrying the human SMN2 transgene were genetically homozygote. 
Figure 34 shows the bar diagram representing ddCt values for each sample, significant 
outliers of +0.8 or more indicating 2 SMN2 copies and are marked in red. 
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Figure 34 
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4.3.1.2 Effects of SAHA treatment in the SMAB mouse model 
As a first mouse model of SMA the severe affected SMA type I mouse was chosen. This 
mouse model was generated in the year 2000 by the group of Arthur Burghes, and will 
therefore be subsequently entitled SMAB mouse (Monani et al. 2000) (see chapter 
1.3.1.2). These severely affected SMA-like mice were observed to live for 5 days, 
making it applicatory for the investigation of the potency of SAHA to prolong the survival 
of these respective animals. Importantly, the mice described in the original publication 
were on a C57BL6/J inbred strain background. 
 The mice finally used for the experiments were kindly provided by a collaborator of 
Arthur Burghes, Michael Sendtner. However, those animals were on a FVB/N in bred 
strain background. Importantly, the SMAB mice on the FVB/N background were so far 
uncharacterized in terms of survival and SMA progression. 
 The high impact of the different background was unexpected, but led to the 
following observations. 
 After exactly determining the number of SMN2 transgene copies of the potential 
breeder pair animals (see chapter 4.3.1.1), mice carrying the genotype Smn-/+;SMN2tg/tg 
were bred with each other. Following a mendelian inheritance, ¼ of the offspring was 
expected to carry a Smn-/-;SMN2tg/tg –genotype, which would resemble the expected 
SMA-like mice. However, SMA-like animals with this respective genotype were never 
observed to be born. Five breeder pairs produced 35 offspring with an average litter size 
of 7.2±1.2, but none of the theoretically expected 9 SMA-like animals was observed 
(Table 13). 
In order to proof whether SAHA could prevent the SMA-like animals from prenatal 
death, the pregnant mother mice were treated from gestational day 15 on either with 
SAHA or with its respective solvent. Since SAHA is a hydrophobic substance, which is 
impossible to be solved in water, SAHA was solved in water supplemented with the 
carrier substance hydroypropyl-β-cyclodextran (HP-β-CD). Given the fact that a 20 g 
mouse drinks 3 ml water per day, this dosage equals 200 mg SAHA per kg body weight 
per day, which was previously described to be well tolerated in wild-type mice and shown 
to increase H3/H4 acetylation levels in the CNS (Hockly et al. 2003). 
Strikingly, prenatal SAHA treatment resulted in a first observation of born living 
SMA-like animals. In contrast, the treatment with the solvent alone failed to result in a 
significant change in the number of born SMA mice, although one SMA-like animal was 
detected, which died at postnatal day one. The five observed SMA-like mice, which were 
born under SAHA treatment, survived for 2 (two mice), 8, 11, and 14 days, respectively 
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(Figure 35). This suggests a beneficial effect of SAHA on the in utero progression of 
SMA (Table 13). 
 
 
Table 13 Observed discrepancy between expected number of SMA mice and de facto born 
amount of SMA-like animals. P-values suggest that the treatment of pregnant mice leads to a 
higher in utero survival rate of SMA-like mice. 
 
 
 
 
Figure 35 Number of born SMA mice increases after SAHA treatment of the pregnant mothers 
 
Substance # SMA-mice expected # SMA-mice observed p-value (χ2-test) 
water control 9 0 0,012 
HP-β-CD 8 1 0,042 
SAHA  12 5 0,119 
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Moreover, the SMAB mice revealed a severely reduced fertility starting at breeder pair 
age of 6 months (Figure 36). Since SMA is a neuromuscular disorder leading to 
impairment in motor abilities, it was necessary to find a SMA-like mouse model, which 
reaches an age where motor abilities may be assessed.  
Hence, the adversities in the breeding performance of the SMAB mice, and the fact 
that the SMAB mice on FVB/N background are so severely affected that they die 
prenatally, suggested the urgent need for a different mouse model. 
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Figure 36 Smn-/+;SMN2tg/tg animals show a severely reduce fertility starting at 6 months of age. 
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4.3.2 SAHA treatment of the SMAH mouse model 
As previously described, the SMAB mouse model revealed multiple disadvantages for a 
proper study of the effect of SAHA in an in vivo model. The group of Hung Li generated a 
alternative mouse model in the year 2000. This mouse model is subsequently referred to 
as the SMAH mouse (Hsieh-Li et al. 2000). The SMAH mouse model was purchased from 
the Jackson´s Laboratory.  
The SMN2 copy number strongly influences the severity of SMA. Thus, although 
homozygously knocked-out for the murine Smn gene, the SMAH mice are viable and 
fertile, if they carry the SMN2 transgene also in a homozygous manner. This main 
phenotypic difference between the SMAB and SMAH mice is based on the difference of 
the respective transgene. While each transgene allele of the SMAB mice carries one 
SMN2 copy, each transgene of the SMAH mice carries two SMN2 copies. This feature 
protects Smn-/-;SMN2tg/tg  animals from developing a SMA phenotype. 
 Since it was known that the SMAH carry four SMN2 copies in a homozygous state, 
the transgene copy number of the four purchased founder animals was proven by the 
already described method (chapter 4.3.1.1). Here the DNA of the transgene-
homozygous SMAB mice served as a “heterozygous” control for the SMAH mice. 
 Since the Smn-/-;SMN2tg/tg  animals are viable and fertile, these mice were bred with 
Smn+/-;SMN2wt/wt mice, providing a 50% chance to receive Smn-/-;SMN2tg/wt  animals, 
which present a SMA-like phenotype. This was a major advantage to produce large 
amounts of SMA-like mice. As described in the following chapters, SMA-like mice were 
virtually detected in every respective litter, living to a mean age of ~9.9 days. 
 
4.3.2.1 Establishment of the treatment concentration and application method 
Since this was the first time that SAHA was used in newborn mice, in a first step the right 
application method and adequate treatment concentration had to be determined. 
Previously published data suggested a SAHA concentration of 200 mg per kg per day in 
an adult mouse (Hockly et al. 2003) to be well tolerated. 
 SAHA is not soluble in water. Drinking water was supplemented with hydroypropyl-
β-cyclodextran (HP-β-CD), to use that substance as a carrier. The maximum amount of 
SAHA to be solved in HP-β-CD-water is 2 g per 1 l. This results in a maximum treatment 
concentration of 12,5 mg per kg mouse, providing an applicable liquid volume of 12.5 µl 
to administer to a 2 g mouse. 
 Initially 13 SMA mice and 13 healthy littermates were orally fed with 12.5 µl HP-β-
CD-supplied water twice daily (procedure see Figure 37b) starting from postnatal day 
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one. Since this treatment regimen revealed no significant impact on the survival time of 
both, SMA-like mice and littermates (see Figure 38b); next litters were also treated with 
12.5 mg/kg SAHA solved in HP-β-CD-water two times a day. This respective 
concentration of SAHA had no significant impact on the mean survival of the SMA-like 
mice. However, 12.5 mg/kg/2xdaily orally applied SAHA revealed no toxic effect neither 
in SMA nor in heterozygous mice (Figure 38d).  
Thus, to apply the previously published treatment concentration of 200 mg/day, 
SAHA had to be dissolved in dimethyl sulfoxide (DMSO), because of the relatively low 
solution capability of HP-β-CD-water. Both application methods, the oral and the 
subcutaneous (s.c.) administration of 12.5 µl DMSO twice per day revealed no significant 
decline of the median survival of SMA mice or littermates (see Figure 38a,c, 
subcutaneous injection procedure see Figure 37a). One single oral application of 200 
mg/kg SAHA solved in DMSO was not tolerated by the newborn mice (P1). SMA-like 
mice and their healthy littermates died one day after the treatment (Figure 38g). 
Moreover, the oral application of 50 mg/kg/2xday (solved in DMSO) revealed no 
improvement in the survival time of the SMA-like mice. However, the 50 mg/kg/2xday 
(solved in DMSO) treatment showed a significant toxicity in the treated heterozygous 
littermates, since ~80% of the control littermates died during the treatment period (see 
Figure 39f). Also no improvement in the survival time of the SMA-like mice was observed 
in the animals, which were subjected to the subcutaneous application of 25 mg/kg/2xday 
(solved in DMSO). Repeated injections of SAHA (solved in DMSO) in the neck of young 
mice resulted in a severe necrosis of the respective tissue. Furthermore, the s.c. 
application of SAHA (25 mg/kg/2xday (solved in DMSO)) was followed by a detrimental 
effect on the mean lifespan of the heterozygous littermates, indicating a severe 
intolerance to s.c. application of SAHA (Figure 39e). 
 Despite the above mentioned side effects, the oral application of 25 mg/kg/2xday 
SAHA showed a significant improvement in the mean survival of the severe affected 
SMA-like mice. Thus, the oral application of 25 mg/kg/2xday SAHA revealed no 
significant reduction in the mean survival of heterozygous littermates. Hence, the oral 
treatment with a dosage of 25 mg/kg/2xday SAHA was extended to a treatment of 42 
SMA-like animals and 38 healthy littermates (see chapter 4.3.2.1). 
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Figure 37 a Subcutaneous injection of SAHA (solved in DMSO). Lower right corner: the white 
arrow marks the location of SAHA escape and onset of necrosis. b oral application of SAHA 
(solved in DMSO) with the help of a feeding needle (blunt ended syringe). 
 
a b 
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4.3.2.2 Effects of SAHA treatment on survival of the SMAH mice  
Since the adequate SAHA treatment regimen was determined, in all subsequent 
experiments SMA-like mice and their unaffected littermates were treated twice daily with 
25 mg/kg SAHA solved in DMSO by oral application with a feeding needle. 
 The mean survival of the untreated SMAH mice was 9.905 days (boxplot in Figure 
39a). The treated group of SMA-like mice revealed a mean survival of 12.905 days, 
which indicates a significant increase in the mean survival time of 30.288% (p<0.001). 
Noteworthy, the mouse representing the longest survivor in the untreated group lived for 
16 days, while ~10% of the SAHA treated animals lived 16 days or longer: one mouse 
died at the age of 16 days, two mice lived for 20 days, one mouse for 23 days, one 
mouse for 24 days, and one mouse lived for 32 days (Figure 39b). However, the single 
mouse under SAHA treatment, which reached an age of 32 days, developed a severe 
necrosis of the tail and the hind limbs (Figure 40). Therefore this mouse had to be 
sacrificed at day 32. Remarkably, the onset of a necrosis of the hind limbs and the tail 
was also observed for the treated SMA mice, which survived for 20 days or longer. Thus, 
it is important to mention that the necrosis is not an effect of SAHA, but rather a known 
feature of progressing SMA (Araujo Ade et al. 2009). Necrosis was never observed in 
SAHA-treated littermates. Hence, the SMA-like mice developed the necrosis, because 
they reached under SAHA treatment a far longer survival than the untreated ones. 
Untreated SMA mice did not develop necrosis, since they have a severely reduced life-
expectancy. Importantly the mean survival of the treated SMA mice was shifted 
significantly. Both, the rank-sum t-test and the Mann-Whitney rank sum test for 
significance clearly revealed that the difference in the median values between the two 
groups is greater than would be expected by chance; there is a statistically significant 
difference (p <0.001), suggesting that SAHA is reducing the progression of SMA 
development. 
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Figure 39 Comparison of the mean survival of SMA mice SAHA-treated vs. untreated presented 
in boxplot (mean value=red line; median value=black line) in a) and in a Kaplan-Meier-curve in b) 
red dashed line=heterozygous treated (n=38); red line=SMA treated (n=42); blue line=SMA 
untreated (n=42) 
 
 
 
 
 
 
Figure 40 SAHA-treated SMA mouse developing a necrosis of tail and hind limbs at the age of 25 
days. This mouse had to be scarified at an age of 32 days. 
a b 
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4.3.2.3 Effects of SAHA treatment on body weight of SMAH mice  
To characterize the progression of SMA and the development of the SMA-like animals 
with or without SAHA treatment, the weight of each mouse was determined daily. Every 
single animal was weighed each morning before the first application of SAHA. 
 Interestingly, all mice regardless of the respective genotypes show the same 
weight gain up to postnatal day 3, where the mean weight ranges from ~2.1 to ~2.3g. 
However, from this time point on, the weight of the SAHA-treated heterozygous control 
littermates increases in an almost linear manner. In contrast to this continuous 
augmentation, the mean weight of both, the untreated and the SAHA-treated SMA-like 
mice reveal a rather slow elevation up to postnatal day 8. The treated SMA-like mice 
show a mean weight of ~4g at P9, whereas the untreated ones reach a mean weight of 
3.6g at the same age. From P10 to P12, the mean weight of the untreated SMA-like mice 
and the SMA-like mice under SAHA regimen shows slight fluctuations, but remain static 
just under ~4g. However, for comparison, the SAHA-treated heterozygous littermates 
reveal a mean weight of 8.1g at P12, which is twice the amount of SMA-like animals at 
this respective age. Strikingly, from P12 on the untreated SMA-like animals continuously 
lose weight until P16, where the last untreated mouse died. In contrast to the decline of 
mean weight in the untreated SMA-like mice, the SAHA-treated mice showed an 
increase in mean weight to a maximum level of ~5.5g at P16. The obvious steep ascent 
of the weight progression curve from P14 to P15 or from P24 to P25 in Figure 41 of the 
SAHA-treated SMA-like mice is explainable by the fact that some mice died around that 
age (Kaplan-Meier-Curve Figure 39b), after they lost some weight. Therefore, only the 
long-surviving SAHA-treated SMA-like mice make up the mean weight value from P15 
onward. The mean weight of the SAHA-treated SMA-like mice surviving longer than 14 
days stays nearly unchanged around ~5g. The steep ascent in the weight curve from 
P24 to P25 again resembles the death of a mouse, which lost weight before dying. The 
weight progression of the long-survivor SMA-like mouse stagnated until this mouse had 
to be sacrificed because of the progressing necrosis of the hind limbs (see Figure 40 and 
chapter 4.3.2.2). 
 Taken together, these data indicate that SAHA treatment prolongs the survival of 
SMA-like mice but does not normalize the weight progression of these animals. Thus, 
the weight progression of the treated SMA-like mice rather stays static, comparable to 
the untreated SMA-like mice. Therefore, a dwarf-like phenotype was observed for the 
SAHA-treated SMA-like mice of an older age. These animals were only half as large as 
their heterozygous littermates at an age of 14 days. This discrepancy was even higher at 
later ages (see Figure 42). 
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Figure 41 Diagrammatic representation of the mean weight progression of SAHA-treated 
heterozygous mice (n=38), SAHA-treated SMA-like mice (n=42) and untreated SMA-like mice 
(n=42). red line=SMA-like mice treated, green line=SMA-like mice untreated, black 
line=heterozygous SAHA-treated. 
 
 
 
 
 
 
Figure 42 This photo resembles the obvious size difference between two SAHA-treated SMA 
mice (marked with arrows) and one SAHA-treated heterozygous littermate. All mice were at an 
age of 14 days. The size discrepancy was even higher at later ages.  
Results 
 
 
111 
4.3.2.4 Effects of SAHA treatment on motor ability of SMAH mice  
Since SMA is a motor neuron disease, severely affecting the motoric abilities of patients, 
a potential prospective therapy should ameliorate motor impairments. Therefore, the 
effect of SAHA treatment on the motor abilities of SMA-like mice was chosen as major 
outcome criterion of the SAHA treatment experiment. 
 As a first motor test the commonly used so-called righting-reflex-test was 
performed (Avila et al. 2007). Since the neonatal SMA-like mice showed no differences 
in their ability to right compared to the healthy littermates (appendix Figure 59) the so-
called tube test was performed instead. It was especially developed to be performed with 
neonates (El-Khodor et al. 2008). In brief, to perform a tube test each pup was placed 
one by one headfirst into a vertical 50 ml reaction tube, thereafter, depending on the 
motor ability, meaning the spreading of the hind limbs, each mouse was rated from 4 
(best tube score wide spreading) to 1 (bad tube score, hind limbs in a clasped position) 
(see Figure 43). The worst tube score of 0 was noted when the mouse was not able to 
hold onto the tube (for a detailed description see chapter 3.10.2). 
 Interestingly, the motor performance of all neonates, regardless of their genotype 
and treatment situation, developed similar from P0 to P2. As expected, the motor abilities 
of the SAHA-treated heterozygous animals were developing normal and reached a mean 
tube score of ~4 at P8. From this age onward, virtually every SAHA-treated 
heterozygous mouse performing the tube test was rated with a tube score of 4. However, 
the motor abilities of the SAHA-treated SMA-like mice developed similar to that of their 
heterozygous littermates and reached a mean tube score of ~3.8 at P6. The mean tube 
score of the untreated SMA-like mice reached a value of ~2 at P2, which is concordant 
with the observations of the treated SMA-like and heterozygous mice. Strikingly, the 
untreated SMA-like animals showed from P2 on a clear stagnation in their motor 
performance development. Beside some fluctuations, the mean tube score of the 
untreated SMA-like mice showed no significant increase, but was oscillating between 
values of 2 to 2.5. From P9 to P13 the mean tube score of the untreated SMA-like mice 
revealed a very steep decline from ~2.5 to ~0. This reflects the progression of SMA, 
which was previously described by the survival time evaluation (see chapter 4.3.2.2) and 
the characterization of the weight progression (see chapter 4.3.2.3).  
However, the SAHA treatment is able to ameliorate the motor impairment of SMA-
like mice. The SAHA-treated SMA-like and the heterozygous animals showed a very 
similar development of motor ability. Noteworthy, the motor development of the SAHA-
treated SMA-like mice was delayed for one day. The heterozygous mice revealed a 
mean tube score of ~3.7 at postnatal day 5, whereas the SAHA-treated SMA-like mice 
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reached this tube score only at P6. This developmental delay was also observed for the 
time points P3 to P6. Although the SAHA-treated SMA-like mice revealed a decline in 
motor performance starting at P9, their achieved tube score was always significant 
higher than the tube score of the untreated SMA-like mice. The observed fluctuations in 
tube score values are again explainable by the fact that, some SAHA-treated SMA-like 
mice became moribund and therefore revealed deterioration in motor performance 
shortly before death (see Figure 44).  
As a concluding remark, it is noteworthy to state that SAHA treatment ameliorates 
the motor impairment of SMA-like mice. The SAHA-treated SMA-like mice do not show a 
full rescue of the motor ability deterioration, but compared to untreated SMA-like mice 
those mice reveal a significant improvement of motor ability. 
 
 
Figure 43 Overview of the tube test scoring scale. Tube score of 4 indicates normal hind-limb 
separation with tail raised (A); score of 3, hind limbs are closer together but they seldom touch 
each other (B); score of 2, hind limbs are close to each other and often touching (C); score of 1, 
hind limbs are almost always in a clasped position (D) with the tail raised (E); a score of 0 
indicates failure to hold onto the tube. (Taken from (El-Khodor et al. 2008)). 
 
 
Figure 44 Diagrammatic representation of the mean motor ability progression of SAHA-treated 
heterozygous mice (n=38), SAHA-treated SMA-like mice (n=42) and untreated SMA-like mice 
(n=42). red line=SMA-like mice treated, green line=SMA-like mice untreated, black 
line=heterozygous SAHA-treated.  
Motor strength   
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4.3.2.5 Effects of SAHA treatment in the SMAH mouse model on SMN2tg 
expression 
In order to evaluate the impact of SAHA treatment on the Smn/SMN2 expression in vivo, 
mice were sacrificed by decapitation either at day P5 or P10. SAHA-treated SMA-like 
mice (Smn-/-; SMN2tg/wt), or SAHA-treated heterozygous littermates (Smn+/-; SMN2tg/wt) 
were opened by abdominal incision and subsequently RNA or protein was prepared out 
of the respective organs (see chapters 3.11.4 and 3.12.1). Therefore, whole liver, whole 
brain, the gastrocnemius muscle and spinal cord were removed. All animals, which were 
used were orally treated with SAHA twice daily, started at P1; the last treatment took 
place 1 hour prior to decapitation. All data, which will be discussed in the following are 
based on organ extracts derived from 3 SAHA treated P5 SMA, 3 untreated P5 SMA, 3 
SAHA treated P5 heterozygous, and 3 untreated P5 heterozygous animals were 
counted. The same organ extracts were derived from respective P10 mice. 
 
• SMN protein levels 
In order to investigate the impact of SAHA on protein level, semi-quantitative Western 
blotting was performed using β-actin as internal control. All experiments were carried out 
with the protein extracts from liver, brain, the gastrocnemius muscle and spinal cord 
derived from the respective mice. 
First the whole protein extracts were measured by the Bradford method, 
subsequently 7.5 µg protein were loaded onto SDS PAGE gel and after electrophoresis, 
a Western blot was performed. The results of the densitrometrical analysis were 
evaluated and depicted in a histogram. Here the SMN signal-intensity was quantified in 
relation to the internal control β-actin. Due to the high grade of homology between the 
murine Smn and the human SMN protein, the used antibody is not able to distinguish 
between both, therefore the term SMN stands for both proteins, which may be derived 
from Smn+/-; SMN2tg/wt-mice. 
Strikingly, in all tissues derived from SAHA-treated SMA-like animals an up-
regulation of SMN protein level was observed. Importantly, SMN protein levels derived 
from neuronal tissues, such as spinal cord in P5, as well as brain in P10 SAHA-treated 
SMA-like animals showed a positive response to SAHA. This finding proofs that SAHA 
not only crosses the blood-brain barrier, but also is able to augment the SMN expression 
in the main SMA-target tissues. In the spinal cord of P5 SMA-like mice SAHA treatment 
increased the mean SMN level significantly 2.7-fold compared to untreated, the age 
matched heterozygous animals showed a significant ~1.5-fold increase (Figure 45a). 
Similar to this finding, the SAHA regimen resulted in a slightly and not significant 
Results 
 
 
114 
increase of the mean SMN protein level of ~15% in the spinal cord of P10 mice. The 
SAHA treatment of heterozygous P10 mice revealed a non-significant down-regulation of 
the SMN amount from ~300% to ~240% (relative to untreated SMA) in the spinal cord 
(Figure 46a). 
In contrast, the SMN protein level derived from the brain tissue of heterozygous P5 
and P10 mice revealed a non-significant positive response to the SAHA regimen. Also 
the ~18%-increase of SMN in the SAHA-treated SMA mice reached no statistical 
significance (Figure 45b). However, the in SMN protein level derived from the brain 
tissue of treated P10 mice a massive significant augmentation to ~550% was identified 
(Figure 46b). 
The muscle tissue of all treated animals responded in massive up-regulations of the 
SMN-protein levels. In the case of the P5 mice, the SMA-like animals showed a massive 
and significant 17.6-fold increment, whereas the heterozygous littermates responded in a 
2.3-fold augmentation of the mean SMN level (Figure 45c). Moreover, the SMN protein 
level derived from P10 SMA-like mice displayed a significant 3.5-fold up-regulation under 
SAHA treatment, while the heterozygous control mice presented a non-significant ~1.3-
fold augmentation of the respective SMN amount (Figure 46c). 
Lastly, the SMN amount derived from the liver of P10 remained unchanged in the 
heterozygous mice, whereas it was ~30% up-regulated by SAHA in the P10 SMA-like 
mice. Nevertheless, neither in the untreated nor in the SAHA-treated P5 SMA-animals a 
SMN protein band was detected (Figure 45d). However, the P5 heterozygous mice 
responded in a ~100% up-regulation in the SMN-protein level, indicating a response to 
SAHA regimen. 
To summarize these data, it was proven that SAHA is able to up-regulate the SMN 
expression in all tested tissue, except the liver. Moreover, it is obvious that SAHA 
crosses the blood-brain barrier, confirming earlier reports (Hockly et al. 2003). Thus, 
SAHA treatment is capable of incrementing the SMN expression in neuronal tissues, 
such as brain and spinal cord. This issue is of particular interest, since the α-motor 
neurons are the primary target tissue of a prospective SMA therapy. However, the SAHA 
regimen could not elevate the SMN level of tissues derived from SMA-like mice to the 
respective levels of heterozygous animals. This suggests that SAHA treatment could not 
lead to a full protection of SMA, but may ameliorate the disease progression. This 
speculation is concordant with the previously described results from the survival and 
motor test analysis. 
Results 
 
 
115 
   
 
   
 
   
 
  
Figure 45 Impact of in vivo SAHA treatment on SMN expression in P5 mice. Western blots 
loaded with equal protein amounts were simultaneously stained with anti-β-actin and anti-SMN. 
The pictures show representative Western blot analyses and the diagrammatic representation of 
the semi-quantitative protein quantification. Mean SMN protein levels (± SEM) in a) spinal cord, b) 
brain, c) muscle, d) liver relative to β-actin (* p < 0.05; ** p < 0.01; *** p < 0.001) SMA=SMA-like 
mouse; het=heterozygous mouse 
a 
b 
c 
d 
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Figure 46 Impact of in vivo SAHA treatment on SMN expression in P10 mice. Western blots 
loaded with equal protein amounts were simultaneously stained with anti-β-actin and anti-SMN. 
The pictures show representative Western blot analyses and the diagrammatic representation of 
the semi-quantitative protein quantification. Mean SMN protein levels (± SEM) in a) spinal cord, b) 
brain, c) muscle, d) liver relative to β-actin (* p < 0.05; ** p < 0.01; *** p < 0.001) SMA=SMA-like 
mouse; het=heterozygous mouse 
d 
a 
b 
c 
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• Sfrs10 protein levels 
Since it is well known that the splicing factor SFRS10 is competent to reverse the 
splicing pattern of SMN2 pre-mRNA in human (Hofmann et al. 2000), semi-quantitative 
Western blots of the murine orthologue (Sfrs10) were performed, to address the question 
whether the expression of this factor is up-regulated by SAHA treatment in mice. Again, 
the protein expression of β-actin served as an internal control. 
 The Sfrs10 protein level in the spinal cord of SMA-like mice was not significantly 
changed under SAHA treatment, neither in the P5 nor in the P10 animals. In case of the 
heterozygous mice, a doubling of the Sfrs10 protein level was observed for the P5 mice, 
while the protein level in P10 spinal cord showed no change (Figure 47a and Figure 
48a). Thus, the Sfrs10 level of the spinal cord seemed to be subjected to individual 
fluctuations. 
 Neither in the brain derived Sfrs10 protein level of P5 nor in the respective protein 
level of P10 mice any impact of SAHA was detected. This finding was true for both, the 
SMA-like and the heterozygous mice (Figure 47b and Figure 48b). 
These findings suggest that SAHA treatment has no direct effect on the Sfrs10 
expression in neuronal tissues. 
 Strikingly, the muscle tissue revealed a significant positive response to SAHA in all 
tested mice. While the P5 SMA-like mice displayed a 4-fold up-regulation, their 
heterozygous littermates revealed a 3.3-fold augmentation (Figure 47c). Moreover, the 
Sfrs10 protein level in the muscle of P10 SMA-like mice increased ~2-fold under SAHA 
regimen, whereas the heterozygous mice showed ~1.5-fold increment (Figure 48c). 
  However, the Sfrs10 level of the liver of P5 SMA-like mice was too low, to be 
detected by Western blotting. Nevertheless, the heterozygous P5 mice displayed a weak 
down-regulation after SAHA treatment of ~25% (Figure 47d). The SAHA treatment of 
P10 SMA-like mice resulted in a significant 6.9-fold augmentation of the Sfrs10 level in 
the liver tissue. Still, the heterozygous mice manifest no significant change in the Sfrs10 
amount in the liver (Figure 48d). 
 To summarize these results, SAHA has no influence on the Sfrs10 expression in 
the brain and the spinal cord of SMA-like mice. Nevertheless, SAHA is able to act in 
neuronal tissues, since Sfrs10 was 2-fold elevated in the spinal cord of heterozygous P5 
mice. However, SAHA treatment elevates the Sfrs10 level in the liver of P10 SMA-like 
mice, whereas the P5 SMA-like mice display virtually no expression of Sfrs10. 
Importantly, the muscle tissue of every SAHA-treated responded in a significant 
augmentation of the Sfrs10 level. Noteworthy, the Sfrs10 expression in the liver and in 
the muscle was observed to be strongly correlated with the respective genotype. Thus, 
the SMA-like mice showed a significant lower expression of Sfrs10 than the 
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heterozygous mice. This indicates an unexpected and not previously described 
expression correlation of SMN/Smn and Sfrs10 in mice. 
   
   
     
     
Figure 47 Impact of in vivo SAHA treatment on Sfrs10 expression in P5 mice. Western blots 
loaded with equal protein amounts were simultaneously stained with anti-β-actin and anti-Sfrs10. 
The pictures show representative Western blot analyses and the diagrammatic representation of 
the semi-quantitative protein quantification. Mean Sfrs10 protein levels (± SEM) in a) spinal cord, 
b) brain, c) muscle, d) liver relative to β-actin (* p < 0.05; ** p < 0.01; *** p < 0.001) SMA=SMA-
like mouse; het=heterozygous mouse 
d 
a 
b 
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Figure 48 Impact of in vivo SAHA treatment on Sfrs10 expression in P10 mice. Western blots 
loaded with equal protein amounts were simultaneously stained with anti-β-actin and anti-Sfrs10. 
The pictures show representative Western blot analyses and the diagrammatic representation of 
the semi-quantitative protein quantification. Mean Sfrs10 protein levels (± SEM) in a) spinal cord, 
b) brain, c) muscle, d) liver relative to β-actin (* p < 0.05; ** p < 0.01; *** p < 0.001) SMA=SMA-
like mouse; het=heterozygous mouse 
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• SMN RNA expression levels 
To address the question if SAHA has an in vivo effect on the expression level of SMN2, 
the total amount of both SMN2 transcripts, FL-SMN2 and ∆7-SMN2, was quantified. 
Since it is known that HDACis may influence the expression of housekeeping genes, 
total RNA amount was taken as internal control. To do so, the RNAs derived from the 
respective murine organs of the untreated or SAHA treated SMA-like or heterozygous 
mice were precisely determined on a microplate reader using the RiboGreen® dye. 
Afterwards a total of exactly 150 ng RNA was subjected to reverse transcription. 
The interpretation of the real-time RT-PCR revealed a substantial effect of the 
SAHA regiment on the SMN2 transgene expression. The used primer for the real-time 
PCR were especially designed to detect only the FL- or the ∆7-SMN2 transcript, which 
was only derived from the human SMN2 transgene, regardless whether the respective 
mouse was heterozygous for the murine Smn gene. For a better comparison, the 
respective transcript levels of the untreated mice were always set to 1. The relative 
amount of the transcript levels of the SAHA-treated animals was therefore normalized to 
1. 
The FL-SMN2 expression levels of the P5 heterozygous littermates were subjected 
to a down-regulation after SAHA treatment in the brain, muscle and spinal cord, whereas 
the liver revealed a significant 20% up-regulation. Moreover, the SAHA treatment 
resulted in down-regulations of the ∆7-SMN2 levels in all tested organs derived from 
heterozygous P5 mice (Figure 49a). In contrast, the P5 SMA-like mice responded in 
virtually all organs in a weak up-regulation of both FL- and ∆7-SMN2 to the SAHA 
regimen, solely the spinal cord derived ∆7-SMN2 transcript amount was reduced to 
~80%, which was statistically not significant (Figure 49b). This might suggest an impact 
of Sfrs10 on the splice-reversion. Contrary to the P5 mice, the SMA-like as well as the 
heterozygous P10 mice showed a massive response to the SAHA regimen. The FL-
SMN2 level was twofold augmented after SAHA treatment in virtually every tested tissue. 
Moreover, the muscle tissue of the heterozygous P10 mice displayed a 16-fold increase 
in FL-SMN2 amount (Figure 49c). Only the ∆7-SMN2 level of the P10 heterozygous mice 
remained nearly unchanged in the brain and the liver. In contrast, the ∆7-SMN2 amounts 
were significantly elevated due to the SAHA regimen (Figure 49c). The P10 SMA-like 
mice, revealed a massive augmentation of both, the FL- and the ∆7-SMN2 transcript 
level in nearly all tested tissues. Except the FL-SMN2 level of the brain and the ∆7-
SMN2 amount derived from the liver were not elevated significantly (Figure 49d). All 
other transcript amounts were twofold significantly augmented under SAHA regimen. 
Again, the gastrocnemius muscle derived transcripts were vastly increased (>10-fold) 
(Figure 49d). 
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To summarize the results of the transcript quantification, it is important to state that 
the P10 animals revealed a far higher response to the SAHA treatment on the transcript 
level than the P5 mice. Interestingly, no significant impact on the splicing reversion was 
detectable. Interestingly, the P10 mice, regardless of the genotype, revealed a massive 
increase of both FL-SMN2 and ∆7-SMN2 amounts, suggesting that the transcription per 
se is activated but no reversion of the splicing is facilitated. Also on protein level muscles 
revealed a 4 to 10-fold increase in the SMA-like mice. These findings suggest that this 
respective tissue is quite prone to the SAHA regimen. Importantly, transcript levels 
derived from the brain as well as from the spinal cord show elevations, although less 
pronounced than in muscle. This finding underlines the potential of SAHA to cross the 
blood-brain barrier, an essential feature for a potential SMA drug.  
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Figure 49 SMN2 mRNA levels derived from brain, muscle, spinal cord and liver of SMA-like mice 
and heterozygous littermates treated with SAHA. Quantitative real-time PCR results are 
summarized as bar graphs. Mean values (± SEM) for FL-SMN2 and ∆7-SMN2 relative to total 
RNA amount in heterozygous P5 mice a), in SMA-like P5 mice b), in heterozygous P10 mice c) 
and in SMA-like P10 mice d). (* p < 0.05; ** p < 0.01; *** p < 0.001). 
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4.3.2.6 Histological changes in the SMAH mouse model after SAHA treatment 
 
• Change in number of motor neurons 
The primary feature of SMA is the deterioration of the α-motor neurons in the anterior 
horns of the spinal cord, which causes the subsequent muscular atrophy. A potential 
drug for SMA therapy should be able to ameliorate this phenotype and protect the α-
motor neurons from the progressing deterioration. To check whether SAHA is capable to 
rescue the α-motor neurons, these neurons were quantified in P5 and P10 SMA-like 
mice and heterozygous littermates. To do so, motor neurons of 20 cross-sections 
derived from each 3 SAHA-treated P5 SMA, 3 untreated P5 SMA, 3 SAHA-treated P5 
heterozygous, and 3 untreated P5 heterozygous animals were counted and the mean 
number of motor neurons per anterior horn was evaluated. Therefore, cross-sections of 
the spine derived from the lumbar region of the respective mouse were generated and 
stained by Nissl staining. The specific localization in the anterior horns of the spinal cord 
and the specific size and shape of the α-motor neurons allowed a clear discrimination 
between the α-motor neurons and the surrounding remaining neurons (Figure 50). 
 The evaluation of the number of α-motor neurons in the spinal cord revealed in five 
days old mice no significant difference between heterozygous mice and SMA-like 
animals. This is true for untreated as well as SAHA-treated mice. Moreover, no obvious 
discrepancy between SAHA-treated and untreated mice was observed, regardless of the 
respective genotype. The mean number of α-motor neurons in each anterior horn region 
ranged between 12 and 13 (Figure 51).  
 In contrast, the SAHA-treated as well as the untreated P10 heterozygous mice 
displayed ~18 α-motor neurons in each anterior horn cross-section. In untreated SMA-
like mice of the same age the progression of SMA was reflected by a significant 
reduction of the mean number of motor neurons down to ~8. The P10 SMA-like mice 
under SAHA regimen showed a significantly higher mean value of motor neurons of ~14, 
suggesting a neuroprotective effect of SAHA. However, the SAHA treatment did not fully 
rescue the deterioration of the motor neurons, since the difference between the mean 
values of the untreated or SAHA-treated heterozygous P10 mice and the SAHA-treated 
SMA-like P10 mice is still significant. Nevertheless, the mean value of the number of 
motor neurons of the P10 SAHA-treated SMA-like animals was virtually equal to the 
mean number of motor neurons in P5 heterozygous mice (Figure 51).  
Taken together, these findings indicate that SAHA ameliorates the deterioration of 
motor neurons, but is not able to fully rescue the SMA progression. SAHA treatment is 
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able to “stabilize” the mean number of motor neurons at the level of P5 old heterozygous 
mice, and thus can only delay the neuronal impairment observed in SMA-like mice. 
 
    
Figure 50 Nissl stainings of cross-sections derived from the lumbar region of spines a) overview 
of a cross-section of the spine of an untreated heterozygous mouse. The red circles highlight the 
localization of the α-motor neurons in the anterior horns. b) depiction of the characteristic shape 
and size of α-motor neurons in the anterior horns of the spinal cord. Cross-section of an untreated 
P5 SMA-like mouse. 
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Figure 51 Diagrammatic representation of the α-motor neuron counts of cross-sections derived 
from P5 SAHA-treated and untreated SMA-like and heterozygous mice as well as P10 SAHA-
treated and untreated SMA-like and heterozygous mice. For each age, each treatment status and 
each genotype n=3. The mean values of 20 cross-sections per animal were used. 
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• Change in size of motor neuron junctions (NMJs) 
The axon terminals of a motor neuron together with the motor end plate of a muscle are 
called neuromuscular junctions (NMJs) synapses. It has been shown that in SMA-like 
mice, in which SMN protein levels are severely reduced, the maturation of the NMJs is 
seriously impaired. Furthermore, it has been proven that the size of the NMJs is severely 
reduced in murine SMA mouse models (Kariya et al. 2008). Thus, to investigate the 
effect of SAHA regimen on the size of the NMJs, the area of the NMJs was measured (in 
µm²). To do so, 200µm thick longitudinal sections of the gastrocnemius muscle were 
stained with anti-Neurofilament M (green), which labels the neurons and α-Bungarotoxin 
(labeled with rhodamine: red), which binds to the muscular acetycholine-receptors 
(AChR). The surface area of each NMJ was measured with the help of Axio Vision 
computer software (Zeiss). 100 NMJs were measured in that way for each respective 
animal: 3 SAHA treated P10 SMA, 3 untreated P10 SMA, 3 SAHA treated P10 
heterozygous, and 3 untreated P10 heterozygous animals. Only mice at P10 were 
chosen, assuming the highest discrepancy between SMA-like and heterozygous mice. 
This assumption was based on the finding that the motor neuron number is significantly 
reduced at that respective age (Figure 51). 
 As expected the mean NMJ-size showed no difference between the heterozygous 
untreated and heterozygous SAHA-treated mice. The mean surface area sizes ranged 
between 230 and 240µm². However, the untreated SMA-like mice revealed a severely 
reduced area size of 100µm², indicating the progression of SMA. Notably, the SAHA-
treated SMA-like mice displayed a significantly higher mean NMJ size of 160µm². 
Nevertheless, SAHA treatment was not capable to fully rescue the NMJ phenotype, 
since the difference between of the mean NMJ size of the untreated or SAHA-treated 
heterozygous mice and the SAHA-treated SMA-like mice remained significant (Figure 
53). 
 Taken together, these results suggest that SAHA treatment ameliorates the NMJ-
phenotype of SMA-like mice. However, the SAHA regimen is not sufficient to fully protect 
the NMJ size to be reduced. 
 
 
Results 
 
 
126 
 
Figure 52 Representative microscopic illustration of the immunofluorescence staining of the 
NMJs derived from longitudinal sections of the gastrocnemius muscle of an untreated 
heterozygous mouse, a SAHA-treated heterozygous mouse and an untreated SMA-like mouse 
and a SAHA-treated SMA-like mouse. (red: α-BTX-rhodamine, stains Ach-receptors; green: anti-
neurofilament M (labeled with AlexaFlour 488), stains neurofilament M-ptoteins) 
 
 
 
Figure 53 Boxplot of surface area sizes of NMJs measured in longitudinal-sections derived from 
P10 SAHA-treated and untreated SMA-like and heterozygous mice, For each treatment status 
and each genotype n=3. 100 NMJs per mouse were measured. (mean value=red line; median 
value=black line). 
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• Change in size of muscle fibers 
One major hallmark of SMA is - as the name says - the atrophy of the proximal muscles. 
It has been described that mouse models of SMA show a reduction of the muscle fiber 
size in the hind limb muscles (Gavrilina et al. 2008a). Since the previously described 
data from motor ability tests, motor neuron counts and NMJ characterization suggest that 
SAHA might influence the SMA phenotype also on the muscular level, change in the size 
of muscle fibers were evaluated. Therefore, cross-sections of the rectus femoris muscle 
were stained with an H&E staining. Like previously described the surface area of each 
sliced muscle fiber was measured with the help of Axio Vision computer software (Zeiss). 
The surface area size of 100 muscle fibers was measured in that way for each 
respective animal: 3 SAHA treated P10 SMA, 3 untreated P10 SMA, 3 SAHA treated 
P10 heterozygous, and 3 untreated P10 heterozygous animals. Like for the NMJ-
characterization, only mice at P10 were chosen, assuming the highest discrepancy 
between SMA-like and heterozygous mice. This assumption was based on the finding 
that motor ability, motor neuron number as well as NMJ surface area sizes were 
significantly reduced at that respective age (Figure 44, Figure 51 and Figure 53). 
 Expectedly, the mean surface area sizes of the untreated and the SAHA-treated 
heterozygous mice showed virtually no difference and was ~280µm² for both. 
Nevertheless, the untreated SMA-like mice showed a severe reduction in the surface 
area size down to ~125µm², which resembled the profound progression of SMA. 
Strikingly, the SAHA-treated SMA-like mice revealed a significantly augmented mean 
muscle fiber size of ~190µm². Comparable to the already described findings, SAHA 
treatment was also not able to fully rescue the muscle fiber size phenotype, since the 
difference between the mean muscle fiber size of the untreated or SAHA-treated 
heterozygous mice and the SAHA-treated SMA-like mice were still significantly different 
(Figure 55). 
 To summarize these results, SAHA treatment ameliorates the muscle fiber size 
phenotype in SMA-like mice, most likely as a secondary effect, by protecting the α-motor 
neurons from deterioration. However, as already described for the motor neuron and the 
NMJ phenotype, the muscle fiber phenotype is not fully rescued by the SAHA regimen, 
since there was a significant discrepancy between the treated or untreated heterozygous 
and the SAHA-treated SMA-like mice detectable (Figure 55). 
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Figure 54 Representative microscopic illustration of the H&E staining of the muscle fibers derived 
from cross-sections of the rectus femoris muscle of an untreated heterozygous mouse, a SAHA-
treated heterozygous mouse and an untreated SMA-like mouse and a SAHA-treated SMA-like 
mouse. The surface area size of the muscle fibers of the untreated SMA-mouse is obviously 
smaller than the surface area sizes of a SAHA-treated SMA-mouse. 
 
 
Figure 55 Boxplot of surface area sizes of muscle fiber sizes measured in cross-sections derived 
from P10 SAHA-treated and untreated SMA-like and heterozygous mice. For each treatment 
status and each genotype n=3. 100 muscle fibers per mouse were measured. (mean value=red 
line; median value=black line). 
Discussion 
 
 
129 
5 Discussion 
It has been shown that 96% of all patients with proximal spinal muscular atrophy (SMA) 
lack the survival motor neuron gene 1 (SMN1), which is either caused by a deletion or a 
gene conversion of SMN1 into its almost identical copy gene SMN2 (Wirth et al. 1999). 
The loss of the SMN1 gene causes SMA. A unique feature of SMA is that all patients 
with this hereditary disease carry at least one copy of the main disease modifying gene, 
the SMN2 gene. It has been described that the disease severity inversely correlates with 
the SMN2 copy number (Brahe 2000; Burghes 1997; Feldkotter et al. 2002). However, 
the SMN2 is not able to fully compensate the loss of SMN1 in SMA patients. Because of 
a silent nucleotide exchange in exon 7 of SMN2 an exonic splicing enhancer is 
destroyed (Lorson and Androphy 2000; Lorson et al. 1999) and an exonic splicing 
silencer is newly created (Kashima and Manley 2003). Thus, the pre-mRNA of SMN2 is 
predominantly wrongly spliced. Only ~10% of the SMN2 transcripts are spliced like the 
SMN1 transcripts, producing fully functional full-length SMN2 mRNA/protein, whereas 
~90% of the SMN2 transcripts lack exon 7 (Gennarelli et al. 1995; Lefebvre et al. 1995; 
Lorson et al. 1999).  
The SMN2 gene is therefore the main target gene for a potential SMA therapy. The 
activation of transcription of SMN2 and the correction of the splicing pattern by in vitro or 
ex vivo treatment with histone deacetylase inhibitors, has been described to elevate the 
SMN protein level (Brichta et al. 2003; Chang et al. 2001; Garbes et al. 2009; Hahnen et 
al. 2005). 
In the present work the epigenetic modification of the SMN2 gene by means of 
histone deacetylase inhibitors (HDACi) was performed. Previously, our group could show 
that the well-known HDACi valproic acid (VPA) is capable to up-regulate SMN 
expression in vitro and in vivo in SMA carriers and patients (Brichta et al. 2003; Brichta 
et al. 2006a). Moreover, the favorable effect of VPA in terms of a potential SMA therapy 
has recently been proven by in vivo findings in an SMA mouse model (Tsai et al. 2008a).  
Nevertheless, the search for more potential SMA neurotherapeutics is ongoing, 
since a recent clinical trial of VPA in SMA patients revealed minimal positive effect on the 
SMA progression suggesting the need for alternatives to VPA (Swoboda et al. 2009).  
Therefore, in this study the search was focused on new HDACi substances from 
different chemical groups: the benzamide M344 and the bicyclic tetrapeptide 
depsipeptide (FK228). 
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5.1 In vitro experiments with the pan-HDACis M344 and FK228 
The in vitro treatment of SMA patient derived fibroblast cell lines revealed that the novel 
compounds M344 and FK228 have the ability to extensively stimulate the expression of 
SMN2. A massive 3- to 7-fold up-regulation of the SMN protein level was determined at 
concentrations ranging between 30 and 50 µM M344 after 64 h of treatment; whereas 
the peptide FK228 was acting in far lower doses on the SMN protein level. Here, FK228 
revealed its highest impact (~4-fold) on the SMN protein level at 250 nM. Interestingly, 
the SMN2-activating ability of FK228 was also found in a murine embryonic fibroblast 
line (MEF14), which was derived from SMAB-like mouse (Smn-/-;SMN2tg/tg). In the MEF14 
250 nM of FK228 caused a 4-fold up-regulation of the SMN protein. This finding was of 
particular interest, since this revealed the first proof that FK228 is able to activate the 
SMN2 expression in a heterologous background such as the mouse. Also M344 was 
shown to act at quite low concentrations like 5 µM, where a 1.5- to 4-fold augmentation 
of SMN was still measured. While M344 had a significant impact on the elevation of the 
SMN protein level, FK228 failed to augment the SMN level extensively in ML16. This 
finding suggests that cell lines differ in their response to diverse HDACis inter-
individually. This hypothesis is supported by the previously described findings that the 
pan-HDACi VPA augmented SMN levels in only one third of the treated SMA patients, 
whereas one third responded in a decline of the SMN protein level and the last third has 
been found to be non-responders to VPA regimen (Brichta et al. 2006a). The search for 
biomarkers concerning a susceptibility to VPA treatment is of particular interest and 
therefore research subject in our laboratory. However, the weak response of ML16 to the 
FK228 treatment suggests a similar mode of predisposition for a respective FK228 
regimen.  
Concordantly, the up-regulation of the SMN protein level under FK228 and M344 
treatment resulted in a marked increase of nuclear gems, particularly for M344. These 
nuclear dot-like structures are widely understood to resemble functioning enrichments of 
SMN proteins (Liu and Dreyfuss 1996; Liu et al. 1997; Young et al. 2000). Thus, it is of 
particular interest that both test substances were able to elevate the number of gems. 
Moreover, it was obvious that the increase in the number of gems strongly correlated 
with the effect, which was found on SMN protein level. Noteworthy, not only the mean 
number of gems per 100 nuclei increased, but also the number of cells, which contain 
gems, was augmented. This indicates a profound up-regulation of gems numbers in 
virtually every treated fibroblast, suggesting an augmentation of functioning SMN 
complexes.  
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Interestingly, although several other HDACis such as sodium butyrate, valproic 
acid, phenylbutyrate, suberoylanilide hydroxamic acid and LBH589 (Andreassi et al. 
2001; Brichta et al. 2003; Chang et al. 2001; Garbes et al. 2009; Hahnen et al. 2006c; 
Sumner et al. 2003) have in the last years been reported to activate SMN2, none of 
these compounds were members of the chemical groups of benzamides (M344) or 
tetrapeptides (FK228). The most potent HDACi in terms of elevating the SMN protein 
level is the hydroxamate LBH589, as shown in our laboratory (Garbes et al. 2009). 
However, M344 was shown in this work to elevate the SMN protein level ~7-fold, which 
is the second highest augmentation of SMN by HDACi treatment. The 4-fold increase of 
SMN after FK228 treatment resembles a similar effect like the treatment with 1 mM VPA 
(Brichta et al. 2003).  
Beside the effect of M344 and FK228 on the SMN protein level, also the effect on 
the SMN2 transcript level was investigated. Quantitative analysis of SMN2 mRNA 
revealed considerably increased FL-SMN2 transcript levels. In contrast, ∆7-SMN2 levels 
were almost unchanged or even reduced, suggesting an efficient reversion of the 
splicing pattern of SMN2 pre-mRNA by M344 and FK228 treatment. The effect on the 
reversion of the pre-mRNA splicing pattern of FK228 was even higher than the observed 
effect of M344. Interestingly, the ∆7-SMN2 transcript level decreased at the highest 
treatment concentrations of FK228 of 250 and 500 nM to 50% of the mock treated 
amounts. This indicates a very strong reversion of the splicing pattern. Because of the 
observed reversion of the SMN2 pre-mRNA splicing, the expression of the splicing factor 
SFRS10, which is well known to be capable to revert the SMN2 splicing (Hofmann et al. 
2000), the protein level of this respective factor was investigated. SFRS10 protein levels 
were indeed elevated under the regimen with M344 as well as with FK228, supporting 
the hypothesis of splice reversion by SFRS10. The impact of the HDACi treatment was 
reflected in the reversion of the splicing pattern in virtually all tested cell lines. However, 
the high levels of FL-SMN2 RNA and protein can be explained only by additional 
transcription activation of SMN2. Similar to the results obtained for other HDAC inhibitors 
(Brichta et al. 2003; Brichta et al. 2006a), the effect especially of M344 observed on the 
SMN protein level is much higher than the effect seen on RNA level.  
This is not an unexpected finding, since SMN transcript levels are quite uniformly 
expressed among all tissues whereas the protein level reveals marked differences 
(Coovert et al. 1997; Lefebvre et al. 1997). Moreover, recent data could proof that the 
HDACi LBH589 is capable to stabilize the SMN protein by reducing its ubiquitinylation as 
well as favoring incorporation into the SMN complex (Garbes et al. 2009). A similar 
mechanism could also be activated by the treatment with M344 and FK228. Both, M344 
and FK228 are potent pan-HDAC (Hahnen et al. 2008), therefore it is obvious that these 
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substances are also changing the expression levels of other genes. In a recent 
microarray based study it has been described that the unspecific inhibition of virtually all 
present HDACs alters the transcription of up to 22% of all investigated genes (Peart et 
al. 2005). Therefore it was not unexpected that M344 was found to up-regulate SRp20, 
another splicing factor, which is not involved in SMN2 splicing. Hence, the ability of M344 
to stimulate the expression of a number of splicing factors should be considered for 
further potential therapies of other diseases. Moreover, these data underline the 
unspecific transcriptional activation by HDAC inhibitors in general and in particular of 
M344. With regard to a prospective SMA therapy, it is important to mention that severe 
side effects caused by some HDACis are relatively rare as it is well-known from valproic 
acid, which is successfully used in epilepsy treatment for more than three decades. In 
contrast to SFRS10 and SRp20, SF2/ASF expression is subject to fluctuations and not 
clearly influenced by M344 treatment. This observation differs from the finding of 
increased SF2/ASF levels found after treatment with valproic acid and demonstrates that 
diverse HDAC inhibitors act on a varying spectrum of target genes. Moreover, a 
reduction of cell viability of fibroblasts was detected at high M344 concentrations above 
30 µM. In agreement with this observation, SMN2 protein levels decreased at doses of 
50 µM (ML12) and 100 µM (ML17 and ML20) M344, respectively. Additionally, 
significantly increased SMN protein levels with maximum levels ranging between 3- to 6-
fold were already determined at low concentrations of 5–30 µM M344, which is below the 
drug amounts causing increased cell death. Thus, M344 remains highly promising for a 
future application in an SMA therapy. In contrast to this finding, FK228 revealed a 
significant cytotoxicity starting from the lowest concentration of 10 nM. Nevertheless, the 
cytotoxicity found in ML16 was reflected by the weak response of this cell line to the 
FK228 regimen. Because of the unfavorable toxicity profile of FK228, a further in vivo 
animal trial was neglected.  
Since also M344 has never been described to be tested in vivo, we also rejected to 
deepen our research efforts on this particular substance. In contrast, we focused our 
search for new substances, which might be able to elevate the SMN level, on 
compounds, which are FDA-approved or at least subjected to clinical trials. 
Nevertheless, the in vitro experiments using FK228 and M344 gave deep insight into the 
epigenetic regulations of SMN2 expression. Moreover, it was proven that the HDACi 
FK228 is able to up-regulate SMN2 expression in human cells and on a heterologous 
background such as mouse fibroblasts. For the first time it was shown that substances 
belonging to the chemical classes of benzamides (M344) and bicyclic tetrapeptides 
(FK228) are able to elevate SMN levels in SMA fibroblast lines. 
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5.2 Identification of HDAC8 to be specifically involved in SMN2 expression 
regulation 
It has been described that the unspecific inhibition of virtually all classic HDACs by the 
use of pan-HDACis alters the expression of up to 22% of all genes (Peart et al. 2005). In 
that study the pan-HDACis SAHA and FK228 have been described to regulate 
unspecifically the expression of about one fourth of all tested transcripts. However, the 
microarray chip analysis, which has been performed after treating Jurkat cells with the 
respective substances, revealed that the gene set, which was regulated by both HDACis, 
was highly overlapping but not identical (Peart et al. 2005). This suggests that different 
pan-HDACis, although unspecifically targeting all classic HDACs, might have slight 
differences in their functional outcome. While one HDACi might activate a whole 
pathway, the other one might down-regulate the activation. Moreover, it has recently 
been shown that certain HDACs additionally to the epigenetic modifications exhibit 
important cytoplasmatic functions by controlling the acetylation status and function of 
numerous cytoplasmatic proteins and transcription factors (Yang and Seto 2008). 
Therefore, not only the altered transcription but also direct regulation of numerous 
proteins should be considered when applying HDACis.  
With regard to a prospective therapeutic use of HDACis in SMA, it remains quite 
questionable to apply unspecific HDACis to patients, since numerous unfavorable side 
effects might emerge. Hence, for the long-term used unspecific HDACi VPA a number of 
unfavorable side effects have been described (reviewed in (Gerstner et al. 2008)). 
To avoid the majority of side effects, which arises by the unspecific up-regulation of 
genes, an HDACi should be identified, which specifically is able to up-regulate SMN2 
expression. Therefore, the identification of the specific HDAC, which controls the SMN2 
expression, was attempted in this work. 
To identify the HDAC, which regulates the SMN2 expression, a siRNA based 
knock-down approach was applied. To specifically investigate the SMN2 protein 
expression, a SMN1 deleted SMA fibroblast line was subjected to the knock-down 
approach. After knocking-down each of the eleven classical HDACs, the SMN protein 
amount was quantified. Interestingly, the only significant up-regulation of the SMN 
protein level was observed after the knock-down of HDAC8. This finding was of 
particular interest, since the literature so far stated that HDAC2 is the main HDAC to 
regulate SMN2 expression (Kernochan et al. 2005). However, this respective study 
proposed HDAC2 to be the SMN2 regulating enzyme because of the finding that HDAC2 
binds to the promoter region of SMN2 in transgenic murine NSC34 cells. Nevertheless, 
HDAC2 binding has been observed to be enriched in the close proximity (0 to 500 bp 
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upstream) to the transcription initiation site of SMN2, whereas we found HDAC8 to be 
most enriched in the SMN2 promoter regions upstream to the transcription initiation site. 
This suggests a possible simultaneous action of HDAC8 and HDAC2. Moreover, it has 
been postulated that HDAC2 binds the murine Smn promoter during embryonic 
development, which is associated with a significant decline in the acetylation status of 
the histones bound to this respective region (Kernochan et al. 2005). However, the 
function of HDAC8 has not been investigated in this respective study. Noteworthy, it has 
been observed in our laboratory (PhD thesis of L. Brichta and (Hahnen et al. 2006b)) that 
the benzamide MS-275 is not able to up-regulate SMN. Nevertheless, MS-275 is known 
to inhibit HDAC1, HDAC2 and HDAC3, but not HDAC8 (Witt et al. 2009). Therefore, 
HDAC8 might be suspected to play an important role in the expression regulation of 
SMN2. To prove the possibility of HDAC8 to be involved in the histone deacetylation in 
the promoter region of SMN2, ChIP experiments were performed. Hence, the ChIP 
experiment revealed that HDAC8 is obviously bound to the SMN2 promoter region. This 
finding indicated that HDAC8 is able to regulate the expression of SMN2 by histone 
deacetylation in its promoter region upstream of the transcription initiation site of SMN2. 
To gain a deeper insight into the capability of HDAC8 to regulate the SMN2 expression, 
HDAC8 overexpression experiments were applied. Therefore, a plasmid containing the 
human HDAC8 cDNA was transfected into SMN1 deleted SMA fibroblast cells. As 
expected the overexpression of HDAC8 was able to reduce the SMN protein level in a 
concentration dependent manner. In contrast, the overexpression of HDAC2 and 
HDAC11 (as negative control) did not reveal any decrease of SMN protein level 
(appendix Figure 57). The higher the amount of expressed HDAC8 was the lower was 
the SMN protein level. This correlation suggested a role of HDAC8 in regulating the SMN 
protein level.  
HDAC8 was identified and characterized for the first time in the year 2000 by three 
independent groups (Buggy et al. 2000; Hu et al. 2000; Van den Wyngaert et al. 2000). It 
has been described that HDAC8 is able to deacetylate histone H3 and H4 in vitro and to 
repress transcription (Hu et al. 2000). More recently, it has been shown that the specific 
inhibition of HDAC8 induces apoptosis in T-cell lymphomas (Balasubramanian et al. 
2008). In the present year a knock-out mouse model of HDAC8 has been described. 
Knock-out of HDAC8 in mice led to specific disturbances in the skull morphogenesis 
(Haberland et al. 2009). Moreover, this study revealed 838 genes to be up-regulated and 
928 genes to be down-regulated after HDAC8 knock-out in the mouse at least twofold. 
However, the expression of the murine Smn gene was not affected. This finding might be 
explained by the fact that SMN is per se highly expressed during embryogenesis, or that 
HDAC8 might not control the expression of the murine Smn gene. The main impact of 
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the HDAC8 knock-out was observed in the neural crest cells, which resemble a 
subpopulation of cells derived from the ectoderm. Interestingly, the ectoderm forms also 
the neural tube, which later during embryogenesis develops among others into motor 
neurons. This might give evidence for speculations about a neuron specific role of 
HDAC8. 
However, if HDAC8 is the main HDAC to be involved in SMN2 expression 
regulation, it would be important to find a HDAC8 specific inhibitor for a prospective SMA 
treatment. Therefore, we focused on the search for a compound, which is capable to 
specifically inhibit the function of HDAC8. It has recently been shown that the substance 
PCI-34051 is able to specifically inhibit the function of HDAC8. Moreover, researchers 
have been able to induce apoptosis in T-cell lymphomas by the specific inhibition of 
HDAC8 by the hydroxamate PCI-34051 (Balasubramanian et al. 2008).  
The murine SMA-like fibroblast line MEF5 (Smn-/-;SMN2tg/tg) and the human SMA 
fibroblast line ML17 were treated with PCI-34051 in order to investigate its capability to 
up-regulate the SMN2 expression. Interestingly, the human cell line responded in an up-
regulation of the protein level to a maximum level of ~185%, whereas the murine reacted 
only in a not significant increase to only ~120%. This fact might be explainable by the 
heterologous background of SMN2. While in the native situation the promoter region of 
the human SMN2 is regulated by the deacetylation of HDAC8, in the artificial situation 
where the SMN2 transgene is located in the genetic murine environment, HDAC8 may 
not regulate the SMN2 transgene expression. Strikingly, PCI-34051 up-regulates the 
mean SMN protein for virtually every tested concentration to ~150%, which resembles 
the elevation of the protein level after the knock-down of HDAC8. Moreover, the 
specificity of PCI-34051 was proven by an in vitro HDAC activity test. The test showed 
clearly that PCI-34051 was not able to fully inhibit the total function of a HDAC extract 
from rat liver, whereas the pan-HDACs M344, FK228 and SAHA were able to fully 
deplete the function (appendix Figure 58). Unexpectedly, the FL-SMN2 transcript level 
was not significantly elevated by PCI-34051 treatment in ML17. Moreover, the human 
cell line revealed no change in ∆7-SMN2 levels, whereas the murine cell line MEF5 
neither displayed an increase in FL- nor in ∆7-SMN2 levels. Additionally, the protein level 
of the main splicing factor capable to restore the SMN2 splicing namely SFRS10 
(Hofmann et al. 2000), revealed no elevation under PCI-34051 regimen. This finding 
might be explained by the fact that the specificity of PCI-34051 prevents the unspecific 
up-regulation of the splicing factor SFRS10. However, this might explain also the weak 
effect of PCI-34051 on the FL-SMN2 as well as the SMN protein level. 
The attempt was performed to avoid negative side effects by the specific inhibition 
of the respective HDAC that regulates SMN2 expression. However, the specific enzyme 
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inhibition led to the reduction of “positive side effects” seen in the treatment with 
unspecific HDACis, such as up-regulation of genes that help to correct the SMN2 pre-
mRNA splicing or, which stabilize the SMN protein. Several pan-HDACis have been 
shown to possess the “positive side effects” to restore the SMN2 splicing (Brichta et al. 
2003; Hahnen et al. 2006c; Hahnen et al. 2005), to stabilize SMN protein and to protect 
SMN from degradation (Garbes et al. 2009). Thus, prospective animal trials might help to 
gain insight into the advantages and disadvantages of a potential therapy by the use of 
specific or unspecific histone deacetylase inhibitors.  
5.2.1 In vitro findings with regard to the current state of research  
To date several diverse attempts have been undertaken to increase the SMN protein 
level in vitro. Virtually all research groups made use of cell lines derived from SMA 
patients (overview of in vitro drug-attempts to elevate SMN is given in Table 14).  
 It has been proven that the cell cycle inhibitor hydroxyurea is able to elevate the 
SMN level ~1.9-fold in lymphoblastoid cell lines from SMA patients. As the underlying 
mechanism of action transcriptional activation and splicing correction has been proposed 
(Grzeschik et al. 2005). The antibiotics aclarubicin and diverse aminoglycosides have 
been assessed in fibroblast cell lines derived from SMA patients. Aclarubicin has been 
observed to restore the SMN protein level, via splicing correction, to levels comparable 
to healthy controls (Andreassi et al. 2001). Various aminoglycosides have been shown to 
augment the number of gems 20-fold by the skipping of the stop codon of SMN2 (Mattis 
et al. 2006). Phosphatase inhibitors like Na-vanadate and diverse quinazolines have 
been shown to elevate the protein level 2- to 3-fold by transcriptional activation (Jarecki 
et al. 2005). Moreover, Na-vanadate has been observed to correct the splicing and 
therefore to increase the activity of a specific luciferase reporter assay 6- to 8-fold 
(Zhang et al. 2001). The transcriptional activation of SMN2 in SMA fibroblasts by the 
cytokines interferone β and γ has been shown to restore the SMN protein level to control 
levels (Baron-Delage et al. 2000). The nonsteroidal anti-inflammatory drug indoprofen 
has been found to activate the transcription of SMN2 in SMA fibroblasts and thereby to 
modestly elevate the SMN level ~1.13-fold (Lunn et al. 2004). Moreover, the inhibition of 
the proteasomal degradation of SMN by MG-132 in SMA fibroblasts resulted in a 1.5-fold 
increase of the SMN levels (Chang et al. 2004). Also a 1.5-fold SMN protein elevation 
has been described for fibroblasts treated with the β2-adrenergic agonist salbutamol. 
This increase has been discussed to be accomplished by the transcriptional activation of 
SMN2 and by the activation of the cyclic adenosine monophosphate (cAMP) pathway 
(Angelozzi et al. 2008).  
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Additionally, several HDACis have been shown to possess capability to up-
regulated the SMN protein level in SMA cell lines. Sodium butyrate has been observed to 
elevate the SMN protein level in lymphoblastoid cell lines from SMA patients by 
transcriptional activation and splicing correction ~3-fold (Chang et al. 2001). VPA has 
been proven to augment SMN levels in SMA fibroblasts by transcriptional activation, 
splicing correction and protein stabilization up to ~4-fold (Brichta et al. 2003). The FDA-
approved drug 4-phenylbutyrate has been shown to activate SMN2 transcription and 
therefore to augment the SMN protein level ~1.9-fold (Andreassi et al. 2004). Our group 
could previously show that SAHA and LBH589 are also able to massively increase the 
SMN level in vitro (Garbes et al. 2009; Hahnen et al. 2006c). In SMA fibroblasts it has 
been proven that SAHA activates the transcription and restores the splicing of SMN2 and 
thereby elevates the SMN level ~3-fold (Hahnen et al. 2006c). LBH589 in contrast, has 
been shown to act on the transcriptional activation, the splicing correction and the protein 
stabilization of SMN, and therefore to tremendously increase SMN levels up to 10-fold 
(Garbes et al. 2009). 
To compare these previously reported results with the results obtained during this 
work, it is of high interest that the two tested pan-HDACis M344 and FK228 are able to 
increase the SMN protein levels in human and murine (FK228) SMA fibroblast lines ~7- 
and ~4-fold, respectively. Moreover, it was proven that both substances act via 
transcriptional activation and splicing correction of SMN2. Additionally, it can be stated 
that M344 is second and FK228 is the third most potent substance to increase the SMN 
protein level. Furthermore, both compounds were found to elevate gem levels in SMA 
patient cell lines, indicating the production of functional SMN protein. Moreover, for the 
first time it was shown that an isoenzyme specific HDACi is able to increase the SMN 
level. Here it was proven that the HDAC8 specific HDACi PCI-34051 is capable to 
activate the transcription of SMN2 and thus to increase the SMN protein level up to 1.8-
fold. 
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Table 14 Overview of diverse drugs shown to elevate the SMN protein level in vitro in comparison to the results discussed in this thesis (marked in grey). 
Results are summarized from given publications 
Mechanism of 
action Compound 
Experimental setup 
(in vitro) Modification of SMN 
Maximum SMN protein 
increase Original publication 
M344 Fibroblast cell lines from SMA patients Transcriptional activation, Splicing correction ~7-fold This thesis, (Riessland et 
al. 2006) 
Histone deacetylase 
inhibition 
FK228 Fibroblast cell lines from SMA patients and mice Transcriptional activation, Splicing correction ~4-fold This thesis 
Histone deacetylase 
8 inhibition (specific) 
PCI-34051 Fibroblast cell lines from SMA patients and mice Transcriptional activation ~1.8-fold This thesis 
Sodium butyrate Lymphoblastoid cell lines from SMA patients Transcriptional activation, Splicing correction ~ 3-fold (Chang et al. 2001) 
Valproic acid (VPA) Fibroblast cell lines from SMA patients 
and motor neurons derived from rat stem cells 
Transcriptional activation, Splicing correction, 
Protein stabilization 
~4-fold (Brichta et al. 2003) 
(Hahnen et al. 2006c) 
4-Phenylbutyrate Fibroblast cell lines from SMA patients Transcriptional activation ~1.9-fold (Andreassi et al. 2004) 
Suberoylanilide 
hydroxamic acid 
(SAHA) 
Fibroblast cell lines from SMA 
patients and rat motor neurons 
Transcriptional activation, Splicing correction ~3-fold (Hahnen et al. 2006c) 
Histone deacetylase 
inhibition 
LBH589 Fibroblast cell lines from SMA patients Transcriptional activation, Splicing correction, 
Protein stabilization 
~10-fold (Garbes et al. 2009) 
Cell cycle inhibitor Hydroxyurea Lymphoblastoid cell lines from SMA patients Transcriptional activation, Splicing correction ~1.9-fold (Grzeschik et al. 2005) 
Aclarubicin Fibroblast cell lines from SMA patients Splicing correction restoration to control levels 
(healthy individuals) 
(Andreassi et al. 2001) Antibiotics 
Aminoglycosides Fibroblast cell lines from SMA patients Skipping of stop codon ~20-fold elevation in number 
of gems 
(Mattis et al. 2006) 
Na-vanadate fibroblast cell lines from SMA patients, 
NSC34 motor neuron like cells containing 
anSMN-Luciferase-modified construct 
Splicing correction 
 
6-8-fold increase in Luciferase 
reporter activity 
(Zhang et al. 2001) Phosphatase 
inhibitor 
Quinazolines fibroblast cell lines from SMA patients, 
NSC34 motor neuron like cells containing 
anSMN-Luciferase-modified construct 
Transcriptional activation 2-3-fold (Jarecki et al. 2005) 
Cytokine IFN-β and IFN-γ Fibroblast cell lines from SMA patients Transcriptional activation restoration to control levels 
~4-fold induction of 
transcription 
(Baron-Delage et al. 
2000) 
Nonsteroidal anti-
inflammatory drug 
Indoprofen Fibroblast cell lines from SMA patients Transcriptional activation 1.13-fold (Lunn et al. 2004) 
Proteasome inhibitor MG-132 Fibroblast cell lines from SMA patients inhibition of proteasomal degradation 1.5-fold (Chang et al. 2004) 
β2-adrenergic 
agonist 
Salbutamol Fibroblast cell lines from SMA patients Transcriptional activation, 
cAMP pathway activation 
1.5-fold (Angelozzi et al. 2008) 
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5.3 In vivo characterization of SAHA treatment in mouse models for SMA  
It has been widely described that the deterioration of the α-motor neurons in the anterior 
horns of the spinal cord leads to a progressive muscle weakness and following atrophy 
(Zerres and Rudnik-Schoneborn 1995). Nonetheless, in the past years a debate has 
been ongoing, whether either the motor neurons or the muscles are the primary affected 
tissue. Finally, the attempt to rescue the severe SMA phenotype in a Smn-/-;SMN2tg/tg 
(SMAB) mouse model, by overexpressing SMN1 muscle- or neuron-specific, has shown 
that the onset of SMA can be hindered by neuron specific SMN1 expression (Gavrilina et 
al. 2008b). This was the final proof that the main target cells for a potential SMA therapy 
are the α-motor neurons. However, so far the common way to test the efficiency of new 
compounds to up-regulate the SMN2 expression is to administer the respective 
substances in cell culture to SMA fibroblasts or SMA patient derived lymphoid cell lines 
(Brichta et al. 2003; Chang et al. 2001). This way of in vitro testing may not be the 
method of choice, since very recent studies have been proven that the HDACi VPA is not 
able to elevate SMN protein levels in Smn-/-;SMN2tg/tg murine fibroblast lines, whereas the 
same substance elevates the SMN level in neural precursor cells (NSCs) of the identical 
genotype (Hauke et al. 2009; Rak et al. 2009). This indicates that the up-regulation of 
SMN expression could most likely differ between cell types. Although the SMA-like 
murine fibroblast lines showed no up-regulation under VPA regimen, a recent study has 
proven that VPA is able to ameliorate the SMA phenotype in type III-like SMA mice. In 
this respective study it has been shown that VPA treated mice show better motor 
function, less degeneration of spinal motor neurons, less muscle atrophy and better 
neuromuscular junction innervations than non-treated SMA-like animals (Tsai et al. 
2008b). Moreover, the study has displayed an up-regulation of the SMN protein level in 
the spinal cord of VPA-treated SMA-like mice. 
 In order to test whether the in vitro influence of suberoylanilide hydroxamic acid 
(SAHA) can be confirmed also in vivo, SAHA was tested in SMA-like mice. Since we 
have been able to show earlier that SAHA, a pan-HDACi (Hahnen et al. 2008), is able to 
elevate SMN levels in vitro in SMA patient derived cells and ex vivo using cultured 
hippocampal brain slices derived from rat and human (Hahnen et al. 2006a). In view of a 
prospective SMA therapy in humans it was also of essential importance that SAHA was 
recently approved (in 2006) by the U.S. Food and Drug Administration (FDA) for the 
treatment of cutaneous T cell lymphoma (CTCL) (www.merck.com/finance 
/annualreport/ar2006/pipeline.html). Therefore, this substance would be feasible to 
directly apply to SMA patients. Additionally, it has been shown that SAHA crosses the 
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blood-brain barrier and that the oral therapy with SAHA in a mouse model of 
Huntington's disease ameliorates motor deficits of the animals (Hockly et al. 2003).  
 A type I SMAB mouse model was chosen to apply an in vivo study of SAHA 
treatment. The respective mouse model has been reported to live for a mean survival 
time of ~5 days (Monani et al. 2000). This relatively short survival time was a favourable 
feature of the mouse model, since the major outcome measurement of the SAHA animal 
trial was survival time. However, the transgenic mice, which were characterized in the 
original publication, were on a C57BL/6J background. The SMAB mouse model we 
obtained from Prof. Dr. M. Sendtner was in contrast on a FVB/N background. A high 
impact of the inbred strain background on the SMA-phenotype was detected, since no 
living SMA-like animals were born. It is well-known that the inbred strain background has 
a high impact on the phenotype of transgenic or knock-out animals. A recent example for 
this characteristic is the HDAC8 knock-out mouse model. These animals were viable on 
a mixed background (SV129/C57BL/6/CD1), whereas on a pure C57BL/6 background 
they showed 100% prenatal lethality (Haberland et al. 2009). Additionally, several 
studies have been shown that strain related differences have led to estimates that 1-2% 
of the genes may vary in expression between the six brain regions, which were 
investigated in the particular projects of C57BL/6 and 129SvEv mice (Pavlidis and Noble 
2001; Sandberg et al. 2000). These findings underline the differences in gene expression 
in neuronal tissues of different mouse strains, which might lead to variable SMA 
phenotypes in the respective mouse models. Moreover, it has been published that the 
C57BL/6 background ameliorates the SMA-phenotype in SMAH mice. In this case it has 
been stated that the mice on pure C57BL/6J background live for 13±2 months (Tsai et al. 
2008b), while the survival on FVB/N background was only 9.9 days (own observations). 
However, the oral SAHA treatment of the pregnant mothers of severely affected 
SMAB-mice, starting at gestational day 15, resulted in an elevation of living born SMA-
like animals. This reflected the capacity of SAHA to ameliorate the severe SMA 
phenotype in utero. However, only an amelioration of the SMA phenotype was observed, 
since all animals died soon after birth. With regard to a potential SMA therapy the 
treatment of a pregnant mother with HDAC inhibitors had to be performed very carefully, 
since it is well known that these substances, like VPA, are severely teratogenic in human 
in the first trimester of pregnancy (Alsdorf and Wyszynski 2005; Kultima et al. 2004; 
Wyszynski et al. 2005). To avoid the maternal treatment and to assess the outcome of 
SAHA regimen on the motor ability of the SMA-like mice, another SMA mouse model 
was applied. The used SMAH mouse model carries in contrast to the SMAB mouse model 
2 SMN2 transgenes (concatemers) per transgene integrate, whereas the SMAB mouse 
model carries only one per integrate. First, the SMAH mouse model, which was also on a 
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FVB/N background, had to be comprehensively characterized in our mouse facility. It 
was proven that heterozygous transgenic mice on a null Smn background (Smn-/-
;SMN2tg/wt) develop a severe SMA phenotype and show a mean survival of ~9.9 days. 
Contrary to the homozygous transgenic SMAB mice on a null Smn background, the 
homozygous transgenic SMAH mice on a null Smn background (Smn-/-;SMN2tg/tg) were 
viable and fertile, but display necrosis of the tail and the ears later in life. Therefore, one 
major advantage of the SMAH mouse model is that the breeding of one homozygous 
transgenic SMAH mouse on a null Smn background (Smn-/-;SMN2tg/tg) with one 
homozygous knock-out SMAH mouse (Smn+/-;SMN2wt/wt) gives rise to 50% SMA-like 
animals (Smn-/-;SMN2tg/wt). Whereas in the case of SMAB mice, the breeding of two 
Smn+/-;SMN2tg/tg mice results in only 25% SMA-like (Smn-/-;SMN2tg/tg) mice in each litter. 
This high percentage of offspring developing a SMA-like phenotype accelerated the in 
vivo treatment approaches. Moreover, the SMA-like mice revealed a progressing SMA, 
which was reflected by the deterioration of α-motor neurons in the anterior horns of the 
spinal cord and by the progressive decline of motor ability compared to healthy 
littermates. These advantageous features, which were firstly characterized in this work, 
make the SMAH mouse model the best SMA mouse model for the in vitro 
characterization of potential SMA drugs. This opinion is substantiated by the following 
comparison of the commonly used SMA mouse models. 
The phenotypic appearance of the so far described mouse models for SMA is quite 
diverse. It has been shown that the introduction of a mutated SMN transgene (SMNA111G) 
leads to the complete rescue of the SMA phenotype. Smn-/-;SMN2tg/tg;SMNA111Gtg/wt-mice 
have a normal life expectancy and show no symptoms of SMA (Workman et al. 2009). 
Another SMN missense mutation (SMNA2G) has been proven to lessen the SMA 
phenotype. Smn-/-;SMN2tg/tg;SMNA2Gtg/wt-mice live for ~15 months and display first of SMA 
after ~3.5 month of life (Monani et al. 2003). A SMA mouse model, which is frequently 
used for in vivo drug testing, is the Smn-/-;SMN2tg/tg;SMN∆7tg/tg mouse. These animals 
have been shown to present first symptoms of SMA after ~9 days of life and die at the 
age of ~14 days. These SMA type I-like mice are on FVB/N background and carry 
homozygously the SMN2 and the SMN∆7 (the cDNA of SMN∆7) transgene on a null 
Smn background (Le et al. 2005). These animals are well suitable for drug testing but 
have two disadvantages: 1. The SMN∆7 transgene is artificial and does not reflect the 
natural situation in SMA patients, 2. Due to the fact that Smn-/-;SMN2tg/tg;SMN∆7tg/tg mice 
die at the age of ~14 days, it is necessary to breed Smn-/+;SMN2tg/tg;SMN∆7tg/tg animals, 
which results in only 25% of SMA-like mice per litter.  
 Interestingly, in this study it was proven that the inbred strain background has a 
major influence on the SMA phenotype of SMA-like mice. Smn-/-;SMN2tg/tg (SMAB) on 
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100% C57BL/6 background have been described to live for ~5 days and display first 
symptoms of SMA at ~2-3 days of life (Monani et al. 2000). However, in this work it was 
observed that the animals with exactly the same genotype on 100% FVB/N background 
are prenatally lethal. Moreover, it has been published that (SMAH) SMA-like mice on 
100% C57BL/6 background display a mild form of SMA (type III) and live for ~13 month. 
We could prove that SMA-like mice carrying the same genotype but on 100% FVB/N 
background display a SMA type I-like phenotype, show first symptoms at P5 and die at 
the age of 9.9 days. Since Smn-/-;SMN2tg/tg (SMAH) mice are fertile and live longer than 
~1.5 year, it is possible to breed them with Smn-/+;SMN2wt/wt mice and thus to produce 
50% SMA-like mice (Smn-/-;SMN2tg/wt) per litter. This feature makes the SMAH –like mice 
the best SMA mouse model for drug screenings. 
 
Table 15 Overview of commonly used SMA mouse models. The two mouse models, which were 
used and characterized in this thesis, are marked in grey. 
Genotype 
SMN2 
copies 
per 
integrate 
SMA 
 type 
Inbred stain 
background Mean survival 
Age of onset 
of SMA 
SMA-
like 
animals  
per 
litter 
First 
characterization 
of phenotype 
Smn-/-;SMN2tg/wt 
(SMAB) 
1 I FVB/N Prenatal lethality 25% This thesis 
Smn-/-;SMN2tg/wt 
(SMAH) 
2 I FVB/N ~9.9 days ~5 days 50% This thesis, 
and (Hsieh-Li et 
al. 2000) 
Smn-/-;SMN2tg/wt 
(SMAH) 
2 I, II, 
III 
FVB/N Heterogeneous Heterogeneous 50% (Hsieh-Li et al. 
2000) 
Smn-/-;SMN2tg/wt 
(SMAH) 
2 III C57BL/6 13±2 months 6 months  50% (Tsai et al. 
2008b) 
1 I C57BL/6 ~5 days ~2-3 days 25% Smn-/-;SMN2tg/tg 
(SMAB) 8 SMN2 
copies 
No 
SMA 
C57BL/6 Complete rescue of the 
phenotype 
25% 
(Monani et al. 
2000) 
Smn-/-;SMN2tg/tg; 
SMN∆7tg/tg 
1 I FVB/N ~14 days ~9 days 25% (Le et al. 2005) 
Smn-/-;SMN2tg/tg; 
SMNA2Gtg/wt 
1 III FVB/N ~15 months ~3.5 months 25% (Monani et al. 
2003) 
Smn-/-;SMN2tg/tg; 
SMNA111Gtg/wt 
or 
Smn-/-;SMN2tg/wt; 
SMNA111Gtg/wt 
1 No 
SMA 
FVB/N Complete rescue of the 
phenotype 
25% (Workman et al. 
2009) 
 
After finding the right SAHA treatment concentration and application method - such 
as the oral application of 25 mg/kg SAHA twice daily - the SAHA regimen revealed a 
significant amelioration of SMA progression. The SAHA regimen significantly prolonged 
the mean survival time of the SMA-like mice by more than 30%. Interestingly, ~10% of 
the treated SMA-like mice lived longer than the longest surviving untreated SMA mouse. 
However, some of the SAHA-treated mice died within the first days of life. On the one 
hand these mice might have died due to severe side effects of SAHA, since also ~10% 
of the heterozygous, healthy littermates died under SAHA regimen. On the other hand 
these findings might indicate that some mice respond beneficial to SAHA, whereas 
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others might be non-responders. Similar observations have been described for the VPA 
treatment in SMA patients. In that case only one third of the treated individuals reacted 
with an up-regulation of the SMN protein level in blood, one third revealed no reaction, 
and one third even displayed a down-regulation of the SMN level (Brichta et al. 2006a). 
The reason for the difference in response to VPA is so far unknown, but currently under 
investigation in our laboratory. A similar difference in responders and non-responders 
might explain the heterogeneity of the life prolonging effect of SAHA. However, even in 
the SAHA responders, SAHA treatment was not capable to restore the lifespan to 
normal.  
It is obvious that SAHA treatment was not able to restore the normal development, 
since the weight of the treated SMA-like mice correlated stronger with the weight of the 
untreated SMA-like mice than with the normal weight gaining healthy littermates. The 
treated SMA-like mice showed a stagnation of weight improvement starting around day 
P10. This resulted in a dwarf-like appearance of the long-surviving SMA-like mice. 
Moreover, some of the long-surviving SAHA-treated SMA-like mice showed a severe 
necrosis of the hind limbs. Remarkably, onset of necrosis was only observed for the 
treated SMA mice, which survived for 20 days or longer. Importantly, the necrosis is not 
an effect of SAHA, but rather a characteristic of progressive SMA as previously reported 
(Araujo Ade et al. 2009). Untreated SMA-like mice did not develop necrosis, since they 
have a severely reduced life-expectancy. The motor abilities were significantly improved 
under the SAHA regimen. The applied motor function test (tube test (El-Khodor et al. 
2008)) revealed that the SAHA-treated SMA-like mice have a significantly better motor 
function than the untreated SMA-like mice. The motor function of the treated SMA-like 
mice developed comparable to the healthy littermates, but declined at later stages, 
resembling the progression of SMA in some of the animals. Nevertheless, the untreated 
SMA-like mice never reached the level of motor ability of heterozygous animals. The 
decline of motor function started earlier in life and therefore reflects the severe 
progression of SMA. Also the motor function deficits of the SMA-like mice were 
ameliorated but not restored by the SAHA regimen.  
It was detected that SAHA stimulated the SMN2 transcript expression in virtually all 
tested organs, such as brain, liver, spinal cord and muscle. Interestingly, both splice 
variants FL-SMN2 and ∆7-SMN2 were up-regulated by SAHA. This indicates that Sfs10, 
the main splicing factor known to be able to correct the SMN2 pre-mRNA splicing 
(Hofmann et al. 2000), which was also up-regulated in some tested tissues, does not 
significantly influence the SMN2 splicing in these mice. The SMN2 transcript levels 
appeared far higher up-regulated (especially in the muscle tissue) in the P10 than in the 
P5 mice, regardless of their respective genotypes. This might be explained by a long-
Discussion 
 
 
144 
term effect of SAHA treatment. Additionally, the SMN protein level was also significantly 
augmented under SAHA treatment in virtually all tissues derived from SMA-like mice but 
never reached the SMN protein level found in heterozygous mice. Of particular 
importance was the finding that SAHA increased the SMN level also in neuronal tissues, 
underlining its ability to cross the blood-brain barrier. This would be essential for a 
prospective SMA drug.  
Furthermore, histological examinations revealed that the SAHA regimen reduces 
the loss of spinal motor neurons, improves the size of neuromuscular junctions and most 
likely as a secondary effect is able to increase the surface area size of cross sections of 
muscle fibers. All histological improvements of the phenotype resembled an amelioration 
of the SMA progression, but also revealed that SAHA treatment is not able to restore the 
phenotypic appearance of the investigated healthy littermates. This finding holds true for 
every investigated feature of the SMA-like animals: lifespan, weight progression, motor 
ability, SMN expression, degeneration of motor neurons, size of neuromuscular 
junctions, and size of muscle fibers. The SMA effect in each of these features was 
ameliorated by SAHA treatment, but the appearance of the healthy heterozygous 
animals was never reached. The lack of potency of SAHA to fully rescue the SMA-like 
phenotype is explainable by its relatively short half-life time. SAHA has been described 
to have a half-life time in humans of ~2 h, whereas in mice ~45 min (Duvic et al. 2007; 
Venkatesh et al. 2007). However, higher dosages of SAHA were not tolerated by the 
mice. Nevertheless, the very clear favorable function of SAHA might be realized not only 
by the activation of SMN2 but by an additional neuroprotective property of SAHA. It has 
previously been described that SAHA possesses neuroprotective efficacy (Hockly et al. 
2003). 
So far, several in vivo approaches have been performed in order to ameliorate the 
SMA phenotype in a mouse model for SMA (overview in Table 16). The attempts to 
prolong the survival of SMA-like mice are quite versatile.  
Three independent studies have been focused on the SMA-like mice treatment 
with different HDACis, namely the pan-HDACis sodium butyrate (NaBu), trichostatin A 
(TSA) and valproic acid (VPA). NaBu treatment has been shown to prolong survival 
(+39%) and to ameliorate muscular atrophy of tails. Treatment of mothers has been 
shown to overcome embryonic lethality (Chang et al. 2001). TSA has been found to 
increase the SMN level 2-fold and to attenuate weight loss. Additionally, TSA elevated 
the myofiber size and number and anterior horn cell size. TSA-treated mice showed 
better motor behavior and a 19% increased survival (Avila et al. 2007). A more recent 
study revealed that the TSA treatment plus nutritional support extended median survival 
of spinal muscular atrophy mice by 170%. Treated mice have been observed to continue 
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to gain weight, maintain stable motor function, and retain intact neuromuscular junctions 
long after TSA was discontinued. These findings are of particular interest, since feeding 
problems are known for SMA patients as well as SMA-like mice, to worsen the SMA 
phenotype (Narver et al. 2008a). VPA-treated SMA type III-like mice revealed better 
motor function, larger motor-evoked potentials, less degeneration of spinal motor 
neurons, less muscle atrophy and better neuromuscular junction innervation (Tsai et al. 
2008b). VPA has been shown to elevate SMN levels ~1.4-fold in spinal cord. Since the 
chosen mice showed a very mild form of SMA, the impact of VPA treatment on the 
survival was not determined. 
Two attempts to force the read-through of the premature stop-codon in ∆7-SMN2 
mRNA and therefore facilitate the production of a more stable protein (by the addition of 
5 amino acids) have been performed. Geneticin (G418) has been shown to improve 
motor function and up-regulate SMN ~3-fold. Nevertheless, an increase in survival has 
not been observed (Heier and DiDonato 2009a). The experimental compound TC007 
has been shown to increase survival by 30%, increase the number of ventral horn cells 
and improve motor function (Mattis et al. 2009b). 
It has been proven that treatment of pregnant mothers of very severely affected 
SMA-like mice with the nonsteroidal anti-inflammatory drug indoprofen, overcomes 
embryonic lethality. This finding has been explained by the observation that indoprofen 
up-regulates the transcription of SMN2 (Lunn et al. 2004). 
During the annual meeting of the “Families of SMA” preliminary data have been 
presented regarding the treatment of SMA-like mice with the phosphatase inhibitor 
quinazoline D157495. This substance has been shown to increase the survival to 400%. 
Two studies have been concentrating on the idea to correct the splicing of SMN2 
pre-mRNA by the use of antisense oligonucleotides (ASOs). In one study one ASO has 
been used, which was able to bind with one side specifically to the SMN2 sequence (in 
intron 6) and was able to recruit SFRS10 to the other side. Therefore, SFRS10 has been 
shown to restore the SMN2 splicing. This ASO was directly injected into the central 
nervous system (CNS) of SMA-like mice. The treated mice showed an increased weight 
gain and a 2-fold elevated SMN level (Baughan et al. 2009b). Another study made use of 
a steric block ASO. Here it has been shown that this ASO did not recruit a splicing factor, 
but rather blocked an intronic suppressor element (Williams et al. 2009a). After injecting 
the respective ASOs directly into the CNS, the SMA-like mice revealed an increase in 
weight gain and a partial correction of motor deficits (righting reflex).  
The previously discussed in vivo approaches to ameliorate the SMA phenotype in 
mice were all based on the possibility to positively influence the SMN2 gene, either by 
transcriptional activation, or by splicing correction, or by forcing a read-through of the 
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premature stop-codon. However, several attempts were performed to treat SMA-like 
mice without targeting the SMN2 transgene. These SMN2 independent approaches are 
discussed in the following. 
The delivery of recombinant follistatin, which is a natural antagonist of myostatin 
and known to increase skeletal muscle mass, has been shown to lessen the disease 
severity in a SMA-like mouse. The treated SMA-like mice revealed an increased muscle 
mass, increase in number of ventral horn cells, a 30% longer survival and motor function 
improvement, whereas the SMN level remained unchanged (Rose et al. 2009a) 
By the use of lentiviral gene transfer, researchers have been succeeded to 
introduce a human SMN1 gene copy into the motor neurons of SMA-like mice. The 
respective animals revealed an increase in weight gain and motor neuron survival. 
Additionally, the SMN expression has been shown to be restored to normal in the motor 
neurons. Treated SMA-like mice were observed to live 20% to 38% longer (Azzouz et al. 
2004). 
A recent study has proven that the intrathecal introduction of neuronal stem cells 
into SMA-like mice increased motor neuron survival and weight gain, improved the 
muscular phenotype and the motor function. Additionally, the treated mice were shown to 
live ~40% longer and the stem cell introduction has been proven to act neuroprotectively 
(Corti et al. 2008). 
Moreover, it has been observed that the transplantation of wild-typic bone marrow 
into a SMA mouse model (HSA-Cre; Smnfl7/fl7 (Muscle specific Smn exon 7 KO)) was 
able to improve the myopathic phenotype (muscular regeneration) and the motor 
performance (+85%) (Salah-Mohellibi et al. 2006). However, no increase in the SMN 
expression was observed. 
Interestingly, researchers have found out that regular physical exercises increase 
the mean survival by 57.3%. Moreover, it has been shown that trained mice revealed 
increased motor neuron survival, SMN2 splicing correction, improvement in muscular 
phenotype and a certain neuroprotection (Grondard et al. 2005). 
 To compare these findings with the present study, it is noteworthy that SAHA 
treatment resulted in the fourth highest increase of survival, which was ever observed by 
the treatment with a chemical compound. Moreover, the SAHA-treated SMA-like mice 
revealed increased muscle mass, increase in number of motor neurons, motor function 
improvement and bigger neuromuscular junction size. Additionally, the SAHA treatment 
of mothers is able to overcome embryonic lethality. SAHA regimen resulted in a profound 
increase of SMN levels in all tested tissues except the liver. The ~17-fold increase of the 
SMN amount in the muscle was the highest ever observed. Strikingly, this compound 
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was shown to ameliorate the SMA phenotype in two different mouse models for SMA, 
highlighting its potency.   
To summarize these results, SAHA was proven to ameliorate the SMA progression 
in two different SMA mouse models. However, SAHA treatment was not capable to 
protect against the onset of SMA. For future in vivo approaches for a SMA therapy it 
would be necessary, to identify substances, which are well tolerated by the test animals 
and moreover have a longer half-life time than SAHA in order to reduce the number of 
disturbing applications of the test substance. Importantly, SAHA turned out to efficiently 
ameliorate the SMA phenotype in type I-like SMA mouse models. Since SAHA is a FDA-
approved drug, it is worth to be examined in clinical trials with SMA patients. These 
findings are of particular interest, since recent studies revealed only modest beneficial 
improvement in SMA patients, which were treated with valproic acid (Swoboda et al. 
2009). SAHA is therefore the only alternative FDA-approved HDACi, which was shown to 
ameliorate the SMA phenotype in SMA-like mice. Moreover, SAHA is the only FDA-
approved second generation HDACi shown to significantly increase the mean lifespan of 
SMA-like animals. 
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Table 16 Overview of in vivo approaches to ameliorate the SMA phenotype of diverse SMA mouse models in comparison to the results discussed in this 
thesis (marked in grey). Results are summarized from the given publications. 
Mechanism of action Compound SMA mouse model Increase in mean survival Effect on SMA progression 
SMN protein 
increase 
Original 
publication 
Histone deacetylase 
inhibition (activation of 
SMN2 transcription and/or 
splicing) 
Suberoylanilide 
hydroxamic acid 
(SAHA) 
SMAH (Smn-/-;SMN2tg/tg) 
(on FVB/N) 
SMAB (Smn-/-;SMN2tg/wt) 
(on FVB/N) 
30%  
 
Treatment of 
mothers overcomes 
embryonic lethality 
Increased muscle mass, increase in 
number of ventral horn cells, motor 
function improvement, treatment of 
mothers overcomes embryonic lethality, 
bigger neuromuscular junction size 
~17-fold in 
muscle 
~2-5-fold mean 
increase 
This thesis 
Sodium butyrate 
(NaBu) 
SMAH (Smn-/-;SMN2tg/wt) 
(on FVB/N) 
39% Treatment of mothers overcomes 
embryonic lethality, muscular atrophy of 
tails is ameliorated 
Slightly 
increased (not 
quantified) 
(Chang et al. 
2001) 
Valproic acid (VPA) SMAH (Smn-/-;SMN2tg/wt) 
(on C57BL/6) 
Not determined better motor function, larger motor-evoked 
potentials, less degeneration of spinal 
motor neurons, less muscle atrophy, and 
better neuromuscular junction innervation 
~1.4-fold (Tsai et al. 
2008b) 
Trichostatin A (TSA) Smn-/-;SMN2tg/tg;SMN∆7tg/tg 19% Increased myofiber size and number, 
better motor behavior, attenuated weight 
loss, increased anterior horn cell size  
1.5-2-fold (Avila et al. 
2007) 
Histone deacetylase 
inhibition  
(activation of SMN2 
transcription and/or splicing) 
Trichostatin A (TSA) 
plus nutrition 
Smn-/-;SMN2tg/tg;SMN∆7tg/tg 170% Increased myofiber size, weight gain, 
maintained stable motor 
function, retained intact neuromuscular 
junctions, long-lived mice show necrosis  
Not determined (Narver et al. 
2008a) 
TC007 Smn-/-;SMN2tg/tg;SMN∆7tg/tg ~30% Increase in number of ventral horn cells, 
motor function improvement 
~2-4-fold (Mattis et al. 
2009a) 
Read-through of stop 
codon 
 
Geneticin (G418) Smn-/-;SMN2tg/tg;SMN∆7tg/tg No increase (due to 
toxicity) 
Motor function improvement ~3-fold (Heier and 
DiDonato 
2009b) 
Nonsteroidal anti-
inflammatory drug 
(Transcriptional activation) 
Indoprofen SMAB (Smn-/-;SMN2tg/wt) 
(on C57BL/6/FVB/N) 
Treatment of mothers overcomes embryonic lethality Not determined (Lunn et al. 
2004) 
Phosphatase Inhibitor 
(Transcriptional activation) 
Quinazoline 
(D157495) 
Humanized SMA mouse (B2-strain, 
(AGG-TTT)) 
(not published)  
400% Motor function improvement 
(not published) 
(not published) (DiDonato et al. 
2009, FSMA 
meeting) 
Bifunctional RNA (high 
affinity to SFRS10) 
Smn-/-;SMN2tg/tg;SMN∆7tg/tg, 
SMAH (Smn-/-;SMN2tg/wt) 
 (on C57BL/6) 
“trend towards 
increased life 
expectancy” 
Increase in weight gain ~2-fold (Baughan et al. 
2009a) 
Oligonucleotides 
(splicing correction) 
Steric block antisense 
oligonucleotide 
Smn-/-;SMN2tg/tg;SMN∆7tg/tg Not determined Increase in weight gain, partial correction 
of motor deficits (righting reflex) 
~2-3-fold (Williams et al. 
2009b) 
Induction of muscle growth Recombinant follistatin Smn-/-;SMN2tg/tg;SMN∆7tg/tg 30% Increased muscle mass, increase in 
number of ventral horn cells, motor 
function improvement 
unchanged (Rose et al. 
2009b) 
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Lentiviral gene transfer Lentivector expressing 
human SMN 
Smn-/-;SMN2tg/tg;SMN∆7tg/tg 20% to 38% Increase in weight gain, increased motor 
neuron survival 
Restoration in 
motor neurons 
(Azzouz et al. 
2004) 
Stem cell therapy Neuronal stem cells Smn-/-;SMN2tg/tg;SMN∆7tg/tg ~40% Increased motor neuron survival,  
improvement in muscular phenotype, 
neuroprotection, motor function 
improvement, Increase in weight gain 
~2-fold (Corti et al. 
2008) 
Transplantation Bone marrow 
transplantation (wt) 
HSA-Cre; Smnfl7/fl7 
(Muscle specific Smn KO) 
Not determined Improvement of myopathic phenotype 
(muscular regeneration), improvement of 
motor performance (+85%) 
Not determined (Salah-
Mohellibi et al. 
2006) 
Physical training Exercises (running) SMAH (Smn-/-;SMN2tg/tg) 
(on FVB/N) 
57.3% Increased motor neuron survival, splicing 
correction, improvement in muscular 
phenotype, neuroprotection 
Not determined (Grondard et al. 
2005) 
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5.4 Future prospects  
The results, which were observed and discussed in this work, give rise to several 
possible future prospects. 
 Since it was found that the inbred strain background of the SMA-like mice has a 
major influence on the severity of the disease, one project, which has already been 
started in our laboratory, addresses the question what modifies the SMA phenotype. 
Therefore, the SMAH mice on FVB/N background will be crossed back onto pure 
C57BL/6 background. During back crossing, the phenotypic appearance of the animals 
will be characterized with regard to the percentage of the respective backgrounds. 
Finally, an array-based expression profile comparison of the 100% FVB/N and the 100% 
C57BL/6 SMAH mice will give information about possible modifying factors. The 
identification of modifiers of the SMA disease severity is of particular interest, since these 
factors could serve as new targets for a potential SMA therapy. 
 HDAC8 was identified in this work as the main HDAC involved in the expression 
regulation of SMN2. Since the HDAC8-specific inhibitor PCI-34051 was able to elevate 
the SMN level in SMA fibroblast cells, a further proof of principle is currently ongoing in 
our laboratory to prove the capability of other HDAC8 specific inhibitors to augment SMN 
levels. Moreover, it would be interesting whether the crossbreeding of SMA-like mice 
with HDAC8 knock-out mice, would ameliorate the SMA phenotype. Since the ubiquitous 
HDAC8 knock-out has been shown to be lethal at P0 (Haberland et al. 2009), a inducible 
conditional knock-out in the motor neurons would most likely be the suitable tool to 
investigate the impact on SMN2 in the SMA-like mice. To assess the in vivo impact of 
the lack of the different HDACs on the SMN2 expression, it would be worth to crossbreed 
all motor neuron specific knock-out mice of the HDAC class I one by one to SMA-like 
mice and investigate the change in the SMA phenotype.  
 Since this study proved that the prenatal treatment with SAHA overcomes prenatal 
lethality of a very severe SMA mouse model, it might be worth to combine a prenatal and 
a postnatal SAHA treatment in the milder SMAH mouse model. The prenatal treatment 
might increase the SMN2 expression during the embryonic development and therefore 
support the development and especially the maintenance of the motor neurons in SMA-
like mice. It has been shown that the combination of HDACi treatment plus nutritional 
support ameliorates the SMA phenotype more than HDACi treatment alone (Narver et al. 
2008b). Also physical exercises have been shown to lessen the SMA phenotype in SMA-
like mice (Grondard et al. 2005). Thus, the combination of SAHA treatment, physical 
training and nutritional support might be the optimal therapeutic strategy for SMA-like 
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mice. Moreover, the treatment of the vascular problems, which result in severe necrosis, 
might prolong the survival of SMA-like mice. 
 This combination therapy might be the optimal care for SMA-like animals and thus 
lead to the best effect in SMA amelioration. 
5.4.1 Future prospects for potential SMA therapy 
The findings gained in this study together with previously described data open different 
possible strategies for prospective SMA therapies. Since all SMA patients retain the 
SMN2 the activation of this gene is a unique opportunity for a SMA therapy. As already 
discussed, several compounds have been described to be capable to massively 
augment the SMN2 transcription and to correct the splicing of SMN2. Since some of 
these drugs, like phenylbutyrate, VPA and SAHA are FDA-approved and therefore 
clinically available, they are very promising candidates for a SMA therapy. Since first 
clinical trials with VPA revealed only a very modest effect on SMA progression, it is 
crucial to find further potential SMA drugs (Swoboda et al. 2009). Moreover, the FDA-
approved drugs aclarubicin and indoprofen revealed positive effects on SMN2 splicing 
correction and SMN protein stabilization, respectively. Therefore, it is of highest interest 
to find out whether a combination therapy with e.g. SAHA together with aclarubicin and 
indoprofen would lead to an amelioration of the SMA phenotype. However, the 
combination of these drugs has to be monitored quite carefully, since there is an obvious 
potential for the development of unfavorable side effects. 
Moreover, several therapy strategies are possible without targeting the SMN2 
gene. One theoretically possible strategy is the SMN1 gene replacement. In mouse 
experiments it has been shown that the lentivector SMN1 gene transfer into SMA-like 
mice increased their survival by 3-5 days (Azzouz et al. 2004). However, it is 
questionable, whether this method is applicable for a human therapy. Another possible 
approach has recently been discussed in more detail. The growing field of stem cell 
research might help to find a way to introduce stem cells (or induced pluripotent stem 
cells) into the spinal cord of SMA patients in order to produce new motor neurons. 
Recently, it was proven that it is possible to generate induced pluripotent stem cells 
(iPSCs) from skin SMA fibroblast cells. Researchers used these cells to generate motor 
neurons that showed selective deficits compared to those derived from an unaffected 
control. Therefore, these cells were proposed as a new, promising resource to study 
disease mechanisms, screen new drug compounds and develop new therapies (Ebert et 
al. 2009). Additionally, it was recently shown that the intrathecal introduction of neuronal 
stem cells into SMA-like mice ameliorated the SMA phenotype, revealed a 
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neuroprotective effect and the treated mice were shown to live ~40% longer  (Corti et al. 
2008). 
Interestingly, the FDA-approved drug riluzole has been shown to act as a 
neuroprotective agent, reducing the death of neurons and therefore attenuating the SMA 
progression in a SMA-like mouse (Haddad et al. 2003). Since recent clinical trials have 
been proven that this compound is well tolerated by SMA patient, it could be another 
drug to be evaluated in a combination therapy for SMA (Russman et al. 2003). 
Since SMA is a progressing disease, the starting time point of the therapy is 
absolutely crucial. Soon after onset of disease and if a patient still possesses a sufficient 
amount of functional motor neurons, it is necessary to apply directly a therapy to 
maintain the neuron integrity with neuroprotective agents or by the elevation in SMN 
levels. However, if a patient already lacks functional motor neurons, stem cell therapy is 
the only possible therapy. Nevertheless, supporting muscle strength e.g. by the induction 
of muscle growths, and supplying nutritional support may help every SMA patient, 
regardless of the status of the disease. 
 Probably the best approach for a potential SMA therapy would be the combination 
of substances, which activate the SMN2 expression, correct the splicing of SMN2, 
stabilize the SMN protein and act neuroprotectively. Moreover, this therapy should be 
combined with so-called aggressive ancillary care (nutritional support). SAHA has been 
shown to be neuroprotective (Hockly et al. 2003). Additionally, in this study it was proven 
that SAHA was able to activate the SMN2 expression and to elevate the SMN level. 
Thus, we propose to use SAHA in clinical trials with SMA patients. 
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6 Summary 
Proximal spinal muscular atrophy (SMA) is a common autosomal recessive 
neuromuscular disorder and the leading hereditary cause of death in early childhood. To 
date, no cure is available. The disease determining gene for SMA is the survival motor 
neuron gene 1 (SMN1). SMN1 produces full length transcripts only (FL-SMN), whereas 
the majority (~90%) of transcripts derived from the copy gene SMN2 lack exon 7 (∆7-
SMN2) due to alternative splicing. Although the amount of fully-functional SMN2-derived 
FL-SMN protein is not sufficient to overcome the absence of SMN1 and to prevent 
disease onset, SMN2 has been shown to be the main disease modifying gene. SMN2 is 
present in all SMA patients, which all lack functional SMN1. Therefore, and due to its 
disease modifying property, SMN2 became the most interesting target for a potential 
SMA therapy. It has been proven that epigenetic modification by histone deacetylase 
inhibitors (HDACis) successfully activates the transcription of SMN2. Additionally, HDACi 
treatment has been shown to modulate the splicing pattern of SMN2 by the up-regulation 
of the splicing factor SFRS10, resulting in increased FL-SMN levels. The elevation of the 
SMN protein level has been proven to ameliorate disease progression in vitro, ex vivo 
and in vivo. 
In the present work two newly identified second generation HDAC inhibitors of 
different chemical classes, namely M344 (benzamide) and FK228 (tetrapeptide, also 
known as depsipeptide, or romidepsin), were shown to be able to elevate SMN and 
SFRS10 protein levels in fibroblast cell lines derived from SMA patients. Moreover, it 
was proven by quantitative real-time PCR that both HDACis up-regulated the FL-SMN2 
transcript amounts and revealed no change or even a decrease in the ∆7-SMN2 level 
indicating a reversion of the splicing pattern. The ability to correct the SMN2 splicing was 
confirmed by the finding that both substances were able to elevate SFRS10 protein 
levels. Semi-quantitative Western blot analysis revealed that the treatment with M344 
resulted in an up to 7-fold and with FK228 in an up to 4.4-fold augmentation of the SMN 
protein level. FK228 proved its efficacy to elevate SMN levels also in a murine fibroblast 
line derived from a SMA-like mouse, indicating potency to modulate SMN2 expression 
regardless of the genetic background. Moreover, fluorescence microscopy revealed that 
both substances were able to increase the number of subnuclear gems, indicating the 
elevated production of fully-functional SMN proteins. However, the performed MTT-
assays revealed for both substances an in vitro toxicity profile, which restrained further in 
vivo characterization. 
In order to identify the respective HDAC isoenzyme mainly involved in SMN2 
expression regulation, all eleven classical HDACs were knocked-down by siRNA. Only 
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after the knock-down of HDAC8, the SMN protein level was significantly up-regulated. 
Thus, HDAC8 overexpression experiments were performed, which could clearly prove 
that HDAC8 activity regulates the SMN protein expression. Furthermore, chromatin 
immunoprecipitation experiments revealed that HDAC8 binds to the promoter region of 
SMN2, resembling the involvement in the epigenetic regulation of SMN2 expression. 
This finding was confirmed by treating SMN1 deleted fibroblasts with HDAC8 specific 
inhibitor (PCI-34051). Real-time PCR expression analysis and semi-quantitative Western 
blots revealed that the up-regulation of SMN by PCI-34051 resembled the elevation of 
SMN by the knock-down of HDAC8. Moreover, a cell viability assay revealed virtually no 
cytotoxicity. The great advantage of using an isoform specific HDACi in a potential SMA 
therapy is the reduction of unfavorable side effects. 
To identify a potential drug for a prospective SMA therapy, it is necessary to 
confirm its potency in vivo. Previously, our group has shown for the first time that the 
FDA-approved drug suberoylanilide hydroxamic acid (SAHA) is able to elevate the SMN 
level in vitro (SMA fibroblasts) and ex vivo (rat and human hippocampal brain slices). 
Thus, this work proved that SAHA is a potent and non-toxic candidate drug for SMA 
treatment, since the in vivo characterization of this compound revealed a beneficial effect 
on disease progression in two different SMA mouse models. First, since the SMN2 copy 
number is crucial for the severity of SMA, a real-time PCR based assay was developed 
to precisely determine the SMN2 copy number of SMA-like mice. In the very severe SMA 
mouse model SAHA treatment of the pregnant mother mice could prevent embryonic 
lethality of the SMA-like mice. In another SMA mouse model, which was here 
characterized for the first time in detail, the direct application of SAHA to the SMA-like 
mice revealed a significant amelioration of the SMA progression. The mean lifespan was 
increased by ~30%, from 9.9 to 12.9 days. Moreover, the SAHA-treated SMA-like mice 
showed better motor function abilities. Additionally, in histochemical attempts it was 
shown that SAHA-treated SMA-like mice revealed less degeneration of the α-motor 
neurons in the anterior horns of the spinal cord and larger muscle fibers. 
Immunofluorescence stains could prove that SAHA-treated SMA-like mice showed an 
increase in neuromuscular junction size. Furthermore, real-time PCR approaches as well 
as semi-quantitative Western blotting displayed that SAHA treatment elevated SMN 
protein and transcript levels in the brain, spinal cord, muscle and liver. Although SAHA 
was able to ameliorate the SMA phenotype, it was not able to fully rescue the mice from 
disease progression.  
Since SAHA is an FDA-approved drug and was shown to ameliorate the SMA 
progression, it can be considered as an attractive candidate for a potential SMA therapy. 
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7 Zusammenfassung 
Proximale spinale Muskelatrophie (SMA) ist eine häufige autosomal rezessive 
neuromuskuläre Erkrankung und die häufigste genetisch bedingte Kindestodesursache. 
Bis heute kann SMA nicht geheilt werden. Die Krankheit wird hervorgerufen durch den 
homozygoten Verlust des survival motor neuron Gens (SMN1). SMN1 produziert 
ausschließlich Volllänge-Transkripte (VL-SMN2), wohingegen bei ~90% der Transkripte 
der Genkopie SMN2, bedingt durch alternatives Spleißen, das Exon 7 fehlt (∆7-SMN2). 
Obwohl die Menge des vom SMN2 Gen produzierten voll funktionstüchtigen VL-SMN 
Proteins nicht ausreicht, das Ausbrechen der Krankheit zu verhindern, ist dennoch 
SMN2 das wichtigste krankheitsmodifizierende Gen. Zudem trägt jeder SMA Patient 
mindestens eine SMN2 Kopie. Aus diesen Gründen wurde SMN2 zum interessantesten 
Zielgen für eine potenzielle SMA Therapie. Es konnte gezeigt werden, dass durch 
epigenetische Modifizierung durch Histondeacetylase-Inhibitoren (HDACis), die SMN2 
Transkription aktiviert werden kann. Zudem konnte durch HDACi-Behandlung die Menge 
des Spleißfaktors SFRS10 heraufreguliert werden, was in einer Revertierung des SMN2 
Spleißmusters resultierte. Die Steigerung der SMN Proteinmenge milderte die 
Ausprägung der SMA in vitro, ex vivo und in vivo. 
 In der vorliegenden Arbeit konnte gezeigt werden, dass zwei neu identifizierte 
HDACis aus unterschiedlichen chemischen Substanzklassen, M344 (Benzamid) und 
FK228 (Tetrapeptid), in der Lage sind, sowohl die SMN, als auch die SFRS10 
Proteinmenge in Fibroblastenkulturen von SMA Patienten heraufzuregulieren. Außerdem 
konnte mit Hilfe von quantitativer real-time PCR gezeigt werden, dass beide Substanzen 
eine Erhöhung der VL-SMN2 Transkriptmenge und keine Veränderung oder sogar eine 
Abnahme der ∆7-SMN2 Transkriptmenge verursachen, was für eine Revertierung des 
SMN2 Spleißmusters spricht. Die Fähigkeit, das SMN2 Spleißmuster zu korrigieren, 
wurde durch die Beobachtung bestätigt, dass beide Substanzen in der Lage sind, die 
SFRS10 Proteinmenge zu erhöhen. Durch semiquantitative Western blots konnte 
gezeigt werden, dass die Behandlung mit M344 zu einer 7-fachen und mit FK228 zu 
einer 4,4-fachen Steigerung der SMN Proteinmenge führte. FK228 sorgte auch in einer 
murinen Fibroblastenkultur, die von einer SMA-Maus stammte, für eine Erhöhung der 
SMN Proteinmenge. Dies spricht dafür, dass FK228, unabhängig des genetischen 
Hintergrunds in der Lage ist, SMN2 Expression zu aktivieren. Außerdem zeigten 
fluoreszenzmikroskopische Untersuchungen, dass beide Substanzen die Anzahl 
subnukleärer gems steigerten. Die Neubildung von gems spiegelt die erhöhte Produktion 
funktionstüchtiger SMN Proteine wider. Die in vitro Toxizitätsprüfung (MTT-Assay) 
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jedoch, stellte eine weitergehende in vivo Charakterisierung beider Substanzen vorerst 
zurück. 
 Um dasjenige HDAC-Isoenzym zu identifizieren, welches hauptsächlich in der 
Regulation der SMN2 Expression involviert ist, wurde die Expression aller elf 
„klassischen HDACs“ mit Hilfe von siRNA ausgeschaltet (knock-down). Nur nach 
Ausschalten von HDAC8 zeigte sich die SMN Proteinmenge signifikant erhöht. 
Desweiteren konnte durch Überexpression von HDAC8 die SMN Proteinmenge 
herunterreguliert werden. Chromatin-Immunopräzipitationsexperimente bewiesen, dass 
HDAC8 in der Promoterregion des SMN2 Gens bindet, was eine Beteiligung in der 
epigenetischen Regulation der SMN2 Expression nahe legt. Diese Ergebnisse konnten 
durch die Behandlung von SMN1-deletierten Fibroblasten mit einem HDAC8-
spezifischen Inhibitor (PCI-34051) bestätigt werden. Real-time PCR Expressionsanalyse 
und semiquantitative Western blots bestätigten, dass das Ausmaß der Heraufregulierung 
von SMN durch PCI-34051 dem entsprach, welches nach dem knock-down von HDAC8 
beobachtet wurde. Die in vitro Toxizitätsprüfung (MTT-Assay) zeigte keinerlei 
Zytotoxizität. Der grundlegende Vorteil eines Isoform-spezifischen HDACis in einer 
potenziellen Therapie für SMA, läge in der Vermeidung von einem Großteil 
unerwünschter Nebenwirkungen. 
 Um ein potenzielles Medikament für eine SMA-Therapie zu identifizieren, ist es 
nötig, seine Wirksamkeit in in vivo Versuchen zu bestätigen. Vorausgehend konnte 
unsere Arbeitsgruppe zum ersten Mal zeigen, dass das von der FDA zugelassene 
Medikament suberoylanilide hydroxamic acid (SAHA) in der Lage ist, die SMN Mengen 
in vitro (SMA Fibroblasten) und ex vivo (Hirnschnittkulturen von Mensch und Ratte) zu 
erhöhen. Diese Arbeit zeigt, dass SAHA ein sehr potenter Wirkstoff für eine SMA-
Therapie ist, da diese Substanz in der in vivo Charakterisierung sehr positiven Einfluss 
auf den Krankheitsverlauf in zwei unterschiedlichen Mausmodellen für SMA zeigte. Da 
die Anzahl der SMN2 Genkopien entscheidend für den Schweregrad der SMA ist, wurde 
zunächst eine real-time PCR basierende Methode entwickelt, mit der es möglich ist, die 
exakte SMN2 Kopienanzahl zu bestimmen. In einem Mausmodell mit sehr schwerer 
SMA-Verlaufsform, konnte die SAHA-Behandlung der Muttertiere die embryonale 
Letalität der SMA-Mäuse verhindern. In einem weiteren SMA-Mausmodell, welches hier 
zum ersten Mal ausführlich beschrieben wurde, zeigte die direkte Applikation von SAHA 
in die SMA-Mäuse eine deutliche Abschwächung des Krankheitsverlaufs. Die 
durchschnittliche Lebensdauer der erkrankten Tiere konnte durch SAHA-Behandlung 
von 9,9 auf 12,9 Tage um ~30% verlängert werden. Darüber hinaus zeigten die SAHA-
behandelten SMA-Mäuse im Vergleich zu unbehandelten bessere motorische 
Fähigkeiten. Histochemische Untersuchungen bewiesen, dass die mit SAHA 
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behandelten SMA-Mäuse eine verringerte Degeneration der α-Motoneuronen in den 
Vorderhörnern des Rückenmarks und durchschnittlich im Querschnitt größere 
Muskelfasern aufwiesen. Immunofloureszenz-Färbungen zeigten außerdem in den 
behandelten SMA-Tieren größere neuromuskuläre Endplatten als in den unbehandelten. 
Zudem wurde durch real-time PCR Expressionsanalysen und semiquantitative Western 
blots festgestellt, dass SAHA-Behandlung die SMN2/SMN2 Transkript- und 
Proteinmenge in Gehirn, Rückenmark, Muskel und Leber erhöhte. SAHA ist zwar in der 
Lage den Krankheitsverlauf abzuschwächen, aber nicht den Ausbruch der SMA komplett 
zu verhindern. 
 Da SAHA ein zugelassenes Medikament ist und hier gezeigt werden konnte, dass 
es den Krankheitsverlauf der SMA positiv beeinflussen kann, sollte der Wirkstoff als ein 
vielversprechender Kandidat für eine potenzielle SMA-Therapie in Erwägung gezogen 
werden. 
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Figure 56 Diagrammatic representation of the knock-down efficiency of the respective siRNA 
approach. Knock-down efficiency was checked by quantitative real-time PCR, using primers for 
the respective targeted HDAC. Every knock-down was significant (p<0.01). 
 
 
 
 
Figure 57 Western blot and the respective quantification after overexpression of GFP (as control 
transfection), HDAC2, HDAC8 and HDAC11 in ML17 
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Figure 58 Fluorescent-based in vitro HDAC activity test to determine the inhibitory concentrations 
of the respective HDAC inhibitors. HDAC enzyme mixture was derived from rat liver extracts. 
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Figure 59 Motor ability experiment (righting reflex). Mice were placed on one side and time was 
measured until mice got back on four paws. Since the time [sec.] to right was not directly 
correlated with the genotype and subjected to massive fluctuations, the tube test was performed, 
to assess motor performance of the mice. (het=heterozygous (n=6), SMA=SMA-like mice(n=6)) 
 
 
 pIC50 
M344 6.52 ± 0.04 
 
SAHA 6.30 ± 0.02 
PCI-34051 4.23 ± 0.11 
 
FK-228 8.07 ± 0.07 
SB 3.10 ± 0.10 
VPA# 2.14 ± 0.07 
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